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ABSTRACT  
   
Cancer is the second leading cause of death in the United States and novel methods of 
treating advanced malignancies are of high importance. Of these deaths, prostate cancer 
and breast cancer are the second most fatal carcinomas in men and women respectively, 
while pancreatic cancer is the fourth most fatal in both men and women. Developing new 
drugs for the treatment of cancer is both a slow and expensive process. It is estimated that 
it takes an average of 15 years and an expense of $800 million to bring a single new drug 
to the market. However, it is also estimated that nearly 40% of that cost could be avoided 
by finding alternative uses for drugs that have already been approved by the Food and 
Drug Administration (FDA).  
 
The research presented in this document describes the testing, identification, and 
mechanistic evaluation of novel methods for treating many human carcinomas using 
drugs previously approved by the FDA.  A tissue culture plate-based screening of FDA 
approved drugs will identify compounds that can be used in combination with the protein 
TRAIL to induce apoptosis selectively in cancer cells.  Identified leads will next be 
optimized using high-throughput microfluidic devices to determine the most effective 
treatment conditions. Finally, a rigorous mechanistic analysis will be conducted to 
understand how the FDA-approved drug mitoxantrone, sensitizes cancer cells to TRAIL-
mediated apoptosis. 
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CHAPTER 1 
INTRODUCTION 
 
In 2012, it is estimated that over 570,000 men and women died of cancer related illnesses 
in the United States making cancer the second most lethal affliction in the country.  Of 
this total, 28,000 deaths in men were the results of prostate cancer, 39,500 deaths in 
women were the result of breast cancer, and 37,000 deaths were the result of pancreatic 
cancer [1].  Patient survival can be greatly improved through the early detection and 
treatment of these malignances but there still exist many limitations to the treatment of 
cancer. Difficulties with early diagnosis, tumor metastasis, resistance to 
chemotherapeutic treatments, and limited specificity of chemotherapeutic treatments are 
all prevalent and can reduce the efficacy of clinical treatments.  Developing novel 
treatment methodologies that can overcome the limitations of current treatments and aid 
in the treatment of advanced malignancies are of high importance.   
 
Developing new drugs is both a slow and expensive process.  A 2003 analysis of 68 FDA 
approved drugs found that it takes an average of 15 years and an estimated expense of 
$800 million to bring a single new drug to market [2].  The FDA approval process is also 
very stringent and a study done in 2010 showed that over a 10 year period (1999-2008) 
the number of drugs approved for use by the FDA decreased while the research and 
development costs doubled [3].  Recently there has been a push to find new uses for 
drugs that have already been approved for use by the FDA.  Researchers from the School 
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of Medicine at John Hopkins University released a short article summarizing the need to 
find new uses for old drugs arguing that the current standard for drug discovery is too 
costly and time consuming to effectively combat disease.  They suggest that by finding 
alternative uses for FDA approved drugs, nearly 40% of the total drug development costs 
can be reduced.  These drugs will also see an accelerated approval process for their 
alternative uses since they can progress directly to phase II clinical trials since their 
pharmacological properties have already been determined [4]. 
 
The idea of finding alternative uses for existing drugs is not new, and there are several 
examples of researchers who have identified alternative uses for drugs designed for the 
treatment of different aliments.  The drug ceftriaxone is an antibiotic that can stabilize β-
lactam enzymes which can inhibit the synthesis of bacterial cell walls but researchers 
discovered the drugs could also be used for the treatment of Amyotrophic Lateral 
Sclerosis (ALS) due to the drug's ability to increase the expression of glutamate 
transporters [5].  Similarly, the antibiotic minocycline, which inhibits aminoacyl tRNA, 
was also found to inhibit the release of cytochrome C from the mitochondria which also 
was important for the treatment of ALS [6].  Dapsone, a drug used to treat leprosy, and 
fosmidomycin, a drug used to treat urinary tract infections, were both identified as having 
antimalarial activities when used in combination therapies with other drugs 
(dapsone/chloroproguanil and fosmidomycin/clindamycin) [7-9]; one of our research 
strategies involves the use of combination treatments and these studies show how this can 
be a powerful treatment methodology.  Another example that is directly relevant to our 
line of studies was the identification of the antiamebic, fumagillin as a therapeutic for 
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brain, breast, cervical, and prostate cancer [10, 11].  Finally, the drug eflornithine was 
initially developed for the treatment of cancer but failed clinical trials; the drug was later 
used in the treatment of African trypanosomiasis (African Sleeping Sickness) [12].  
These represent only a few of the cases in which new uses have been identified for pre-
existing drugs but they demonstrate the power of using this methodology for the 
treatment of many ailments.  These cases also demonstrate the flexibility of the treatment 
options be it as a single agent treatment, a combination treatment, or as a treatment with a 
drug that was initially failed clinical trials.   
 
In the studies presented in this document, we will be exploring the use of FDA-approved 
drugs for the treatment of various cancer types and trying to identify novel treatment 
methodologies and drug effects that can be exploited to improve these treatments.  By 
looking specifically at FDA approved drugs we hope to limit the amount of time and 
money spent needed to bring potentially helpful treatments to the public.  To this end we 
are studying two specific treatment options: (1) Identifying FDA-Approved drugs that 
can be used in combination with the protein TRAIL to induce apoptosis selectively in 
cancer cells and working to optimize the effect of the combination treatments using high-
throughput microfluidic devices.  (2) Identifying FDA-Approved drugs that show the 
ability to induce direct damage to the mitochondria and the subsequent testing of these 
drugs in delivery vehicles designed to improve the effects of the drugs while limiting 
damage to healthy tissue. 
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Figure 1.1  Intrinsic and extrinsic signaling pathways of apoptosis.  Proteins that 
contribute to the execution of apoptosis are shown in green while proteins that inhibit the 
process are shown in red.  The mitochondrion is a key regulator of apoptosis and is also 
shown. 
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APOPTOSIS 
One method of minimizing the harmful drug effects of is identify treatment mechanisms 
that induce apoptosis instead of necrosis [13].  Apoptosis is a cellular suicide mechanism 
that is used to eliminate cells that have sustained severe damage or are no longer needed.  
In healthy cells this process is closely regulated and an equilibrium is maintained 
between pro-apoptotic proteins and anti-apoptotic proteins.  If there is an apoptotic 
stimulation, the cell will shift the equilibrium to induce apoptosis resulting in the death of 
the cell [14].  Stimuli that can begin the apoptotic cascade can include developmental 
cues, the activation of proapoptotic receptors, loss of growth factor signals, heat shock, 
irradiation, and cytotoxic drugs [15, 16].  However, in many cases breakdowns in the 
apoptotic process can occur leading to poor regulation of the process.  The result of 
which can be a pro-apoptotic environment where cells undergo apoptosis when they 
should not, as is the case in many degenerative diseases [17, 18].  The result can also be 
an anti-apoptotic environment in which damaged/unhealthy cells grow continuously, as is 
the case in many types of cancer (the relevant case for these studies) [14] [19].  When 
looking at cells that are exhibiting unchecked cell growth (i.e. cancer), it is important to 
understand that the breakdown in the apoptotic mechanism can be beneficial for 
treatment since the damaged cells will not be able to regulate perturbations to the 
mechanism as well as healthy cells.  Essentially, cancer cells acquire an inherent 
resistance to apoptosis but are continually being pushed to initiate the process because the 
cells are malfunctioning.  By stimulating the apoptotic process it is possible to aid the 
malignant cells in their attempts to induce apoptosis.  Conversely, healthy cells are not 
trying to initiate apoptosis and so the stimulation of the process in these cells will be 
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balanced by the anti-apoptotic activity of the cell.  This leads to a degree of selectivity 
when using treatments that attempt to invoke the apoptotic mechanism [20-22]. 
 
The feature that distinguishes apoptosis from other types of programmed cell death (e.g. 
autophagy, paraptosis) is that the mechanism is primarily controlled through the 
activation of cystein-aspartic acid proteases (caspases) that execute the cells [23].  The 
pathways that are used to activate these caspases form the mechanism of apoptosis 
(Figure 1.1).  The induction of apoptosis occurs either through the intrinsic activation of 
the caspases, or the extrinsic activation of the caspases [15].  The intrinsic pathway is 
triggered intercellularly by the loss of growth factors or by severe damage to the cell [24].  
The intrinsic pathway is mainly controlled through interactions between the members of 
the Bcl-2 protein family which includes both pro-survival and pro-apoptotic members.  In 
this pathway pro-apoptotic Bcl-2 members like Bax and Bak, permeate the outer 
membrane of the mitochondria [25, 26].  This causes the release of the soluble proteins 
cytochrome c and Smac/DIABLO into the cytoplasm.  Cytochrome c stimulates the 
formation of a complex known as an apoptosome, and eventually causes activation of 
caspase 9.  Caspase 9 then cleaves the effector caspases 3, 6, and 7 which send the final 
signals to induce apoptosis [23].  Smac/DIABLO works to inhibit the pro-survival protein 
IAP by binding with IAP and reducing its activity [27]. An integral part of regulation in 
the intrinsic pathway is the expression of tumor suppressing protein p53.  Normally, p53 
responds to cellular stress by arresting the cell division cycle.  In the case of severe cell 
damage, p53 promotes apoptosis by the expression of genes such as Puma and Noxa that 
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inhibit pro-survival Bcl-2 members.  Additionally, p53 also plays a role in the extrinsic 
apoptotic pathway by expressing surface death receptors [28]. 
 
In the extrinsic pathway, apoptosis occurs through the activation of proapoptotic 
receptors on the cellular surface by apoptosis inducing ligands.  When these receptors are 
activated, they recruit the adaptor protein Fas-associated death domain (FADD).  FADD 
provides a link between the death receptor and procaspases 8 and 10, which bind to form 
the death-inducing signaling complex (DISC) [29].  During the formation of the DISC 
apoptosis can be regulated by the protein c-FLIP.  c-FLIP is structurally similar to 
procaspases 8 and 10 so it can bind to FADD to prevent DISC formation and it can also 
remove FADD binding sites to caspase 8 [30].  Intercellular signaling can continue in two 
different ways based on the levels of DISC produced and on the activity, after 
stimulation, of caspase 8.  In type 1 cells high levels of DISC are produced and the 
stimulation of caspase 8 is large enough to activate the effector caspases 3, 6, and 7 and 
induce apoptosis.  In type 2 cells lower levels of DISC are produced which are 
insufficient for caspase 8 to activate the effector caspases and instead the signal is 
amplified by cleavage of the protein Bid.  Bid initiates the intrinsic pathway to help 
activate the effector caspases [31]. 
 
In these studies, our research was centered around two different treatment methodologies, 
both of which employ apoptosis as a means of inducing cell death in cancer cells while 
limiting death in healthy tissue.  The first treatment methodology focuses on combination 
type therapies using a drug that is known to induce apoptosis selectively in malignant 
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cells.  The second methodology focuses on the induction of apoptosis by applying 
treatments that directly cause damage to the mitochondria.  The following sections will 
describe these methodologies more fully. 
 
COMBINATION TREATMENTS 
Tumor Necrosis Factor-α Related Apoptosis Inducing Ligand (TRAIL) is a member of 
the Tumor Necrosis Factor (TNF) super-family of cytokines which induces apoptosis 
upon specific binding to death receptors (DR) 4 and 5 expressed on the outer cellular 
membrane.  TRAIL and agonistic antibodies to DR4 and DR5 are attractive treatment 
options due to their ability to induce apoptosis selectively in malignant cells while 
demonstrating minimal cytotoxicity in non-malignant cells [32-36].  Trimeric, soluble 
TRAIL
 
variants are well tolerated in mice and
 
chimpanzees [37] and show little toxicity 
towards primary human hepatocytes and endothelial cells in culture [38, 39]. TRAIL has 
demonstrated significant anti-tumor activity in xenograft models [40-42] and certain 
TRAIL formulations (non-histidine tagged) are considered safe for in vivo applications 
[43].  
 
Despite the promise of TRAIL, many tumor cells are naturally resistant or can developed 
resistance to TRAIL-induced apoptosis [44]. Common resistance developed in PDAC 
cells include over-expression of anti-apoptotic proteins like XIAP [45, 46], survivin [47], 
c-Flip [48, 49] and Bcl-2 [50], and down-regulation of pro-apoptotic proteins (e.g. Bid 
9 
[51]). The inhibition/down regulation of anti-apoptotic proteins and the promotion of pro-
apoptotic proteins can sensitize resistant cells to TRAIL [52-55]. 
 
In our research we try to identify drugs that form a synergistic relationship with TRAIL 
and cause the cancer cells to undergo apoptosis.  The idea is that cancer cells are already 
primed to die but due to defects in the apoptotic pathway they continue to grow and 
divide.  The resistance to TRAIL that many cells have/develop can be overcome using 
small molecule drugs that are able to suppress and negate the resistances.  Since cancer 
cells are already primed to die, the natural response for regulating apoptosis would be in 
favor of cell death as opposed to in healthy cells where the response would be for cell 
survival.  The result would be that the combination drug/TRAIL treatment would be more 
effective in cancer cells then in normal cells leading to fewer side effects of treatment.  
This is in addition to the selectivity that TRAIL shows toward cancer cells.  The hope is 
that the synergistic effect of the sensitizer drug/TRAIL will allow for low concentration 
treatments of the drug to be administered (which may not be cancer cell selective) further 
reducing damage to non-malignant cells.  Once drugs that sensitize cancer cells to 
TRAIL-mediated apoptosis are identified the goal is to determine the concentrations of 
drug and TRAIL that result in the largest loss of cell viability while maintaining the 
synergistic effect of the combination treatments and limiting non-specific damage. 
 
Identifying drugs that show a synergistic relationship with TRAIL has been a research 
pathway that other researchers have previously explored.  TRAIL sensitizing activity has 
been identified for a range of different drugs including daunorubicin [56], doxorubicin 
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[57], epirubicin [58], cisplatin [59], oxaliplatin [60], camptothesin and its derivative 
CPT-11 [61], docetaxel [62], paclitaxel [63], iriontecan [64] and gemcitabine [65] all of 
which are drugs developed specifically for the treatment of cancer.  Additionally, 
compounds like curcumin [66], genistein [67], verticillin A [68], thapsigargin [69], and 
lanatoside C [70] represent natural products and non-cancer specific drugs that have also 
been shown to enhance TRAIL sensitization activity.  These previous studies are 
important because they provide a starting point for our research and they also allow for 
comparisons to be made between our data and previously published work.  Additionally, 
some of these combination therapies with TRAIL (trade name Dulanermin) have 
proceeded to clinical trials.  Phase II trials with TRAIL and rituximab for the treatment of 
Non-Hodgkin's Lymphoma have been shown to be well tolerated but indicate that 
combination treatments did not improve the objective response compared to the single 
agent treatments [71].  Ongoing phase II studies for TRAIL combination treatments with 
carboplatin, paclitaxel and bevacizumab for the treatment of non-small cell lung cancer 
have also shown the treatments to be well tolerated [72], while phase I studies for 
combination treatments of TRAIL with bevacizumab, cetuximab, FOLRIRI, FOLFOX, 
and irinotecan for the treatment of colorectal cancer have also been well tolerated with no 
adverse interactions between the treatments [73, 74]. 
 
It is clear that the field for identifying TRAIL-sensitizing compound is very active but 
our work is novel in that it specifically aims to identify compounds that are already 
approved by the FDA.  Although many of the drugs identified as TRAIL-sensitizers are 
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FDA approved, there has not been a comprehensive screen of FDA approved drugs for 
their sensitization activity.   
 
MITOCHONDRIAL DEPOLARIZATION 
Mitochondria represent a key component in both the intrinsic and extrinsic apoptotic 
pathways.  The an alternative treatment methodology investigated in this research is 
identifying FDA approved drugs that cause direct damage to the mitochondria.  The 
intrinsic and extrinsic apoptotic pathways both are very well regulated process which 
maintain a steady balance between pro- and anti-apoptotic mechanisms.  However, at the 
heart of apoptosis are mitochondria which, aside from the Type 1 activation of the 
extrinsic pathway, are integral to the execution of apoptosis.  One of the final steps in the 
apoptotic process is the permeabilization of the mitochondrial membrane by Bax and Bak 
and the subsequent release of pro-apoptotic proteins (cytochrome c, SMAC/DIABLO) 
into the cytoplasm.  The mitochondrial permeability transition represents a "point of no 
return" in the apoptosis signaling cascade [75].  Traditional chemotherapeutics induce 
genomic DNA damage, which triggers apoptosis signaling in cancer cells from the 
starting point of the process.  While these DNA-damaging treatments can be successful 
[76], several studies indicate that the overexpression of anti-apoptotic proteins can 
overcoming the pro-apoptotic signals triggered by these treatments.  This leads to an 
increased survival of cancer cells which can later manifest itself as additional resistance 
to the treatments [44, 77-79].  It is therefore an attractive therapeutic strategy to induce 
mitochondrial damage directly in order to facilitate the permeabilization of the 
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mitochondrial membrane and bypass any pro-survival mechanisms that act upstream of 
the mitochondria (e.g. Bcl-2 overexpression, p53 inhibition) [80, 81]. 
 
Our strategy for attacking the mitochondria involves identifying drugs that can cause a 
reduction in the mitochondria membrane potential (mitochondrial depolarization).  
Mitochondria are considered to be the "power generators" of cells; they produce most of 
the cell's adenosine triphosphate (ATP) via the process of oxidative phosphorylation.  
During this process a high concentration of protons are pumped into the space between 
the inner and outer mitochondrial membranes (intermembrane space).  Since the 
concentration of protons is much higher in the intermembrane space as compared to the 
mitochondrial matrix, a highly negative electrical gradient (-160 mV) is generated across 
the inner mitochondrial membrane [82].  The electrical potential stored in this gradient is 
what drives the production of ATP.  By finding agents that attack the mitochondria and 
cause a reduction in the mitochondrial membrane potential we will be severely limiting 
mitochondrial function which will have an effect on ATP synthesis, ROS generation, pH, 
as well as other factors [83].  In addition, the loss in membrane potential will cause the 
mitochondria to swell which can result in both the inner and outer mitochondrial 
membranes becoming permeable.  This in turn leads to the release of pro-apoptotic 
proteins like cytochrome c into the cytoplasm thereby beginning the apoptotic cascade 
[84]. 
 
By focusing our efforts to induce direct damage to the mitochondria we will be limiting 
the effect of any inherent apoptotic resistances the cell may have.  This damage can 
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facilitate the induction of apoptosis as well as cause severe damage to the mitochondria 
and limit its function. 
 
REACTIVE OXYGEN SPECIES 
The loss of mitochondrial membrane potential and the generation of reactive oxygen 
species (ROS) are closely related.  During the production of ATP, the mitochondria also 
generate ROS which, when functioning normally, can be regulated.  However, when 
mitochondria undergo some type of damage (e.g. mitochondrial depolarization) the 
generation of ROS increases and the capacity of the mitochondria to regulate the ROS 
decreases.  On the other hand, an increase in ROS will cause oxidative stress which will 
cause damage to the mitochondria.  In essence a feed-forward loop is created between 
oxidative stress and mitochondrial damage [85] and if there is a decrease in the MMP 
then there is likely an increase in ROS generation. 
 
MICROFLUIDIC DEVICES 
Another major component of this research is the design and testing of microfluidic 
platforms for the optimization of drug treatments.  When studying the effect of 
chemotherapeutic compounds it is important to identify the concentrations of the drug 
that maximize the chemotherapeutic effect while limiting the amount of drug needed to 
achieve the effect.  This can limit the non-specific effects of the drug and can also reduce 
the cost associated with the treatment (less material used).  In combination therapies, 
determining the optimum concentration is also of high importance.  In order to optimize 
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treatment effects it is useful to develop systems in which a range of drug concentrations 
can be developed and tested rapidly.  To achieve this goal, microfludic platforms that use 
a diffusion based mixing structure (dilution modules) to generate concentration gradients 
are used [86].  These platforms also provide the added benefit of using less material (i.e. 
the smaller volumes require less drug to be used for a given treatment concentration). 
 
Dilution modules of microfluidic devices operate by taking advantage of the changes in 
fluid dynamics at the micro-scale to produce a diffusive mixing unit that can be produce 
nearly linear concentration gradients [87].  The effects of laminar flow, diffusion, and the 
surface area to volume ratio, become much more important at the micro-scale.  Consider 
the Reynolds number equation:   
   
     
 
     (1.1) 
If there is a change in scale, the characteristic length (l0) and the characteristic velocity 
(v0) are the variables will dominate since density (ρ) and viscosity (µ) are both properties 
of the fluid [88].  In the case of microfluidic devices the characteristic length is very 
small and so the Reynolds number is usually small and the effects of turbulent mixing 
can be negated.  The majority of mixing in microfluidic devices occurs due to diffusion.  
The amount of time needed for a particle to travel over a distance is proportional to the 
square of that distance [89].  As a result, this effect becomes significant over very small 
distances.  In microfluidics it is often convenient to use the dimensionless Peclet number 
to relate the rate of advection of flow to the rate of diffusion via the equation: 
     
    
 
  (1.2)  
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where D is the mass diffusion coefficient [88].  The numerator gives the advection term 
while the denominator gives the diffusion term.  In devices with a high Peclet number 
mixing occurs slowly because the process is controlled by advection.  A low Peclet 
number means mixing will occur faster since the process is dominated by diffusion.  
Since the streams developed in microfluidics are usually laminar, control of flow velocity 
and channel geometry can be used to control diffusion and mixing.  The gradient 
generating dilution modules uses a channel geometry that encourages diffusive mixing by 
keeping a low l0 and v0.  Keep in mind that in this case the characteristic length is the 
width of the channel and not the overall length which should indeed be larger to provide 
more time for diffusion to occur. 
 
The following work will describe the development of a microfluidic screening system 
that is capable of generating gradients using the diffusive mixing system described above 
as well as perpendicular to the flow of the device.  Using these paired concentrations, the 
effects of combination treatments can be studied with this system.  
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CHAPTER 2 
PARALLEL SCREENING OF FDA-APPROVED ANTINEOPLASTIC DRUGS 
FOR IDENTIFYING SENSITIZERS OF TRAIL-INDUCED APOPTOSIS IN 
CANCER CELLS 
 
INTRODUCTION 
Tumor Necrosis Factor- Related Apoptosis Inducing Ligand (TRAIL) is a member of 
the Tumor Necrosis Factor (TNF) super-family of cytokines that engages the cellular 
apoptotic mechanism upon specific binding to death receptors (DRs) 4 and 5 on the cell 
surface [44]. TRAIL has attracted significant attention in recent years due to its ability to 
selectively induce apoptosis in transformed (malignant) cells while demonstrating little 
cytotoxicity in normal cells [32, 34-36, 38, 90]. TRAIL binds cell-surface death receptors 
(DR4 and DR5) as a homotrimer and triggers the formation of the Death-Inducing 
Signaling Complex (DISC); the Fas-Associated Death Domain (FADD) and caspases 8 
or 10 are recruited to the DISC from the cytoplasm. The proteolytic activation of initiator 
caspases leads to the subsequent activation of executioner caspases (e.g. caspase-3), 
which ultimately results in apoptosis in Type I Cells. Activation of caspase-8 engages the 
mitochondria-amplified apoptosis machinery in Type II cells [38]. The binding of TRAIL 
to decoy receptors (DcR) 1 and 2 has also been demonstrated; it is hypothesized that 
these receptors play a role in maintaining the homeostasis of TRAIL activity in vivo [20, 
35]. 
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Recombinant TRAIL induces apoptosis in a variety of human cancer cell lines including 
those of breast, colon, lung, prostate, liver, leukemia, lymphoma, and neuroblastoma [20, 
32, 34, 91]. TRAIL has also demonstrated potent anti-tumor activity in a number of 
xenograft models including those of colon and breast carcinomas [40-42]. Soluble 
TRAIL
 
variants are well tolerated in mice and
 
chimpanzees [37] and demonstrate 
minimal cytotoxicity towards primary human hepatocytes and endothelial cells in culture 
[38, 39]. As a consequence of the selectivity towards malignant cells, certain TRAIL 
formulations (e.g. non-histidine tagged TRAIL) are considered safe for potential 
therapeutic applications [43]. 
 
Although TRAIL and agonistic antibodies to death receptors 4 and 5 are promising 
candidates for cancer therapy, many tumor cells are inherently resistant or acquire 
resistance to TRAIL-mediated apoptosis. Commonly implicated resistance mechanisms 
include dysfunction of the Fas-Associated Death Domain (FADD) / improper assembly 
of the Death-Inducing Signaling Complex (DISC) [48], loss of caspase-8 activity [92-94], 
constitutively active Akt/protein kinase B [95], and over-expression of anti-apoptotic 
proteins such as c-Flip [48, 49] and Bcl-2 [50]. As a result, therapeutic strategies 
involving DNA-damaging radiotherapy [96, 97], genotoxins [76] [98], and peptides [99]  
have been investigated for enhancing cancer cell sensitivity to TRAIL [76] and / or 
agonistic antibodies against DR4/DR5 [100]. 
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This chapter describes the parallel screening of fifty-five FDA-approved and foreign-
approved chemotherapeutic drugs used to identify existing anti-cancer drugs that might 
act as TRAIL sensitizers in resistant prostate, pancreatic, and breast cancer cells. Drugs 
were first pre-screened individually (single agent treatment) for toxicity at a 
concentration of 20 M using TRAIL-resistant PC3-TR prostate cancer cells; candidates 
that resulted in greater than 70% reduction in cancer cell viability were screened for 
TRAIL sensitization activity at a lower concentration of 10 M. A total of fourteen 
potential TRAIL sensitizer leads, including six whose TRAIL sensitization activities 
were previously unknown, were identified from the screen. Five leads were further 
characterized in prostate, pancreatic, and breast cancer cells.  
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METHODS 
Cell Culture Techniques 
Three human prostate cancer cell lines (PC3, PC3-TR, and 22RV1), three human 
pancreatic cancer lines (Panc-1, MIAPaCa2, and BXPC-3), two human breast cancer 
lines (MDA-MB-231, and MDA-MB-453) and one immortalized human pancreatic 
epithelial cell line (HPDE6) were used in the current study. PC3-TR (TR: TRAIL 
resistant) [101] cells were a generous gift from Dr. Aria Olumi at the Massachusetts 
General Hospital in Boston, MA. Cells were grown in 75 cm
2
 Corning cell culture flasks 
with RPMI 1640 tissue culture media supplemented with 10% Fetal Bovine Serum and 
1% penicillin / streptomycin (10000 units/mL penicillin G and 10000 μg/mL 
streptomycin) at 37°C with 5% CO2.  
 
Reagent/Drug Preparation 
The Johns Hopkins Chemical Compound Library (JHCCL) [102] was purchased from 
The Johns Hopkins University School of Medicine. The library contains a total of 1514 
FDA- and foreign-approved drugs. The anti-neoplastic plate (plate #1) consists of 55 
FDA-approved approved anti-cancer drugs and was employed in the screen for 
identifying TRAIL sensitizers. All stock solutions of the drugs from the library were 
supplied at a concentration of 10 mM in either DMSO or water. For expanded dose-
response experiments, additional doxorubicin and mitoxantrone were purchased from 
Sigma while gemcitabine, mithramycin, and thioTEPA were obtained through the 
NCI/NIH Developmental Therapeutic Program. TRAIL was purchased from R&D 
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Systems and reconstituted in PBS at a 10 µg/mL stock concentration in 50 µL aliquots to 
prevent multiple freeze/thaw cycles. All solutions were prepared to ensure that the final 
solvent (DMSO or water) concentration in cell treatments would be less than 1% (v/v) to 
limit non-specific activity.   
 
Single Agent and Combination Treatments 
Cells were plated in 96 well plates at a density of either 8,400 cells/well (prostate and 
pancreatic lines) or 20,000 cells/well (breast cancer lines) and incubated at 37°C and 5% 
CO2 for approximately 24 hours. For single-agent treatments, cells were exposed to drug 
candidates at a concentration of 20 M for 24 hours at which point, cell viability was 
determined using the MTT (3-(4,5-dimethylthiazolyl-2) -2,5-diphenyltetrazolium 
bromide) assay. Single-agent TRAIL treatments were carried out similarly; a dose range 
of 0-100 ng/mL of TRAIL was used. For sequential combination treatments, cells were 
first treated with a sensitizer drug candidate for 24 hours. The media was then removed, 
replaced with fresh serum-containing media, and the cells were treated with TRAIL. 
Cells were incubated for an additional 24 h after which, viability measurements were 
carried out using the MTT assay. In order to determine if dosing of the combination 
treatment had an effect on the efficacy, simultaneous combination treatments were 
carried out by treating cells with the sensitizer drug and TRAIL at the same time for 24 h 
at which point, cancer cell viability was determined using the MTT assay. 
21 
 
Determination of Cell Viability 
Cell viability was assessed using the MTT cell proliferation assay (ATCC CA#30-
1010k). Following addition of the MTT reagent (2 h at 37
o
C), cells were treated with a 
lysis buffer from the kit and kept at room temperature in the dark for two hours in order 
to carry out complete lysis and to solubilize the MTT product. The absorbance of each 
well was measured using a Biotech Synergy 2 Multi-Detection Microplate Reader at 570 
nm. Each experiment included a set of blank wells (media only), a live control (no 
treatment) and a dead control (200 µL of 10 µM H2O2 or 1.5 µL of 20 µM Quillaja were 
employed for inducing death in the cell population). Background absorbance was 
measured using the blank and subtracted from all absorbance measurements. In the case 
of drugs that potentially interfered with the assay, a separate set of media-only wells were 
treated with equivalent volumes of the drug, and the measured absorbance was subtracted 
as the background. This was carried out to eliminate any bias caused by the natural 
absorbance of the drug itself.  Fractional cell viability was calculated as:  (OD of sample 
– OD of dead control)/(OD of live control – OD of dead control) where OD is the optical 
density. Percentage cell viability was calculated by multiplying the fractional viability by 
100. Data are plotted as percentage reduction in cell viability compared to control 
(untreated cells) in which, a 0% value on the graph means 100% viability and 100% 
value on the graph means 0% viability. 
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Statistical Analyses 
Screening experiments were carried out in duplicate and expanded dose responses with 
identified leads were performed at least in triplicate. Data are presented as the mean  
one standard deviation. The standard deviation of each set was calculated based on the 
variation between experiments. ANOVA was performed using the t-test function in 
Microsoft Excel.  Analysis of the single-agent treatment was performed in order to 
determine whether or not a drug had a significant effect when compared to the live 
(untreated) control. Efficacies of sensitization were determined by comparing the 
decrease in cell viability following combination treatments (i.e. drug in combination with 
TRAIL) to the reduction in cell viability as a consequence of the additive effect of single-
agent treatments (drug alone + 10 ng/mL TRAIL alone). 
 
Live/Dead Analysis 
As an alternate assessment of cell viability, a calcein AM /ethidium homodimer-1 
viability/cytotoxicity kit (Invitrogen L3224) was used to measure treatment efficacy for a 
select set of combination treatments. Briefly, a working solution of 2 μM calcien AM and 
4 μM ethidium homodimer-1 (EthD-1) was prepared in a solution of sterile 1X PBS.  The 
working solution was then added to each well of the cell culture plate and incubated at 
37°C with 5% CO2 for 30-45 minutes. Fluorescence imaging was then carried out using a 
Zeiss Observer D1 fluorescent microscope.  A 38 HE filter set (Excitation: 470/40; 
Emission: 525/50) was used to image the fluorescence of the calcein AM (green 
fluorescence) while a 43 HE filter set (Excitation: 550/25; Emission: 605/70) was used to 
measure the fluorescence of the EthD-1 (red fluorescence). 
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Annexin V and Propidium Iodide Analysis 
An annexin V / propidium iodide assay (Invitrogen L3224) was carried out to determine 
if combination treatments induced apoptosis in cells. Briefly, a working solution of 2% 
annexin V and 1 μg/mL propidium iodide (PI) was prepared in a solution of 1X annexin 
binding buffer.  The working solution was added to each well of the cell culture plate and 
incubated at room temperature for 15-20 minutes.  Fluorescence imaging was then 
performed using a Zeiss Observer D1 fluorescent microscope.  A 38 HE filter set 
(Excitation: 470/40; Emission: 525/50) was used to measure the fluorescence of the 
annexin V (green fluorescence) while a 43 HE filter set (Excitation: 550/25; Emission: 
605/70) was used to measure the fluorescence of the propidium iodide (red fluorescence). 
 
Image Analysis 
All image processing was performed using ImageJ [103] image processing software.  For 
the live/dead analysis the threshold of the fluorescent image was adjusted so that any 
background noise was removed and that the boundary between individual cells was well 
defined.  The image was then converted to a binary format.  In some cases, it was 
difficult to differentiate between cell boundaries in which case the Watershed process 
was used to distinguish between individual cells while ensuring that any cells that were 
incorrectly divided were accounted for [104].  The "Analyze Particles" function was then 
used to obtain a final cell count. The live cell count was then normalized against the live 
control cell count to give an indication of the cell viability. The brightness of the images 
was adjusted so that the background had zero pixel intensity value in case of annexin 
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V/PI analyses.  Next, false color was applied to the image; green was applied for the 
annexin V stains and red was applied to the PI stains. 
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RESULTS AND DISCUSSION 
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Figure 2.1  Dose response for TRAIL as a single agent treatment in the PC3-TR cell line.  
Cells were incubated with TRAIL for a 24-hour period followed by analysis with MTT.  
TRAIL at 10 ng/mL concentration causes a 4.3% (+/- 3.2%) increase in viability 
reduction compared to the live control. 
 
In the current study, we screened a small library of fifty-five FDA- and foreign-approved 
antineoplastic drugs from the Johns Hopkins Clinical Compound Library (JHCCL) in 
order to identify chemotherapeutics that sensitize prostate, pancreatic and breast cancer 
cells to TRAIL-induced apoptosis. Identification of FDA-approved drugs as TRAIL 
sensitizers is an attractive discovery strategy since it is possible to rapidly translate these 
novel combinations to the clinic. PC3-TR (TR: TRAIL resistant) human prostate cancer 
cells were used in the primary screening, since it was hypothesized that lead candidates 
discovered for this resistant cell line might be relevant to clinical phenotypes that develop 
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resistance to TRAIL. The cell line demonstrated low susceptibility to single-agent TRAIL 
treatments; a 20% loss of viability reduction was observed in PC3-TR cells at 
concentrations as high as 100 ng/mL (Figure 2.1). We employed a TRAIL concentration 
of 10 ng/mL in subsequent combination treatment experiments in order to keep the 
TRAIL dose at a minimum; under these conditions, single-agent TRAIL induced a loss of 
viability in approximately 4% of the PC3-TR cell population. 
 
Figure 2.2  Flow chart outlining the screening process of the 55 drugs tested. 
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Figure 2.3  Single-agent drug toxicity pre-screen (20 µM) with PC3-TR cell line.  Drugs 
found to induce a decrease in cell viability greater than 30% were retested at an alternate 
drug concentration of 10 µM (drugs circled).  Drugs were incubated with the cells for a 
24-hour period after which an MTT analysis was performed. 
 
Identification of FDA-Approved Drugs as TRAIL Sensitizers in Prostate, 
Pancreatic, and Breast Cancer Cell Lines using Parallel Screening.  The overall 
screening schematic is shown in Figure 2.2. PC3-TR cells were initially treated with 20 
µM of each drug in order to carry out an initial screen for drug toxicity. Eleven drugs 
(arsenic, daunorubicin, doxorubicin, epirubicin, fludarabine, idarubicin, irinotecan, 
docetaxel, mithramycin, gold, mitoxantrone) resulted in > 30% loss in PC3-TR cell 
viability at 20 µM in the initial toxicity screen (Figure 2.3) and were screened for their 
TRAIL sensitization activities at a lower concentration of 10 µM (Figure 2.4).  Use of 
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lower drug concentrations (10 μM) limits the single agent toxicity, which can also allow 
for identification of synergistic interactions with TRAIL. Forty-four drugs from the 
library demonstrated cell viabilities higher than 70% at a concentration of 20 µM and 
were screened for their ability to sensitize PC3-TR cells to TRAIL under these conditions 
(Figure 2.5). 
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Figure 2.4  Parallel screening of drugs from the Johns Hopkins Chemical Compound 
Library as TRAIL sensitizers.  PC3-TR human prostate cancer cells were first incubated 
with drug treatments (10 μM) for 24 hours after which time the media was removed, 
refreshed and cells were treated with TRAIL (10 ng/mL) for an additional 24 hrs. 
 
Combination treatments with sensitizer drugs (24h) followed by TRAIL (24h) were 
carried out in a sequential treatment format to identify candidates that sensitized PC3-TR 
cells to TRAIL-induced apoptosis. Combination treatments that induced statistically 
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significant (p < 0.05) reduction in the viability of PC3-TR cells, compared to the sum of 
the individual treatments (i.e. additive effects of TRAIL alone + chemosensitizer drug 
alone), were identified as leads. Nine drugs, daunorubicn, doxorubicin, fludarabine, 
idarubicin, irinotecan, docetaxel, mithramycin, mitoxantrone and epirubicin, were 
identified as lead sensitizers of TRAIL induced apoptosis from the 10 µM screen (Figure 
2.4). Of these, seven have been previously identified as TRAIL sensitizers for different 
malignancies, but only five have been reported for prostate cancer (Table 2.1) [56, 57, 
105-107]. 
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Figure 2.5  PC3-TR cells were first incubated with drug treatments (20 μM) for 24 hours 
after which time the media was removed, refreshed and cells were treated with TRAIL 
(10 ng/mL) for an additional 24 hrs. 
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To our knowledge, two drugs, idarubicin and mitoxantrone, have not been previously 
described as TRAIL sensitizers for any cancer cell type and are therefore new candidates 
that can be used in combination with TRAIL. The screen with 20 µM drug concentration 
identified the following drugs as TRAIL sensitizer leads:  cladribine, cytarabine, 
gemcitabine, thioguanine and thioTEPA (Figure 2.5). Of these drugs, gemcitabine has 
been previously shown as a TRAIL sensitizer in different malignant cells, including 
prostate and pancreatic cancers [98]. Taken together, the two screens led to the 
identification of fourteen chemotherapeutic drug leads that sensitize PC3-TR prostate 
cancer cells to TRAIL-induced apoptosis; other candidates that demonstrated moderate 
efficacies (for example, toremifene, lomustine, temozolomide, aminoglutethimide, and 
letrozole) were also identified but not pursued further due to the presence of more 
promising leads. These results indicate that the screen accurately identified both, existing 
as well as new TRAIL sensitizers from the drug library. A summary of effective TRAIL 
sensitizers from the screen, along with their corresponding efficacies for reducing cancer 
cell viability, is provided in Table 2.1. 
 
From the TRAIL chemosensitizer leads identified above, five drugs - doxorubicin, 
gemcitabine, mithramycin, mitoxantrone, and thioTEPA were chosen for additional 
evaluation. These drugs have been approved by the FDA for chemotherapeutic 
administration in different malignancies. Doxorubicin and gemcitabine were selected 
since both have been previously characterized as TRAIL-sensitizing agents in prostate 
and / or pancreatic cancer cells [49, 65, 108-110].  Mithramycin has also been shown to 
sensitize prostate cancer cells to TRAIL [107] but to our knowledge, the drug has not 
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been previously demonstrated to possess TRAIL sensitization activity in pancreatic 
cancer cells. Neither mitoxantrone nor thioTEPA has previously been shown to act as 
TRAIL sensitizers in cancer cells to the best of our knowledge. Additional factors that 
were used to determine candidates for subsequent characterization included single-agent 
drug toxicities in the PC3-TR cell line (drugs with lower toxicities were given 
preference), the total loss of cancer cell viability induced by the combination treatment 
compared to the single agent treatments, and prior knowledge of the drugs as TRAIL 
sensitizers.  
 
Table 2.1  Summary of drugs identified as TRAIL sensitizing agents and their previously 
known activity. 
 
10 μM 
Drug Name 
Drug 
Alone 
Drug 
Alone + 
TRAIL 
Alone 
(Additive) 
Combination 
Treatment 
p-
Value 
Known 
TRAIL 
Sensitizer? 
Known 
TRAIL 
Sensitizer 
in Prostate 
Cancer? 
Known 
TRAIL 
Sensitizer in 
Pancreatic 
Cancer? 
Daunorubicin 47 51.3 95.6 < 0.01 Yes No No 
Docetaxel 31.2 35.5 72.7 < 0.01 Yes Yes No 
Doxorubicin 39 43.3 90.8 < 0.01 Yes Yes Yes 
Epirubicin 34.7 39 58.7 < 0.05 Yes Yes No 
Fludarabine 58.6 62.9 86.2 < 0.05 Yes No No 
Idarubicin 53.3 57.6 97.7 < 0.01 No No No 
Irinotecan 30.6 34.9 65.4 < 0.01 Yes Yes No 
Mithramycin 28.6 32.9 95 < 0.01 Yes Yes No 
Mitoxantrone 52.2 56.5 97.7 < 0.01 No No No 
 
20 μM 
Cladribine 0 4.1 38.5 < 0.05 No No No 
Cytarabine 7.9 12.2 32.9 < 0.05 No No No 
Gemcitabine 28.4 32.7 70.5 < 0.01 Yes Yes Yes 
Thioguanine 4.7 9 40.8 < 0.05 No No No 
Thiotepa 6.2 10.5 47.2 < 0.01 No No No 
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Additional evaluation involved expanding the range of the drug dose from 0 to 20 µM for 
doxorubicin and 0 to 100 µM for the other drugs in PC3-TR and PC3 human prostate 
cancer cells, and the Panc-1 human pancreatic cell cancer line. It is important to note that 
the screening experiments employed drugs from the JHCCL (frozen 10 mM aliquots), 
while the lead characterization experiments employed drugs obtained from Sigma 
(doxorubicin, mitoxantrone) and the NCI/NIH Developmental Therapeutic Program 
(gemcitabine, mithramycin, thioTEPA) which were reconstituted in either DMSO or  
water, based on the solvent that was used for the respective drugs supplied in the JHCCL.  
 
Combination treatments were carried out with 10 ng/mL TRAIL, which induced a loss of 
viability of 4.3% (+/- 3.2%) in PC3-TR cells, 8.4% (+/- 4.2%) in PC3 cells, and 1.4% (+/- 
7.4%) in Panc-1 cells, when administered alone. Such low levels of viability loss are 
demonstrative of the resistance of these cancer cells to TRAIL-induced apoptosis. It is 
important to note that while PC3-TR cells are derived from PC3 cells, the two lines are 
inherently different and therefore, it can be expected that the two cell lines respond 
differently to drug treatments. For example, we have previously shown that closely 
related prostate cancer cell lines, PC3 and PC3-PSMA cells, demonstrate markedly 
different behavior in response to nanoparticle treatment [111].  
 
The expanded dose range of the lead candidates in the PC3-TR cell line showed trends 
similar to those seen in the primary screen; all lead candidates induced significant losses 
in cancer cell viability when used in combination with TRAIL (Figures 2.6-2.10). 
Doxorubicin, mithramycin, and mitoxantrone demonstrated synergistic efficacies in 
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combination with TRAIL in PC3 and Panc-1 cells (Figures 2.6-2.8). Conversely, neither 
gemcitabine nor thioTEPA demonstrated significant synergy in these cells (Figures 2.9 
& 2.10). 
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Figure 2.6  Dose response for doxorubicin in malignant cell lines. (a) PC3-TR, (b) PC3 
human prostate cancer cells, and (c) Panc-1 pancreatic cancer cells.  Single-agent 
treatments are shown as "dark grey diamonds" and combination treatments with 10 
ng/mL of TRAIL are shown as "light grey squares". Comparisons were made between the 
single agent and combination treatments; asterisks (*) and (**) indicate p-values < 0.05 
and < 0.01, respectively. (d) molecular structure of doxorubicin. Arrows indicate the 
concentrations at which the enhancement in viability reduction is the greatest. Data are 
presented on a logarithmic scale for x-axes in the plots.  Lines connecting data points are 
for visualization only. 
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The median concentrations of single-agent doxorubicin (Figure 2.6) that resulted in 50% 
loss of viability in the cancer cell population compared to the untreated control (LC50) 
were approximately 0.6 µM, 6 µM and 0.6 µM in PC3-TR, PC3, and Panc-1 cells, 
respectively. However, in combination with 10 ng/mL TRAIL, the LC50 values for 
doxorubicin were 0.25 µM for PC3-TR and PC3 cells, and 0.1 µM (100 nM) for Panc-1 
cells, all of which are substantially lower than the single-agent concentrations (Figure 
2.6). The greatest loss of cancer cell viability for the doxorubicin-TRAIL combination 
treatment compared to single-agent doxorubicin treatment was observed at 0.33 µM 
(42%), 1 µM (44.4%), and 0.33 µM (55%) for PC3-TR, PC3, and Panc-1 cells, 
respectively (Figure 2.6). The cytotoxic effect of doxorubicin is attributed to its DNA 
intercalation as well as its disruption of cellular functions upon cell membrane binding. 
Intercalation inhibits nucleotide replication via the stabilization of type II topoisomerase 
[112]. Doxorubicin is currently approved for the treatment of acute lymphoblastic 
leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and 
bone sarcomas, breast cancer, ovarian cancer, transitional cell bladder cancer, thyroid 
cancer, gastric cancer, Hodgkin’s disease, malignant lymphoma, bronchogenic cancer, 
ovarian cancer, AIDS-Related Kaposi’s sarcoma, and multiple myeloma. The TRAIL 
sensitization activities of doxorubicin are due to the ability of the drug to down-regulate 
the anti-apoptotic protein c-FLIP [108, 113], activate pro-apoptotic caspases [114, 115] 
and induce reactive oxygen species (ROS) formation in cancer cells [116].  Thus, the 
genotoxic activity of doxorubicin activates the internal apoptosis pathway, while 
simultaneously sensitizing the cell to external, receptor-mediated apoptosis by the TRAIL 
ligand. 
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Figure 2.7  Dose response for mithramycin (plicamycin) in malignant cell lines.  (a) 
PC3-TR, (b) PC3 human prostate cancer cells, and (c) Panc-1 pancreatic cancer cells.  
Single-agent treatments are shown as "dark grey diamonds" and combination treatments 
with 10 ng/mL of TRAIL are shown as "light grey squares". Comparisons were made 
between the single agent and combination treatments; asterisks (*) and (**) indicate p-
values < 0.05 and < 0.01, respectively. (d) molecular structure of mithramycin. Arrows 
indicate the concentrations at which the enhancement in viability reduction is the 
greatest. Data are presented on a logarithmic scale for x-axes in the plots.  Lines 
connecting data points are for visualization only. 
 
The LC50 values for single-agent mithramycin were 20 µM, 0.5 µM and 6 µM for PC3-
TR, PC3, and Panc-1 respectively. However, in combination with 10 ng/mL TRAIL, the 
LC50 values for mithramycin were approximately 0.2 µM for PC3-TR and PC3 cells, and 
0.1 µM for Panc-1 cells, respectively (Figure 2.7). Combination treatments with 
36 
mithramycin (plicamycin) demonstrated the greatest enhancement in loss of cancer cell 
viability at 6.6 µM (50.5%), 0.66 µM (24.9%) and 0.33 µM (48.6%) in PC3-TR, PC3, 
and Panc-1 cells respectively, compared to single-agent mithramycin treatment (Figure 
2.7). Importantly, mithramycin demonstrated one of the highest efficacies in combination 
with TRAIL; a difference of 67% in loss of cancer cell viability was seen for the 
combination treatment compared to the additive effect of the single-agent treatments 
(67% increase; Figure 2.4). Mithramycin is an antineoplastic antibiotic derived from 
Streptomyces and is approved by the FDA for the treatment of testicular cancer and 
hypercalcaemia [117]. The antineoplastic properties of mithramycin are likely linked to 
the binding of mithramycin to GC-rich section of DNA and the subsequent inhibition of 
RNA synthesis and regulation of transcription [118]. The TRAIL-sensitization activity of 
mithramycin is not very well characterized, but one study suggests that this activity is 
caused by the down regulation of X-linked Inhibitor of Apoptosis Protein (XIAP) [107]. 
XIAP inhibits apoptosis by binding to and inhibiting caspases 3, 7 and 9.  Mithramycin is 
able to prevent the transcription of XIAP through its binding activity to DNA [107, 117].  
This action would sensitize cancer cells to both, intrinsic and extrinsic apoptosis 
pathways. However, the extent to which mithramycin activated the intrinsic pathway has 
not been elucidated. 
 
LC50 values for single-agent mitoxantrone were approximately 10 µM for PC3-TR and 
PC3 cells, and 5 µM for Panc-1 cells.  However, in combination with 10 ng/mL TRAIL, 
the LC50 values for mitoxantrone were significantly reduced to 0.6 µM, 0.1 µM and 1 µM 
for PC3-TR, PC3 and Panc-1 cells, respectively (Figure 2.8). In the case of  
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Figure 2.8  Dose response for mitoxantrone in malignant cell lines.  (a) PC3-TR, (b) PC3 
human prostate cancer cells, and (c) Panc-1 pancreatic cancer cells.  Single-agent 
treatments are shown as "dark grey diamonds" and combination treatments with 10 
ng/mL of TRAIL are shown as "light grey squares". Comparisons were made between the 
single agent and combination treatments; asterisks (*) and (**) indicate p-values < 0.05 
and < 0.01, respectively. (d) molecular structure of mitoxantrone. Arrows indicate the 
concentrations at which the enhancement in viability reduction is the greatest. Data are 
presented on a logarithmic scale for x-axes in the plots.  Lines connecting data points are 
for visualization only. 
 
mitoxantrone-TRAIL combination treatment, the greatest enhancement in loss of viability 
was observed at 6.6 µM (55.0%) in PC3-TR, 0.33 µM (60.8%) in PC3, and 6.6 µM 
(38.5%) in Panc-1 cells (Figure 2.8), compared to mitoxantrone alone. The 
chemotherapeutic activity of mitoxantrone is attributed to its ability to intercalate into 
DNA, resulting in cross-links and strand breaks. Additionally, mitoxantrone also 
38 
interferes with RNA synthesis and inhibits topoisomerase II [119].  Mitoxantrone has 
been approved by the FDA for palliative treatment of prostate cancer and curative 
treatment of acute nonlymphocytic leukemia; the drug has also been recently approved 
for the treatment of multiple sclerosis. Although we did not find reports that describe the 
use of mitoxantrone as a TRAIL sensitizer, mitoxantrone has been demonstrated to 
possess synergistic relationship with Tumor Necrosis Factor (TNF) for inducing 
apoptosis in cells [120, 121]. A detailed evaluation that describes the mechanisms behind 
the TRAIL-sensitization activity of mitoxantrone is currently under investigation in our 
laboratory. 
 
In the case of gemcitabine, statistically significant enhancement of viability reduction 
occurred in PC3-TR at concentrations above 6.6 µM (Figure 2.9).  Further increase in 
concentration to 100 µM resulted in an enhancement of cell viability loss up to a maximal 
value of 29% for the combination treatment over the single drug treatment. Gemcitabine 
is currently approved for the treatment of ovarian cancer (with carboplatin), breast cancer 
(with paclitaxel), non-small cell lung cancer (with cisplatin), and pancreatic cancer. 
Gemcitabine is metabolized intercellularly to active diphosphate and triphosphate 
nucleosides which work via two mechanisms to inhibit DNA synthesis.  First, 
gemcitabine diphosphate inhibits the enzyme ribonucleotide reductase, which is a catalyst 
of reactions to form deoxynecleoside triphosphates. Second, gemcitabine triphosphate 
competes with other deoxynecleoside triphosphates for incorporation into DNA, which is 
enhanced by the action of gemcitabine diphosphate. Although the TRAIL sensitization 
activity of gemcitabine is not fully understood, it is hypothesized that the response is  
39 
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Figure 2.9  Dose response for gemcitabine in malignant cell lines.  (a) PC3-TR, (b) PC3 
human prostate cancer cells, and (c) Panc-1 pancreatic cancer cells.  Single-agent 
treatments are shown as "dark grey diamonds" and combination treatments with 10 
ng/mL of TRAIL are shown as "light grey squares". Comparisons were made between the 
single agent and combination treatments; asterisks (*) and (**) indicate p-values < 0.05 
and < 0.01, respectively. (d) molecular structure of gemcitabine. Arrows indicate the 
concentrations at which the enhancement in viability reduction is the greatest.  Data are 
presented on a logarithmic scale for x-axes in the plots.  Lines connecting data points are 
for visualization only. 
 
related to the activation of pro-apoptotic caspases [65, 98]. Previous results have shown 
that the combination treatment of gemcitabine and TRAIL increases the activation of 
caspases 8 and 3, while a single agent treatment of gemcitabine increases the activation 
of only caspase 3 [65]. Although synergy was observed in PC3-TR cells with 
gemcitabine, we did not see synergy between gemcitabine and TRAIL in PC3 and Panc-1 
40 
cells, which differs from other reports in the literature [65, 98]. This is likely due to 
differences in the concentrations of both drug and TRAIL conditions that were employed 
in these other studies; for example, other studies have employed 100 ng/mL TRAIL, 
which is ten-fold higher than the concentration used in our study [65, 98]. 
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Figure 2.10  Dose response for thioTEPA in malignant cell lines.  (a) PC3-TR, (b) PC3 
human prostate cancer cells, and (c) Panc-1 pancreatic cancer cells.  Single-agent 
treatments are shown as "dark grey diamonds" and combination treatments with 10 
ng/mL of TRAIL are shown as "light grey squares". Comparisons were made between the 
single agent and combination treatments; asterisks (*) and (**) indicate p-values < 0.05 
and < 0.01, respectively. (d) molecular structure of thioTEPA.  Data are presented on a 
logarithmic scale for x-axes in the plots.  Lines connecting data points are for 
visualization only. 
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ThioTEPA has been approved by the FDA for the treatment of breast cancer, ovarian 
cancer, superficial papillary carcinoma of urinary bladder, lymphosarcoma, and 
Hodgkin’s disease.  ThioTEPA is a radiomimetic drug that can produce ethylenimine 
radicals, which disrupt DNA. ThioTEPA showed a 40% difference in viability reduction 
between the combination treatments and the additive effect of the single agent treatments 
in the initial screen with PC3-TR; however, only an 8% increase was observed in case of 
the combination treatment compared to individual treatments in the subsequent 
experiments (Figure 2.5 & 2.10).  This might be due to the different sources of the drug 
employed in the screening and characterization experiments. 
 
In order to confirm the above results obtained using the MTT assay, a secondary analysis 
method using Live/Dead
®
 fluorescence staining was employed to count living cell 
populations following single-agent mitoxantrone/mithramycin treatments as well as 
TRAIL-based combination treatments in the PC3-TR cell line. Image analysis showed 
that single-agent TRAIL caused a 6% (+/- 4%) decrease in cell viability (not shown). 
Figure 2.11 compares cell viability calculated using the MTT assay to the normalized 
live cell count. The greatest deviation between the MTT and live/dead analysis occurs in 
the combination mitoxantrone and TRAIL experiments.  Deviation is greatest at lower 
concentrations of mitoxantrone but diminishes as the concentration increases. The 
average difference between cell viability data for single-agent mitoxantrone is 12.9% 
between the two methods, while the average difference is 15% for the mitoxantrone-
TRAIL combinations. The single-agent and combination treatments with mithramycin 
show excellent agreement between the two cell viability analysis methods. The average 
42 
difference between analysis methods is 10.4% for mithramycin alone and only 5.6% for 
the mithramycin-TRAIL combination treatment. These results indicate that the MTT and 
the live/dead methods are comparable for these systems, which is an indication that the 
MTT assay is a reliable method for screening and rapidly identifying synergistic 
combination treatments. 
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Figure 2.11  Evaluation of secondary analysis in PC3-TR cells.  (a) Single-agent 
mitoxantrone, (b) single-agent mithramycin, (c) combination treatment with mitoxantrone 
and 10 ng/mL TRAIL and (d) combination treatment with mithramycin and 10 ng/mL 
TRAIL. Analysis results performed using the MTT assay are shown as "dark grey 
diamonds" and analysis results performed using the live/dead stain are shown as "light 
grey squares". Data are presented on a logarithmic scale for x-axes in the plots. 
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Figure 2.12  Evaluation of mitoxantrone and mithramycin in additional malignant lines.  
(a) BXPC-3, and (b) MIAPaCa2 human pancreatic cancer cells.  Single-agent treatments 
are shown as "dark grey diamonds" and combination treatments with 10 ng/mL of 
TRAIL are shown as "light grey squares". Comparisons were made between the single 
agent and combination treatments; asterisks (*) and (**) indicate p-values < 0.05 and < 
0.01, respectively. Data are presented on a logarithmic scale for x-axes in the plots.  
Lines connecting data points are for visualization only. 
 
Following the identification of mitoxatrone and mithramycin as potent sensitizers of 
TRAIL-induced apoptosis in cancer cells above, we further evaluated the activities of 
these drugs in two additional human pancreatic cancer cell lines, BXPC-3 and 
MIAPaCa2 (Figure 2.12). Single-agent TRAIL treatments resulted in a loss of viability 
in 14.3% (+/- 9.8%) in BXPC-3, and 9.2% (+/-3.8%) in MIAPaCa2 cells. The LC50 value 
for single-agent mitoxantrone was approximately 4 µM for BXPC-3 and 3 µM for 
44 
MIAPaCa2 cells. In comparison, the LC50 values for the mitoxantrone-TRAIL 
combination treatments were 0.66 µM for BXPC-3 and 0.1 µM for MIAPaCa2 cells. 
Similarly, LC50 values for single-agent mithramycin were 0.3 µM for BXPC-3 and 0.2 
µM for MIAPaCa2 cells. The LC50 values for the mithramycin-TRAIL combination 
treatments were less than 0.1 µM (100 nM) for both, BXPC-3 and MIAPaCa2 cells. 
 
In BXPC-3 cells, the largest difference in loss of viability induced by the drug-TRAIL 
combination compared to single-agent drug treatment were observed at 6.6 µM (18.5%) 
and 0.33 µM (42.0%) for mitoxantrone and mithramycin, respectively. In MIAPaCa2 
cells, the largest enhancements in viability reduction following combination treatments 
were observed with mitoxantrone and mithramycin doses of 0.33 µM (37.5%) and 33.3 
µM (28.0%), respectively. In case of mitoxantrone, the TRAIL sensitization activity was 
most effective at lower concentrations of the drug; extensive reduction in cancer cell 
viability was observed with high concentrations of mitoxatrone in these cells. In contrast, 
the response was largely invariant as a function of concentration for mithramycin in these 
cells. These results are similar to those observed with other cancer cell lines (Figure 2.7 
& 2.8). Taken together, the significant reduction in the LC50 values observed in case of 
combination treatments, compared to the additive effects of single-agent treatments of 
chemotherapeutic drugs and TRAIL, further demonstrates the efficacy this approach for 
the ablation of pancreatic cancer cells. 
 
In addition to the two pancreatic cancer cell lines, we also tested the efficacy of 
mitoxantrone and mithramycin in two human breast cancer cell lines, MDA-MB-231 and  
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Figure 2.13  Evaluation of mitoxantrone and mithramycin in additional malignant lines. 
(a) MDA-MB-231, and (b) MDA-MB-453 human breast cancer cells.  Single-agent 
treatments are shown as "dark grey diamonds" and combination treatments with 10 
ng/mL of TRAIL are shown as "light grey squares". Comparisons were made between the 
single agent and combination treatments; asterisks (*) and (**) indicate p-values < 0.05 
and < 0.01, respectively. Data are presented on a logarithmic scale for x-axes in the plots.  
Lines connecting data points are for visualization only. 
 
MDA-MB-453 (Figure 2.13).  Single-agent TRAIL treatments resulted in a loss of 
viability in 8.8% (+/- 5.7%) in MDA-MB-231, and 8.0% (+/-10.0%) in MDA-MD-453 
cells. For single-agent mitoxantrone, the LC50 value was approximately 15 µM for MDA-
MB-231 cells and 25 µM for MDA-MB-453 cells. In comparison, the LC50 values for the 
mitoxantrone-TRAIL combination treatments were approximately 5 µM for both MDA-
MB-231 and MDA-MB-453 cell lines.  Over the concentrations tested (0-100 µM), 
46 
single-agent mithramycin did not cause a reduction in viability of 50% or less which 
suggests that the LC50 value of single mithramycin is greater than 100 µM. The LC50 
values for the mithramycin-TRAIL combination treatments were 0.33 µM for MDA-MB-
231 and 0.2 µM for MDA-MB-453. In MDA-MB-231 cells, the largest difference in loss 
of viability induced by the drug-TRAIL combination compared to single-agent drug 
treatment were observed at 6.6 µM for both mitoxantrone (49.7%) and mithramycin 
(58.3%). In MDA-MB-453 cells, the largest reductions in viability following 
combination treatments were observed with mitoxantrone and mithramycin doses of 13.3 
µM (55.6%) and 100 µM (56.3%), respectively. In the case of mitoxantrone, the TRAIL 
sensitization activity was most effective at moderate to high concentrations of the drug.  
There is a complete loss of viability at the three highest mitoxantrone combination 
treatment conditions (33.3, 66.6, and 100 μM) in MDA-MD-453, but even the high 
concentration combination treatments do not fully reduce cell viability in the MDA-MB-
231 cells. This suggests that the MDA-MB-231 cell line may have some inherent 
resistance to mitoxantrone. In both breast cancer lines we again saw the response to 
mithramycin was largely concentration independent. Although the largest difference in 
viability reduction was at 6.6 µM (58.3%) and 100 µM (56.3%) in MDA-MB-231 and 
MDA-MB-453 respectively, in both cases the viability reduction was between 50% and 
60% for almost all the concentrations investigated.  As was demonstrated in the 
pancreatic cancer cells, there is a significant reduction in the LC50 values observed in the 
combination treatments as compared to the additive effects of single-agent treatments of 
the chemotherapeutic drugs and TRAIL. This provides evidence that the chemotheraputic 
47 
drug/TRAIL combination treatments are additionally effective at treating breast cancer in 
addition to the malignancies previously described. 
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Figure 2.14  Evaluation of mitoxantrone in 22Rv1 prostate cancer cells. Single-agent 
treatments are shown as "dark grey diamonds" and combination treatments with 10 
ng/mL of TRAIL are shown as "light grey squares". Comparisons were made between the 
single agent and combination treatments; asterisks (*) and (**) indicate p-values < 0.05 
and < 0.01, respectively. Data are presented on a logarithmic scale for x-axes in the plots.   
 
In addition to the PC3 and PC3-TR cells tested during the initial screening experiments, 
dose response experiments were also conducted using 22Rv1 prostate cancer cells 
(Figure 2.14).  Single-agent TRAIL treatments resulted in a loss of viability in 4.3% (+/- 
2.3%) in 22Rv1 cells. Single-agent mitoxantrone gave an LC50 value approximately equal 
to 13.3 µM and an LC50 value of 0.5 µM for the mitoxantrone-TRAIL combination 
treatments.  In these cells, the largest difference in loss of viability induced by the 
mitoxantrone-TRAIL combination was 54.8% observed at 6.6 µM.  In case of the 22Rv1 
48 
cells, the TRAIL sensitization activity was highly effective at all concentrations tested 
with the exception of the two highest concentrations (66.6 and 100 μM). Taken together 
these results suggests that the 22Rv1 cell line is also sensitized to TRAIL by 
mitoxantrone treatments. 
 
The Combination Treatment of Low-dose Mitoxantrone and TRAIL is Selective 
towards Malignant Pancreatic Cells Compared to Normal Pancreatic Epithelial 
Cells.  With the exception of gemcitabine and thioTEPA, the largest enhancements in 
viability reduction occurred at sub-micromolar or low micromolar concentrations for the 
other drugs. This is significant since the use of lower concentrations of these genotoxins 
can reduce damage to healthy tissue during therapy. This was demonstrated further by 
comparing single-agent verses the combination treatment LC50 values for each of the 
chemotherapeutic drugs. In the case of doxorubicin, mithramycin and mitoxantrone, the 
LC50 values decreased when each of these drugs was used in combination with TRAIL 
regardless of the cell line.  With doxorubicin, this decrease in the LC50 value was 
relatively small in PC3-TR (0.6 µM to 0.25 µM) and Panc-1 (0.6 µM to 0.1 µM) cells, 
but significant in PC3 cells (6 µM to 0.25 µM). Mithramycin exhibited a relatively small 
change in the LC50 value for PC3 cells (0.5 µM to 0.2 µM), a moderate change for Panc-1 
cells (6 µM to 0.1 µM), and the largest total change for PC3-TR cells (20 µM to 0.2 µM). 
Mitoxantrone demonstrated a moderate decrease in the LC50 value for Panc-1 cells (5 µM 
to 1 µM) and significantly larger decreases in LC50 values for the drug in combination 
with TRAIL in both, PC3-TR (10 µM to 0.6 µM) and PC3 (10 µM to 0.1 µM) cells. 
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Figure 2.15  Evaluation of treatments in non-malignant cell line. Mitoxantrone (a) and 
mithramycin (b) in HPDE6 human pancreatic duct epithelial cells. Single-agent 
treatments are shown as "dark grey diamonds" and combination treatments with 10 
ng/mL of TRAIL are shown as "light grey squares". Data are presented on a logarithmic 
scale for x-axes in the plots.  Lines connecting data points are for visualization only. 
 
The effects of mitoxantrone and mithramycin in the non-malignant HPDE6 [122, 123] 
pancreatic cells were tested in order to determine the selectivity of these two drugs and 
their combination with TRAIL for malignant cells compared to normal cells (Figure 
2.15).  Single-agent TRAIL showed a viability loss of 3.3% (+/- 12.4%) in HDPE6 cells 
compared to untreated cell control, suggesting that TRAIL shows little to no activity in 
these cells. Low concentrations (0.33 and 0.6 μM) of single-agent mitoxantrone also 
exhibited minimal loss in HPDE6 cell viability, while the 20 μM treatment resulted in a 
loss of viability of approximately 50% cells. Single-agent mithramycin treatment, 
however, resulted in a loss of viability in 40%-60% of the cell population even at the 
lower concentrations, which was considerably higher than that observed with 
mitoxantrone (Figure 2.15). A comparison of the single agent treatments and the 
combination treatments for mitoxantrone indicated selectivity of the drug at lower 
concentrations. In HDPE cells, 0.33 and 0.6 μM mitoxantrone in combination with 10 
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ng/mL TRAIL induced a 13.9% (+/- 4.5%) and 19.8% (+/-6.6%) loss of viability 
respectively, while mitoxantrone alone resulted in 19.3% (+/- 9.2%) and 18.4% (4.1%) at 
these doses. Importantly, single-agent mitoxantrone and mitoxantrone + TRAIL induced 
a respective loss of cell viability of 16% and 28.4% in Panc-1 cells, 10.6% and 40% in 
BXPC3 cells, 23.4% and 70% in MIAPaCa2 (0.33 μM mitoxantrone). These conditions 
indicate that the combination of low-dose mitoxantrone with TRAIL is selective towards 
malignant pancreatic cells compared to normal cells. As may be expected, this selectivity 
is lost at higher concentrations of mitoxantrone. We did not observe significant 
selectivity for cancer cells compared to non-malignant cells in case of mithramycin. 
While the results with mitoxantrone are promising due to the observed selectivity, an 
effective chemotherapeutic window of operation may be available for the mithramycin-
TRAIL combination in vivo. 
 
Higher Concentrations of TRAIL in Combination Treatments do not Demonstrate 
Increased Efficacies.  The previous studies were carried out with different 
concentrations of the chemosensitizer drug followed by a single dose of TRAIL (Figure 
2.1).  Following identification of mitoxantrone and mithramycin as potential TRAIL 
sensitizers, we investigated the effect of different TRAIL concentrations in combination 
with a single dose of these sensitizer drugs. LC50 values for mitoxantrone-TRAIL and 
mithramycin-TRAIL combination treatments were 0.6 and 0.2 μM, respectively, for PC3-
TR cells. The single-agent 0.6 μM mitoxantrone treatment, resulted in a loss of viability 
of 31.4% (+/- 2.0%) in PC3-TR cells compared to the untreated control (Figure 2.16), 
which is in good agreement with the data trend shown in Figure 2.8.  
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Figure 2.16  Dose response of TRAIL with single mitoxantrone and mithramycin 
concentrations in PC3-TR cells. Mitoxantrone treatments are shown as "dark grey 
diamonds" and mithramycin treatments are shown as "light grey squares".  Comparisons 
were made between the single agent and combination treatments; asterisks (*) and (**) 
indicate p-values < 0.05 and < 0.01, respectively. Data are presented on a logarithmic 
scale for x-axis in the plot.  Lines connecting data points are for visualization only. 
 
The single agent treatment of 0.2 μM mithramycin resulted in a loss of viability of 18.9% 
(+/- 2.1%) of cells compared to untreated cells (Figure 2.16), which is also in good 
agreement with data shown in Figure 2.7. As expected, the loss of cancer cell viability 
upon treatment with single-agent 0.6 μM mitoxantrone and 0.2 μM mithramycin was less 
than 50%, since these are less efficacious than the combination treatments. These single-
agent concentrations were chosen to investigate the efficacy of different TRAIL doses, 
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which were varied from 0-100 ng/mL (Figure 2.16).  Over the concentration range 
studied for TRAIL, the overall reduction in cell viability between the lowest (0.5 ng/mL) 
and highest (100 ng/mL) TRAIL concentrations increases by only 10% for both drug 
treatments, indicating that lower TRAIL doses (e.g. 10 ng/mL) may possess sufficient 
activity in the current combination treatments. 
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Figure 2.17  Comparison between different treatment methodologies in PC3-TR cells.  
(a) Mitoxantrone (b) and mithramycin in PC3-TR prostate cancer cells.  Single-agent 
treatments are shown as "dark grey diamonds", sequential combination treatments with 
10 ng/mL of TRAIL are shown as "light grey squares" and simultaneous combination 
treatments with 10 ng/mL of TRAIL are shown as "grey triangles". Data are presented on 
a logarithmic scale for x-axis in the plots Lines connecting data points are for 
visualization only. 
 
Sequential vs. Simultaneous Combination Treatments.  In the previous experiments, 
combination treatments were performed in a sequential format by first treating cells with 
a sensitizing drug for 24 hours, removing the drug from the cells, and then applying a 
TRAIL treatment for an additional 24 hours. An alternate combination treatment 
methodology is to apply both the sensitizing drug and TRAIL "simultaneously" in which 
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both, the drug and TRAIL are administered together. In our hands, simultaneous 
treatments with mitoxantrone demonstrated a higher loss of PC3-TR cell viability for low 
concentrations of the drug compared to the sequential treatments (Figure 2.17).  
However, this trend is reversed at higher drug concentrations.  
 
The overall increase in loss of cancer cell viability between the lowest concentration of 
mitoxantrone (0.33 μM) and the highest concentration of mitoxantrone (100 μM) for the 
simultaneous treatments is about 25% (Figure 2.17), compared to 65% for sequential 
treatments.  Interestingly, mithramycin did not show large differences in the loss of cell 
viability between the sequential and the simultaneous combination treatments. The 
difference between the two drugs and their dependence on treatment order is likely most 
closely related to the kinetics of how each drug is processed and how quickly the 
sensitization effect is achieved. In the case of mithramycin it is likely that the kinetics of 
sensitization are rapid and that even when the drugs are co-administered, there is 
sufficient time for the drug to sensitize the cells to TRAIL mediated apoptosis. On the 
other hand, it is possible that the kinetics of sensitization are slower for mitoxantrone and 
that the synergy between mitoxantrone and TRAIL is highest when the drug has 
sufficient time to overcome cellular resistances to TRAIL. We are currently following up 
on these observations in our laboratory. 
 
Mitoxantrone-TRAIL and Mithramycin-TRAIL Combinations induce Apoptosis in 
PC3-TR Cells.  In order to verify the induction of apoptosis, cells were treated with an 
annexin V and propidium iodide (PI) stain following incubation with single-agent and 
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combination drug treatment.  The annexin V/PI stain distinguishes between apoptotic and 
necrotic cells based on fluorescence.  In this assay, live cells will not fluoresce, early 
apoptotic cells fluoresce green, while late apoptotic and necrotic cells can fluoresce either 
red or demonstrate both red and green fluorescence. Images were acquired for single 
agent and combination treatments of mitoxantrone (Figure 2.18) and mithramycin 
(Figure 2.19) in PC3-TR cells.  As expected, the live cell control and the 10 ng/mL 
TRAIL-alone treatment control demonstrated little to no fluorescence. Single agent 
treatment with mitoxantrone (0.33 μM) resulted in both apoptotic and necrotic cell 
populations, although the majority of the cell population consisted of live cells. The 
corresponding mitoxantrone-TRAIL simultaneous combination treatment results in a 
large population of apoptotic and necrotic cells (Figure 2.18), which also demonstrate 
changes in cell.  Mithramycin treatments demonstrated similar trends and showed a clear 
decrease in cell population between single agent and combination treatments.  This 
validates results shown in Figure 2.7.  Overall, these results indicate that TRAIL-based 
combination treatments with mitoxantrone and mithramycin induce apoptosis in PC3-TR 
cells. 
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Figure 2.18  Microscopy images of mitoxantrone treated PC3-TR cells.  Left panels are 
phase contrast images and right panels are fluorescence images visualized with an 
annexin V and propidium iodide stain.  Apoptotic cells exhibit green fluorescence only.  
Dead cells can exhibit either lone red fluorescence or red and green fluorescence 
simultaneously.  Live cells are non-fluorescent. 
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Figure 2.19.  Microscopy images of mithramycin treated PC3-TR cells.  Left panels are 
phase contrast images and right panels are fluorescence images visualized with an 
annexin V and propidium iodide stain.  Apoptotic cells exhibit green fluorescence only.  
Dead cells can exhibit either lone red fluorescence or red and green fluorescence 
simultaneously.  Live cells are non-fluorescent. 
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CONCLUSIONS 
In the current study, fifty-five FDA- and foreign-approved antineoplastic drugs were 
screened in order to identify chemotherapeutic candidates that sensitized malignant 
prostate and pancreatic cells to TRAIL-induced apoptosis. The initial screen was 
performed using a TRAIL resistant prostate cancer cell line (PC3-TR) and several drugs 
were identified as potential sensitizing agents. The screen was able to identify drugs with 
previously unknown TRAIL sensitization activities in prostate as well as pancreatic and 
breast cancer cells, which can lead to the identification of new chemotherapeutic drug 
combinations and therefore potentially increase therapeutic options against these 
malignancies. 
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CHAPTER 3 
DESIGN AND TESTING OF A PROGRAMMABLE HIGH-THROUGHPUT 
MICROFLUIDIC CELL ARRAY FOR COMBINATORIAL DRUG SCREENING 
 
INTRODUCTION 
As described in the previous chapter, using a sensitizing drug in combination with 
TRAIL can lead to an enhancement in the treatment of cancer cells in-vitro. When 
identifying drugs that can potentially sensitize cells to TRAIL-mediated apoptosis it is 
necessary to have screening system that can quickly and accurately identify drug 
candidates that demonstrate the desired effect.  Additionally, the efficacy of 
chemotherapeutic drugs, as well as interaction between different drugs, is dose-dependent 
[124, 125].  The number of experiments that are necessary to identify and optimize lead 
drug candidates is quite large and so it is advantageous to have a system in which the 
experimental space can be covered rapidly.  Traditionally, this need is met through the 
use of high-throughput screening equipment (e.g. high-throughput liquid handling 
systems [126]) but these systems are quite expensive and also still require large quantities 
of experimental material, most notably the drug solutions.  One novel way of overcoming 
these limitations is through the use of high-throughput microfluidic devices [127, 128]. 
 
For the identification and optimization of effective combination treatments, a 
microfluidic platform that allows for the rapid generation of combinatorial concentration 
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gradients is necessary.  It is also necessary that such treatments can be administered to 
cells and the effect of the treatments measured.  Several groups have reported the 
development of microfluidic platforms capable of maintain cell cultures which allow for 
the investigation of cell responses and gene expression profiling [87, 129-131].  
Additionally, other groups have also developed combinatorial mixing systems that accept 
multiple inputs and are able to generate combination gradients based on diffusive mixing 
[132, 133].  This chapter will describe the development and testing of a programmable 
microfluidic cell array that combines on-chip cell culture with on-chip generation of drug 
concentrations for combination drug treatment studies. This microfluidic device has 64 
individual cell culture chambers in which, cells can be cultured and exposed to either 
sequentially or simultaneous combination treatments.  Each of the 64 culture chambers is 
exposed to a different treatment thus creating a matrix of varying treatment conditions. 
Testing of this platform is first demonstrated by sensitizing PC3 prostate cancer cells to 
TRAIL-induced death using both doxorubicin and mitoxantrone which were both 
described in the previous chapter to be TRAIL sensitizing agents.  Additionally, the 
performance of the device will be compared to that of the combinatorial drug treatments 
in a well-plate based experiment. These studies were done in collaboration with Texas 
A&M University.  All experimental data collected using the microfluidic platforms was 
done by our collaborators at Texas A&M and data collected for well-plate based 
comparisons was done by our lab at Arizona State University. 
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METHODS 
Cells Culture and Reagents 
Human prostate cancer PC3 cells were cultured and propagated in RPMI medium with 
10% fetal bovine serum and 1% penicillin/streptomycin (10000 units/mL penicillin, 
10000 μg/μL streptomycin). Doxorubicin was purchased from MP Biomedicals and 
stored at a stock concentration of 3 mM.  TRAIL was purchased from R&D Systems and 
reconstituted in PBS at a 10 µg/mL stock concentration in 50 µL aliquots to prevent 
multiple freeze/thaw cycles.  Mitoxantrone was purchased from Sigma and stored at a 
stock concentration of 10 mM. 
 
Design and Fabrication of Microfluidic Devices  
Microfluidic devices were fabricated at Texas A&M University in the Materials 
Characterization Facility using routine soft lithography methods as previously described 
[134, 135]. The device consists of an upstream concentration generation module 
connected to an array of downstream cell culture chambers (Figure 3.1). The cell culture 
module consists of eight rows of chambers, each containing eight distinct culture 
chambers, for a total of 64 chambers. Access to each row of eight cell culture chambers is 
individually controlled using a valve array through a pneumatic channel allowing a 
specific drug concentration to be delivered to each row.  
 
The microfluidic device consists of two PDMS layers:  1) a fluidic layer containing the 
micro-channels required for generating different concentrations of the drug and the cell 
61 
culture chambers, and 2) a pneumatic layer for controlling fluid access to cell culture 
chambers. The PDMS layer for the fluidic layer was 150 µm thick and was fabricated by 
casting the pre-polymer on a master mold, spinning at 1200 rpm for 1 minute, followed 
by curing the pre-polymer. The pneumatic layer for controlling the micro-chamber was 4 
mm in thickness. The channel height for fluidic channels and cell culture micro-chambers 
was 100 µm, and the height of pneumatic layer for controlling the micro-chamber was 
200 µm. Prior to replicating, the SU-8 mold was treated with tridecafluoro-1,2,2,2-
tetrahydrooctyl-1-trichlorosilane so that PDMS membranes could be peeled from the SU-
8 mold without damaging the membrane or the mold. 
 
Microfluidic devices were assembled by exposing the different PDMS layers and glass 
slides to oxygen plasma (150 mTorr, 100 W, 40 sec) in a reactive ion etcher. Then, the 
fluidic layer membrane was aligned and bonded to the pneumatic layer. In order to enable 
actuation of the PDMS micro-chamber, tubing was connected to the pneumatic layer and 
vacuum was applied when the PDMS structure was bonded to glass to prevent 
irreversible bonding between the PDMS micro-chamber and the glass. Access ports were 
punched into the pneumatic layer prior to bonding to the fluidic layer. Holes for access to 
the fluidic layer were punched prior to bonding to the glass slide. 
 
The valve array consisted of eight independently controllable valve groups, with each 
group containing eight valves that are operated simultaneously. The chamber regions can 
be isolated (or exposed) from fluid by lowering (or raising) a ~ 25 nL volume micro-
chamber using a pneumatic source. The chamber valve system was designed such that the 
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center of the valve is fixed and only the boundary wall moves during operation. This is 
important because it minimizes the volume (~ 8 nL) of liquid lost during operation of the 
valve and alleviates pressure on cells. 
 
Generation of Drug Concentrations in the Microfluidic Array 
Different concentrations of drugs were generated in the array using a diffusive mixer in 
conjunction with a syringe pump and automatic valve synchronization system, depending 
on the specific experiment (Figure 3.1). For experiments involving the sequential 
exposure of cells to two drugs, a stock solution of the first drug (A) and a buffer solution 
were introduced into the inlets of a diffusive mixer to generate eight different drug 
concentrations (“horizontal gradient”). After a stable concentration gradient was attained 
(~60 sec), a valve set that control a row of eight cell culture chambers was opened for 10 
sec and closed, capturing the drug containing solution in the culture chambers. Valves 
that control different rows of cell culture chambers were sequentially operated from row 
#1 to #8.  After 24 hours of exposure to drug A, concentration gradients of the second 
drug (B) were generated by mixing a stock solution of drug B with a buffer solution at a 
specific flow rate to generate a single concentration of drug B. This stream of drug B was 
introduced upstream into both streams entering the diffusive mixer thereby making the 
mixer ineffectual. A single valve set that controls access to a row of eight cell culture 
chambers was opened for 10 sec and closed capturing the single concentration of drug B.  
By applying positive pressure to lower a PDMS barrier, pneumatically controlled 
chambers (i.e., a small area isolated from the surrounding regions) are formed and only 
the specified row of cell culture chambers is exposed to the drug combination. Different 
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concentrations of drug B are generated by changing the flow rate of the buffer and 
thereby diluting drug B to different levels. As a new concentration of drug B is fed into 
the device, a different valve set is operated to capture the new drug dilution.  This process 
is continued until rows #1 through #8 are exposed to treatments. The concentrations of 
doxorubicin generated in the diffusive mixer for this study were 0.0, 0.9, 1.7, 2.6, 3.5, 
4.2, 5.2, and 6.0 µM. The concentrations of mitoxantrone generated were 0.0, 1.4, 2.9, 
4.3, 5.7, 7.1, 8.6, and 10 µM. The concentration range for TRAIL was 0.0, 2.9, 5.7, 8.6, 
11.4, 14.3, 17.1, and 20.0 ng /mL.  In these experiments doxorubicin and mitoxantrone 
individually represent drug A while TRAIL represents drug B. 
 
For experiments where cells were simultaneously exposed to pair-wise combinations of 
two drugs, the diffusive mixer was used along with the syringe pump and automatic valve 
synchronization system (Figure 3.1). In this case, the diffusive mixer was used as 
described above to first generate eight concentrations of the drug A. Next, a single 
concentration of drug B was generated as described above and introduced upstream into 
both inlet streams of the diffusive mixer used for generating the concentration range of 
the first drug A (i.e., into streams containing the stock solution of drug A and its buffer). 
This combined solution (i.e., containing a stock concentration of A and a fixed 
concentration of B) was diluted in the diffusive mixer to generate 8 pair-wise 
concentrations. Since drug B is present at the same concentration in both inlet streams, its 
concentration is the same in all the streams exiting the diffusive mixer whereas drug A 
forms a gradient of eight concentrations. This arrangement generates eight pair-wise 
combinations (i.e., eight concentrations of drug A (A1 to A8), each with a single 
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concentration of drug B, B1) used to expose cells cultured in one row of culture 
chambers to the treatments (Figure 3.1). Valve sets are controlled as described above in 
order to isolate a single row of culture chambers to the pair-wise combination. 
 
Figure 3.1  Microfluidic control and gradient generation.  A) Schematic of the 
microfluidic device, valve control, and syringe pump control systems.  A concentration 
gradient for Drug A is generated using the on-chip diffusive mixer.  The concentration 
gradient for Drug B is controlled using LabView through the manipulation of both the 
syringe pump and valve control systems.  B) Representative images of dye-based 
concentration gradients and the combinatorial treatment methodologies associated with 
each gradient. 
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Different concentrations of drug B are generated by changing the flow rate of the buffer 
and thereby diluting drug B to different levels (B1 through B8). A stream containing a 
second concentration of drug B (e.g. B2) is mixed with eight concentrations of drug A 
(A1 to A8) to generate a second set of eight pair-wise concentrations (A1 +B2, A2 + B2, 
etc) and used to expose a second row of cell culture chambers to a unique pair-wise drug 
combination. As a new pair-wise concentration is generated, a different valve set is 
operated to capture the new treatment.  This process is continued until to generate eight 
different concentrations of drug B (B1 to B8), with each concentration of drug B being 
mixed with eight concentrations of drug A. Thus, this scheme resulted in the generation 
of 64 pair-wise concentrations of drugs A and B. The concentrations of doxorubicin, 
mitoxantrone, and TRAIL used for generating the pair-wise combinations are as given 
above.  
 
Operation of the syringe pumps and the valve array was carried out using a 
programmable LabView (Austin, TX) interface (Figure 3.1A). Each group of valves 
(controlling a single row of eight cell culture chambers) in the valve array was 
individually opened or closed by applying vacuum and compressed air through a single 
port on the pneumatic controller.  Since different valve groups were connected to 
different ports on the pneumatic controller, each valve group could be operated without 
affecting other valve groups.  This facilitated exposing cells in only a specific row to a 
given drug combination. 
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Cell culture in microfluidic devices 
The glass slides (bottom) in all devices were coated with 50 μg/mL collagen I (BD 
Biosciences, San Jose, CA) for 16 h at 4ºC and excess collagen I was removed by rinsing 
with 500 μL of RPMI medium. PC3 cells were seeded in each chamber using the 
LabView controlled syringe pump and pneumatic controller. The pneumatically 
controlled chambers were formed as described above by applying positive pressure to 
lower a PDMS barrier which resulted in a small area being isolated from the surrounding 
regions. When this operation was performed with a cell suspension (~ 5 x 10
6
 cells/mL) 
flowing through the device, cells were trapped in specific locations (i.e., in a single row). 
Cells were captured in each chamber sequentially from bottom to top (row #8 to row #1) 
for ~ 2 sec each at a total flow rate of 2 mL/h (or a flow rate of 0.25 mL/h) to ensure 
uniform cell seeding. Cells that were excluded from the culture chamber were washed 
out. Seeded cells were allowed to attach onto the collagen-coated glass surface and 
proliferate for 24 h. To support growth of PC3 cells, RPMI medium was refreshed in 
each chamber every 3 h using the procedure described above. After 24 h, cells were 
exposed to different drugs either sequentially or simultaneously as described. The growth 
medium in each chamber (containing a specific drug combination treatment) was 
replenished every 3 h for the duration of the experiment. Prior to each round of media 
refreshment, the channels were washed with buffer for 30 sec to remove any residual 
drug in the media present outside the cell culture chambers. The entire set of operations – 
generation of drug combinations, trapping of cells in the culture chambers, and perfusing 
cells with drug-containing medium –was carried out over several days by automatically 
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controlling the opening/closing of valves through the LabView interface without any 
manual intervention.  
 
At the end of drug treatment, cells in each of the drug-treated cell culture chambers were 
stained with calcein AM and green-fluorescent cells were counted. The cell viability after 
treatment was determined as the ratio of number of live cells in each drug-treated 
chamber to the number of live cells in the untreated control. Since dead cells are likely to 
be washed away with the periodic media change, the number of dead cells was not 
enumerated. Thus, this approach provides an indicator of loss of viability of cancer cells 
in the device. 
 
The efficacy of sequential and simultaneous treatments were compared analytically using  
LC50 value analysis.  The LC50 values were approximated by drawing a best fit curve 
between data points on a concentration versus cell viability graph; the LC50 value is the 
concentration at which the curve intersected 50% viability.  
 
Cell experiments in well plates 
Well plates (96 wells/plate) were pretreated with 50 μg/mL of collagen I per well for 12 h 
at 4°C and excess collagen was removed.  Cells were plated at a density of 8,400 
cells/well and incubated at 37°C and 5% CO2 for approximately 24 h. For sequential 
exposure treatments, cells were first treated with a sensitizer drug for 24 h. The media 
was then removed, replaced with fresh serum-containing media, and the cells were 
treated with TRAIL. Cells were incubated for an additional 24 h after which cell viability 
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was assessed using the calcein AM stain as described above.  Simultaneous exposure 
treatments were carried out by treating cells with the sensitizer drug and TRAIL at the 
same time for 24 h at which point, calcein AM was used to determine viability. 
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RESULTS AND DISCUSSION 
Characterization of concentration gradients in the device.  Using colored dyes, two 
types of concentration gradients can be generated in the microfluidic device as shown in 
Figure 3.1B. The most basic concentration gradient is generated by mixing two streams 
in a standard diffusive mixer [136]. This is demonstrated in Figure 3.1B (left panel) 
where yellow and blue color dye solutions (representing the minimum and maximum 
concentrations of a drug) were injected through the two inlets of a diffusive mixer and 
resulted in eight outlet concentrations (“horizontal gradient” of colors between yellow 
and blue) were generated. In this arrangement, each cell in a row of culture chambers has 
a different drug concentration and this pattern is repeated in all the rows. This 
arrangement represents the gradient used in experiments where cells were exposed to the 
first chemotherapeutic agent of a sequential treatment (i.e. exposure to eight 
concentrations of drug A).  
 
The second type of concentration gradient was generated through control of the syringe 
pump and automatic valve synchronization system as described in Methods. This is 
shown in Figure 3.1B (middle panel) where yellow and red streams (representing the 
minimum and maximum concentrations of the second drug) were mixed together to 
generate a “vertical gradient” of colors between yellow and red. In this arrangement, each 
cell in a row of culture chambers has the same drug concentration which varies between 
rows.  This arrangement represents the gradient used in experiments where cells were 
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exposed to the second chemotherapeutic agent of a sequential treatment (i.e. exposure to 
eight concentrations of drug B). 
 
The final concentration gradient was generated by merging the two color gradients 
(vertical direction concentration gradient: yellow to blue; horizontal direction 
concentration gradient: yellow to red) as described in Methods to yield an array of pair-
wise combinations.  This arrangement represents the gradient used in experiments where 
cells were simultaneously exposed to two chemotherapeutic drugs at eight concentrations 
each, for a total of 64 pair-wise concentrations (Figure 3.1B right panel). 
 
The sequence of steps involved in operation of the microfluidic device is shown in 
Figure 3.2. Violet dye was initially flowed through the channels with the cell chambers 
closed so that no violet dye was captured in the cell culture chambers and only present 
outside the cell chamber area (Figure 3.2A). Next, the cell culture chambers were opened 
to trap violet dye as described in Methods (Figure 3.2B) in a manner that emulates cell 
seeding in the device. A concentration gradient between yellow and blue dyes was 
established in the diffusive mixer and the solution was trapped in the cell culture 
chambers by opening the valve that controls a specific set of chambers for 10 sec. This is 
shown in Figure 3.2C where the top three rows have a dye solution trapped inside the 
chambers, and in the fourth row where the violet dye is being replaced with the dye 
solution gradient; the four lower rows still have violet dye in them. 
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Figure 3.2  Representative images of the microfluidic device and its operation visualized 
using colored dyes.  A) A single concentration of violet dye is pumped into both inlets of 
the microfluidic device.  The valve system holds the culture chambers closed isolating the 
chambers from the dye.  B) The top five culture chamber rows are individually opened, 
given time to fill, and closed thereby capturing and isolating the dye.  C) Yellow and blue 
dyes are fed into opposite inlets of the device forming a horizontal gradient.  This 
gradient is then trapped in each of the eight rows of cell culture chambers where the 
fourth row shows an open valve set.  D) "Merging" of horizontal and vertical 
concentration gradients.  A single concentration of pre-diluted orange dye is mixed with 
yellow and blue dyes at both inlets.  One row of culture chambers is opened and the 
gradient mixture is captured.  The inlet concentration of the orange dye is changed and 
the process is repeated until all chamber rows are filled.  Captured treatments remain 
isolated and unaffected by E) flowing orange dye and F) empty channels.  G) Operation 
of the pneumatic valve control system demonstrating chambers before, after, and during 
trapping.  H) A representative chamber with cultured PC3 cells.  
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The “merging” of horizontal and vertical gradients to generate an array of pair-wise 
concentrations was carried out as described below. Red and yellow dyes were mixed at a 
ratio of 7:1 (i.e., mimics generation of a single concentration of drug B) (Figure 3.1A) 
and the resultant orange dye stream was added to the blue and yellow streams upstream 
of the gradient mixer. The color (ranging from violet to orange) was used to replace the 
blue-yellow color solution in a single row of the cell culture chambers as described in 
Methods. This step was repeated with a range of red and yellow dye mixtures until each 
row of culture chambers was filled. Figure 3.2D shows the resultant array of colors 
trapped in the device, with each color representing a single pair-wise concentration of 
two drugs automatically generated using the LabView-controlled system. Next, the entire 
channel was filled with orange dye to mimic the media flowing around the cell culture 
chamber. No mixing between the outside orange solution and the solution trapped inside 
the chambers was observed after 24 h (Figure 3.2E). The color dyes trapped in the 
chamber without any liquid surrounding it is shown in Figure 3.2F. The operation of the 
pneumatically controlled trapping system is demonstrated in Figure 3.2G using color 
dyes. Three sets of chambers are shown: empty chambers prior to trapping of color dye 
solution, chambers during trapping, and chambers after trapping of solution. Before 
trapping, each chamber is empty and liquid flows around the closed chamber without 
entering. This demonstrates the fidelity of the valve system in trapping liquid and 
maintaining it separate from the surrounding liquid. 
 
Most microfluidic systems [129, 137] using a diffusive mixer need continuous perfusion 
of two components to generate and maintain concentration gradients. However, the 
73 
pneumatically-controlled system in our device does not require continuous perfusion for 
keeping cells exposed to concentration gradients. This approach has several advantages. 
First, it minimizes the amount of drug used per experiment, which is significant 
considering that the compound libraries used for screening typically contain limited 
amounts of material and are expensive. Second, cells cultured in the chamber are not 
exposed to significant shear stress continuously as the time required for trapping 
solutions inside the cell culture chamber is only ~10 sec. Therefore, this system would be 
especially advantageous when working with cells (e.g. primary cells) that are sensitive to 
shear stress. Moreover, different concentration gradients (e.g., non-linear or exponential 
concentration gradient) can be easily generated by programming the Labview interface 
which gives the system flexibility in designing drug screening experiments.  
 
Cell culture in the microfluidic device.  The prostate cancer cell line PC3 was used for 
these studies. PC3 cells were captured in the array of cell culture chambers and 
maintained for 24 h (with media refreshed every 3 h) in a 5% CO2 incubator at 37
°
C for 
adaptation to the microfluidic environment prior to drug exposure. PC3 cells proliferated 
in the device and were not adversely affected by the microfluidic environment for 5 days 
(not shown). Figure 3.2H shows a representative cell culture chamber with PC3 cells 
grown for 24 h. 
 
Sequential treatment with TRAIL sensitizer drugs and TRAIL.  The microfluidic cell 
array was used to investigate the effect of the combinatorial treatment of 
chemotherapeutic drugs and TRAIL on the viability of PC3 human prostate cancer cells. 
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PC3 cells were cultured on-chip and exposed sequentially to different concentrations of 
doxorubicin and TRAIL or mitoxantrone and TRAIL. In these treatments, the second 
drug treatment (e.g. TRAIL) is administered after a 24 h treatment of a first drug dose 
(e.g. doxorubicin or mitoxantrone). In order to carry out sequential treatments, PC3 cells 
were first exposed to different concentrations of doxorubicin or mitoxantrone as listed in 
Methods. These concentrations were chosen based on their effect on PC3 cells [138] and 
were chosen such that they spanned both sides of the previously identified optimum 
concentration (3 µM for doxorubicin and 5 µM for mitoxantrone).  
 
Different concentrations of drugs were generated by mixing two streams containing 0 and 
6 µM doxorubicin or 0 and 10 µM mitoxantrone using the diffusive mixer described in 
Figure 3.1. After 24 h exposure to doxorubicin or mitoxantrone, a gradient of 0 – 20 
ng/mL TRAIL was generated and sensitized cells were exposed for an additional 24 h. 
The cell viability after 24 h exposure to TRAIL was determined as described in Methods. 
Figure 3.3 shows representative fluorescent images from the array of cells chambers in a 
single experiment. The data in the insets (Figure 3.3B) show that cells not exposed to 
either doxorubicin or TRAIL have proliferated and are confluent in the cell culture 
chamber (top left). Exposure to 6 µM of either doxorubicin (top right) or 20 ng/mL of 
TRAIL (bottom left) alone demonstrate a small loss of viability whereas cells that were 
exposed sequentially to 6 µM doxorubicin followed by exposure to 20 ng/mL TRAIL 
have very few live cells. Images for only the doxorubicin/TRAIL combination are shown, 
and similar results were obtained with the mitoxantrone/TRAIL combination as well. 
75 
 
Figure 3.3  Representative fluorescent images of Calcein AM stained PC3 cells 
following sequential treatments.  A) Cells were treated with 64 unique treatment 
combinations of doxorubicin (0-6 µM) and TRAIL (0-20 ng/mL).  B) Enlarged images of 
selected treatment conditions including:  No Treatment (top left), 6 µM single-agent 
doxorubicin (top right), 20 ng/mL TRAIL single agent (bottom left), and the combination 
treatment of 6 µM doxorubicin and 20 ng/mL TRAIL (bottom right).  
 
The fraction of live cells in the different cell chambers was determined as described in 
Methods. Figure 3.4A shows that exposure to TRAIL alone without doxorubicin 
sensitization led to a dose-dependent decrease in cell viability, with ~40% decrease in 
viability at the highest concentration tested (20 ng/mL). Doxorubicin by itself also 
induces a loss in PC3 cell viability as seen from a dose-dependent decrease in cell 
viability even in the absence of TRAIL (Figure 3.4A). The effect of sensitization is 
evident from the data on PC3 cell exposure to 2.6 μM of doxorubicin. The cell viability 
decreases from ~ 60% in the absence of TRAIL to ~5% with an increase in the 
concentration of TRAIL. This extent of decrease is smaller at lower and higher 
doxorubicin concentrations, as may be expected. In the former case, the concentration of  
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Figure 3.4  Sequential combination treatments with the microfluidic platform.  Cells 
were culture in the microfluidic device and exposed to A) doxorubicin and B) 
mitoxantrone for 24 hours.  After this period, the initial drug treatments were removed 
and the cells were treated with TRAIL for an additional 24 hours.  Fluorescent 
microscopy was then used to count cells labeled with Calcein AM. 
 
doxorubicin used is not sufficient to fully sensitize cells to TRAIL-mediated cell death 
whereas in the latter case, doxorubicin by itself decreases cell viability (Figure 3.4A). 
Since the objective of combination therapy is to achieve maximum possible decrease in 
cell viability with the lowest concentration of sensitizer or chemotherapeutic molecule, 
sensitizing PC3 cells with ~3 µM doxorubicin followed by exposure to ~14 ng/mL of 
TRAIL is sufficient to reduce cell viability by ~95%. Sensitization with mitoxantrone 
prior to TRAIL exposure was somewhat less effective than doxorubicin, with a maximum 
decrease from ~65% to 20% cell viability when PC3 cells were sensitized with 4.3 M of 
mitoxantrone (Figure 3.4B). This indicates that doxorubicin was a marginally more 
effective sensitizer than mitoxantrone in these in vitro investigations. These results are 
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along the lines of what is anticipated, since different drugs will possess differential 
activities depending on the cancer cell lines investigated [138].  
 
Simultaneous treatment with TRAIL sensitizer drugs and TRAIL.  PC3 cells were 
also simultaneously exposed to 64 pair-wise concentrations of doxorubicin and TRAIL or 
mitoxantrone and TRAIL in the microfluidic device. Pair-wise concentrations were 
generated as described in Methods and as demonstrated in Figure 3.3 with color dyes. 
PC3 cells were exposed to different concentration pairs for 24 h. The media in the cell 
chambers was replenished with fresh media with a specific pair-wise combination of the 
two drugs (doxorubicin or mitoxantrone, along with TRAIL). Figure 3.5A shows that 
PC3 cells exposed simultaneously to pair-wise combinations of doxorubicin and TRAIL 
for 24 h demonstrate a dose-dependent decrease in cell viability. However, the decrease 
in cell viability observed with this treatment was less than that observed with sequential 
exposure to doxorubicin and TRAIL. The decrease in cell viability upon simultaneous 
exposure to 2.6 µM of doxorubicin and 20 ng/mL of TRAIL was only 50% (Figure 
3.5A), compared to the 95% decrease observed with the sequential exposure to the two 
drugs at the same concentrations (Figure 3.4A). Similar results were also observed with 
simultaneous exposure of PC3 cells to mitoxantrone and TRAIL (Figure 3.5B); for 
example, the decrease in cell viability with 4.3 µM of mitoxantrone and 20 ng/mL of 
TRAIL was only ~ 40% as compared to the 80% decrease seen with sequential treatments 
(Figure 3.4B). However, a higher decrease in PC3 cell viability was observed at the 
higher concentrations of both doxorubicin and mitoxantrone although this is undesirable 
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since the goal is to achieve the highest level of cell death while minimizing the overall 
treatment concentrations. 
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Figure 3.5  Simultaneous combination treatments with the microfluidic platform.  Cells 
were culture in the microfluidic device and exposed to A) doxorubicin and B) 
mitoxantrone mixed with TRAIL for a total of 24 hours.  Fluorescent microscopy was 
then used to count cells labeled with Calcein AM. 
 
We performed an LC50 analysis in order to further compare simultaneous and sequential 
treatments in the microfluidic device (Table 3.1).  In this analysis, the dose of 
chemosensitizer drug (either doxorubicin or mitoxantrone) required for inducing death in 
50% of the PC3 cell population was determined for each concentration of TRAIL 
employed. As expected, the LC50 value decreases for both sensitizer drugs as the TRAIL 
concentration increases both for simultaneous and sequential treatments. In all cases, the 
LC50 value of doxorubicin is marginally higher than that of mitoxantrone, although they 
are in the same order of magnitude (low micromolar range). As seen in Table 3.1, LC50 
79 
values for both drugs are lower in the case of sequential treatments compared to 
simultaneous treatments, as discussed previously.  
 
Table 3.1  Summary of LC50 value analysis for microfluidic based treatments. 
  Sequential Treatment Simultaneous Treatment 
TRAIL 
(ng/mL) 
Doxorubicin 
(µM) 
Mitoxantrone 
(µM) 
Doxorubicin 
(µM) 
Mitoxantrone 
(µM) 
0 3.2 5 5.6 11 
2.9 2.5 5 5 8 
5.7 2.2 4.6 4.2 8 
8.6 1.9 3.8 3.8 7.1 
11.4 1.9 3.5 3.8 6.8 
14.3 1.5 3.4 3.4 5.8 
17.1 1.4 3.4 2.8 5.7 
20 0.4 3.5 2.6 5.2 
 
Taken together, these results are consistent with our previous findings in well-plate 
screens, which indicated that sequential treatments of mitoxantrone resulted in higher 
efficacies of TRAIL sensitization compared to those observed with simultaneous 
treatments [138]. It is possible that mitoxantrone needs a long time for sensitization 
activity and that it is necessary to treat cells with the drug for 24 hours, and also with 
TRAIL for an additional 24 h. It is still important to note that the microfludic device can 
be operated in a sequential as well as simultaneous drug treatment format, which makes 
this a powerful platform for screening as well as end-point and transient dosing studies. 
The fact that there are significant differences in drug efficacy depending on how the drug 
combinations are applied shows that both concentration gradients and combination 
80 
methods have to be investigated to test the full potential of drugs. While this significantly 
increasing the number of experiments that needs to be conducted, it further underscores 
the necessity of a high-throughput screening platform such as the presented microfluidic 
array. 
 
The utility of the microfluidic array is clearly evident from the PC3 viability data. While 
a maximum decrease in cell viability can be achieved by simply using high 
concentrations of doxorubicin, mitoxantrone, or TRAIL, this is undesirable as the side 
effects observed with use of high drug concentration often outweigh the benefits. Since 
combination therapy seeks to identify the lowest concentrations where maximum possible 
cancer cell death is achieved, the ability to generate different dose-response curves in a 
high-throughput manner is of significant interest. 
 
Comparison of microfluidic device and well plate cultures.  The results obtained with 
the microfluidic device were compared against those obtained from exposing PC3 cells to 
the different drugs under the two treatment regimes (sequential and simultaneous) in a 
96-well plate. Figure 3.6 and Figure 3.7 show the results of these comparisons with 
doxorubicin and mitoxantrone respectively. In general, the combination treatments in the 
device lead to a smaller losses of PC3 cell viability than those in well plates. While 
sequential treatment efficacies were more comparable between the two formats, the 
differences were more pronounced for simultaneous exposure to a sensitizer drug and 
TRAIL. Similar observations can be made for LC50 values of the two drugs determined in 
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96-well plates and the microfluidic device (Table 3.2). For the two conditions tested, the 
values were in the low micromolar range in the device. 
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Figure 3.6  Comparison between microfludic based results and 96-well plate based 
results for doxorubicin.  Cells were treated with equivalent doses of doxorubicin for two 
concentrations of TRAIL in both A) sequential and B) simultaneous combination 
treatments.   
 
Several factors could possibly contribute to the difference in drug efficacy between the 
two formats. First, the microfluidic device was operated with periodic media 
replenishment every 3 h (i.e. in a fed-batch mode) and removal of waste products 
whereas nutrients were not replenished and waste product levels build up for the duration 
of the experiment in the well plate cultures. Given that these treatments typically occur  
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Figure 3.7  Comparison between microfludic based results and 96-well plate based 
results for mitoxantrone.  Cells were treated with equivalent doses of mitoxantrone for 
two concentrations of TRAIL in both A) sequential and B) simultaneous combination 
treatments. 
 
over a period of 24-48 hours, it is possible that the addition of fresh nutrients and/or 
removal of waste products lead to the lower drug efficacy (or higher cancer cell viability) 
seen in microfluidic devices. Second, the high local concentrations of growth factors 
present in the microchannel environment could also lead to an increase in cell viability as 
compared to the macro-scale well plate cultures [139]. Third, the cell density (number of 
cells per unit area) is different between the two systems (higher in the device compared to 
the well plate system), which can potentially contribute to the higher growth rate and cell 
viability observed in the device.  It is also possible that the absorption of drug molecules  
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Table 3.2  Summary of LC50 value analysis for microfluidic device based and 96-well 
plate based treatments. 
 
LC50 Values (Sequential Treatment) 
  Microfluidic Device 96 Well Plate 
TRAIL 
(ng/mL) 
Doxorubicin 
(µM) 
Mitoxantrone 
(µM) 
Doxorubicin 
(µM) 
Mitoxantrone 
(µM) 
11.4 1.9 3.5 < 0.9 < 1.4 
20 0.4 3.5 NA NA 
     
     
 
LC50 Values (Simultaneous Treatment) 
  Microfluidic Device 96 Well Plate 
TRAIL 
(ng/mL) 
Doxorubicin 
(µM) 
Mitoxantrone 
(µM) 
Doxorubicin 
(µM) 
Mitoxantrone 
(µM) 
11.4 3.8 6.8 < 0.9 0.7 
20 2.6 5.2 NA NA 
 
into PDMS [140] leads to the difference between the two systems. However, this effect is 
likely to be minimal as we perfused collagen through the channels prior to seeding, which 
would reduce absorption of drugs into the PDMS [141]. Secondly, fresh medium 
containing the drug molecule was perfused through the channels every 3 h over the 
duration of the experiment, which would be expected to saturate the PDMS and minimize 
absorption at later time points. Nevertheless, it is not possible to completely eliminate the 
possibility that absorption of drugs in the PDMS leads to decreased drug efficacy. It is 
important to note that despite the differences between the microfluidic device and the 
well plate culture, the microfluidic device does capture the synergy between doxorubicin 
and TRAIL and mitoxantrone and TRAIL combination treatments, indicating the utility 
of this approach, for both screening and dosing studies. As with any screening 
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methodology, additional lead validation methods will be necessary when selecting leads 
from microfluidic device based studies. 
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CONCLUSIONS 
We developed a microfluidic cell array capable of generating different concentrations and 
64 pair-wise combinations on-chip in a fully automated process while exposing cells 
cultured on the device to the generated combinations. The cell culture array was used to 
screen and optimize combinatorial drug treatments against PC3 prostate cancer cells. 
While the utility of this device has been described and characterized using 
chemotherapeutic drugs as sensitizer for TRAIL-induced cell death, this work can be 
extended to identifying combinatorial drug treatments for a variety of diseases. The 
ability to carry out sequential and simultaneous combination treatments also facilitates 
exploration of diverse toxicological and biological dosing studies. 
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CHAPTER 4 
MECHANISTIC INVESTIGATION OF THE TRAIL-SENSITIZATION 
ACTIVITY OF MITOXANTRONE 
 
INTRODUCTION 
Up to this point, the work presented has primary focused on the identification and 
optimization of treatment methodologies designed to incorporate repositioned drugs.  
Through screening of the JHCCL and the design/testing of the high-throughput 
microfluidic cell array, the effect of several drugs in novel treatment strategies has been 
shown.  However, these previous studies have not focused on understanding the 
underlying biological mechanism of these treatment strategies.  Understanding these 
mechanisms is of high importance since it gives a fuller understanding of the therapeutic 
process which can facilitate the identification of ways the treatment can be improved and 
enhanced [14, 142-144].  For example, the identification of biological markers specific to 
malignant cells can provide researchers a therapeutic targets that help limit damage to 
healthy tissue [145, 146].  Similarly, by understanding the mechanisms behind a drug's 
effect, it is possible to develop strategies that help enhance the efficacy of the drug [147].  
These mechanisms can also provide a more directed approach to the identification of new 
therapies by providing insight into what drug activities are important.  This information 
can be used to identify drugs that have similar activities which can then be tested for their 
efficacy [148-150].  Although our studies focus on the repositioning of old drugs, the 
mechanistic effects of specific functional groups can also be determined and this 
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information can used to synthesize new drugs designed to enhance positive (or reduce 
negative) drug effects [151, 152]   
 
This chapter describes the mechanistic evaluation of mitoxantrone's TRAIL sensitization 
activity.  In chapter 2 mitoxantrone was identified as a potent TRAIL sensitizing agent 
during a screen of several FDA-approved compounds.  This chapter will being with an 
initial mechanistic characterization of the drug, and include measuring the ability of the 
drug to induce mitochondrial depolarization and generate reactive oxygen species (ROS) 
in several different cell lines using a range of treatment concentrations.  The results from 
these studies suggested that the loss in mitochondrial membrane potential occurs prior to 
the generation of ROS but that both events occurred within 6 hours of the initial 
treatment.  The information presented in this chapter will then expand on these initial 
mechanistic and kinetic experiments in an effort to fully elucidate the cellular mechanism 
responsible for mitoxantrone's TRAIL sensitization activity.  Cell viability, following 
treatments of mitoxantrone/TRAIL, was evaluated at 30 mins, 2, 6, and 24 hours to 
determine how early mitoxantrone mediated, TRAIL sensitization would occur.  These 
results suggested that the sensitization event occurred very early (30 mins- 2 hrs).  Based 
on our and other's results, it likely that mitoxantrone facilitates the generation of ROS, 
which are known to have TRAIL-sensitizing activities including the up-regulation of pro-
apoptotic proteins (cytochrome C [153], DR5 [154]) and the down regulation of anti-
apoptotic proteins (c-FLIP [155], XIAP [116]).  Experiments designed to implicate ROS 
in the sensitization activity represent the latter body of work in this chapter.  These 
studies will attempt to demonstrate the importance of ROS in mitoxantrone's TRAIL-
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sensitizing activity by limiting the concentration of ROS using the ROS scavenger N-
acetylcysteine (NAC).  Additionally, the drug pixantrone, a mitoxantrone analog shown 
to be less cardiotoxic due to a lower production of ROS [156, 157], will be used in 
combination with TRAIL to determine how effective the drug is compared to 
mitoxantrone.  Finally, Western Blot Analysis will be used to evaluate the concentration 
of apoptosis related proteins, specifically those known to be influenced by ROS. 
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METHODS 
Cell Culture Techniques 
Two human prostate cancer cell lines (PC3, and PC3-TR), two human pancreatic cancer 
lines (MIAPaCa2, and BXPC-3), and one human breast cancer line (MDA-MB-231) 
were used in the current study.  PC3-TR (TR: TRAIL resistant) [101] cells were a 
generous gift from Dr. Aria Olumi at the Massachusetts General Hospital in Boston, MA. 
Cells were grown in 75 cm
2
 and 175 cm
2
 Corning cell culture flasks with RPMI 1640 
tissue culture media supplemented with 10% Fetal Bovine Serum and 1% penicillin / 
streptomycin (10000 units/mL penicillin G and 10000 μg/mL streptomycin) at 37°C with 
5% CO2.  
 
Reagent/Drug Preparation 
All reagents and drugs used in this study were reconstituted in either deionized water, 
ethanol, or DMSO depending on solubility.  Solutions were prepared to ensure that the 
final solvent concentration in cell treatments would be less than 1% (v/v) to limit non-
specific activity.   
   
Single Agent and Combination Treatments 
Cells were plated in 96 well plates at a density of 10,000 cells/well and incubated at 37°C 
and 5% CO2 for approximately 24 hours. For single-agent drug treatments, cells were 
exposed to a range of drug concentrations (0-100 μM) for 30 mins, 2, 6, and 24 hours at 
which point the media was refreshed, and cell viability was determined using the MTT 
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(3-(4,5-dimethylthiazolyl-2) -2,5-diphenyltetrazolium bromide) assay. For sequential 
combination treatments, cells were first treated with the sensitizer drug  for 30 mins, 2, 6, 
or 24 hours. The media was then removed, replaced with fresh serum-containing media, 
and the cells were treated with TRAIL. Cells were incubated for an additional 24 h after 
which, viability measurements were carried out using the MTT assay. 
 
Determination of Cell Viability 
Cell viability was assessed using the MTT cell proliferation assay (ATCC CA#30-
1010k). Following addition of the MTT reagent (3 h at 37
o
C), cells were treated with a 
lysis buffer from the kit and kept at room temperature in the dark for at least two hours in 
order to carry out complete lysis and to solubilize the MTT product. The absorbance of 
each well was measured using a Biotech Synergy 2 Multi-Detection Microplate Reader at 
570 nm. Each experiment included a set of blank wells (media only), a live control (no 
treatment) and a dead control (0.5 μL of MTT lysis buffer). Fractional cell viability was 
calculated as:  (OD of sample – OD of dead control)/(OD of live control – OD of dead 
control) where OD is the optical density. Percentage cell viability was calculated by 
multiplying the fractional viability by 100. Data are plotted as percentage reduction in 
cell viability compared to control (untreated cells) in which, a 0% value on the graph 
means 100% viability and 100% value on the graph means 0% viability. 
Mitochondrial Depolarization Experiments 
Cells were plated in black, clear-bottom 96 well plates at a density of 10,000 cells/well 
and incubated at 37°C with 5% CO2 for approximately 24 hours. Cells were then 
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incubated with 6.39 µM of JC-1 dye (Sigma) for 1-1.5 hours after which the cell culture 
media was removed and refreshed.  1-100 μM concentrations of mitoxantrone/pixantrone 
were then added to the dye-treated cells.  After the final treatment, fluorescent 
measurements were immediately taken using the Biotech Synergy 2 Multi-Detection 
Microplate Reader for green fluorescence (Ex. 485/40, Em. 528/20) and red fluorescence 
(Ex. 485/40, Em. 590/35).  Following the fluorescence measurement, cells were 
incubated at 37°C with 5% CO2 and were periodically removed to take readings at 
various time points. 
 
Analysis of the JC-1 fluorescent data was carried out in order to determine changes in the 
mitochondrial membrane potential of the treated cells compared to the live control cells.  
First the ratio of red fluorescent intensity/green fluorescent intensity was calculated for 
each well.  The average R/G ratio for the live control cells was calculated and the 
remaining R/G ratios were normalized against this value.  This is done in order to account 
for the decrease in the R/G ratio caused by the dye.  A second normalization was then 
performed for each treatment against itself at the 0 hour reading (i.e. all R/G ratios 
measured in a given well were divided by the R/G ratio in that well at the 0 hour time 
point).  This normalization is done so comparisons between data can be easily made since 
at the 0 hour time point, all wells will give a normalized value of 100%. 
 
Reactive Oxygen Species Experiments 
The production of reactive oxygen species was accessed using the fluorescent dye 2',7'-
dichlorfluorescein-diacetate (DCFH-DA) (Sigma).  Cells were plated in black, clear-
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bottom 96 well plates at a density of 8,400 cells/well and incubated at 37°C with 5% CO2 
for 24 hours.  Cells were then treated with 100 µM of DCFH-DA and incubated for 45-60 
mins.  The dye-containing media was removed and refreshed and drug treatments were 
added.  Hydrogen peroxide was used as a positive control and the live control consisted 
of cells only treated with DCFH-DA.  Fluorescent measurements were made using the 
Biotech Synergy 2 Multi-Detection Microplate Reader with an excitation of 485/40 and 
emission of 528/20.  After the fluorescence measurements were made, cells were 
incubated at 37°C with 5% CO2 and were removed only when taking measurements at 
additional time points. 
 
The reactive oxygen species scavenger, N-acetylcysteine (NAC) (Sigma), was used to 
protect cells from the effects of reactive oxygen species generated following treatments 
of mitoxantrone.  Cells were pretreated with a 5 mM solution of NAC 1 hour prior to 
treatment with mitoxantrone.  This NAC concentration was maintained following the 
addition of mitoxantrone as the single agent/combination treatments methodologies were 
completed.  
 
Statistical Analyses 
All experiments were performed in at least triplicate. Data are presented as the mean  
one standard deviation.  Standard deviation of a data set was calculated based on 
experimental variation.  ANOVA was performed using the t-test function in Microsoft 
Excel. 
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Annexin V and Propidium Iodide Analysis 
An annexin V / propidium iodide assay (Invitrogen L3224) was carried out to determine 
if combination treatments induced apoptosis in cells. Briefly, a working solution of 2% 
annexin V and 1 μg/mL propidium iodide (PI) was prepared in a solution of 1X annexin 
binding buffer.  The working solution was added to each well of the cell culture plate and 
incubated at room temperature for 15-20 minutes.  Fluorescence imaging was then 
performed using a Zeiss Observer D1 fluorescent microscope.  A 38 HE filter set 
(Excitation: 470/40; Emission: 525/50) was used to measure the fluorescence of the 
annexin V (green fluorescence) while a 43 HE filter set (Excitation: 550/25; Emission: 
605/70) was used to measure the fluorescence of the propidium iodide (red fluorescence). 
 
Western Blot Analysis 
Cells were seeded in 6-well plates at a concentration of 250,000 cells per well and 
incubated for 24 hours.  Cells were then treated according to the different experimental 
conditions.  Treated cells were collected and washed three times with ice-cold phosphate 
buffered saline (PBS) then centrifuged at 1000xg for 5 minutes.  Cellular lysates were 
suspended in 50-200 μL of ice-cold RIPA Buffer (10 mL RIPA base, 1 protease inhibitor 
cocktail tablet (Roche #0469312001), 1 mM sodium orthovanadate, and 1 mM sodium 
fluoride) and rocked for 15 minutes at 4 °C.  The extracts were centrifuged at 14,000xg 
for 10 minutes after which any remaining cell debris was removed.  Protein 
concentrations were measured using the Pierce BCA Protein Assay Kit (Thermo 
Scientific #23225) according to manufacturer's instructions.  Protein lysates were mixed 
with 6X SDS-loading buffer and denatured at 100 °C for 5 minutes.  Samples were 
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applied on an SDS polyacrylamide gel for electrophoresis.  Proteins were transferred to 
PVDF membranes (GE Healthcare RPN2020F).  Blots were then blocked in Tris-
buffered saline and Tween 20 (TBST) with 5% milk for 1-2 hours.  Blots were rinsed in 
TBST (15 minutes; x4) then incubated with primary antibody in 5% milk/TBST 
overnight at 4 °C.  Blots were rinsed in TBST (15 minutes; x4) and incubated with 
secondary antibody in 5% milk/TBST for 1-2 hours.  Blots were rinsed in TBST (15 
minutes; x4) then dried.  SuperSignal West Femto Maximum Sensitivity Substrate 
(Thermo Scientific #34095) was used according to manufacturer's instruction for 
detection.
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RESULTS AND DISCUSSION 
Previous reports have shown that mitoxantrone has the effect of generating losses in 
mitochondrial membrane potential (MMP) and increasing the generation of reactive 
oxygen species (ROS) [158].  These activities are important because when determining 
the mechanisms behind the TRAIL-sensitization activity of the drug, it is important to 
consider any biological changes mitoxantrone is causing since these changes can be 
related to the sensitization activity.  With this in mind, it becomes important to evaluate 
what changes were occurring, when they were occurring, and the effect of these changes 
on the TRAIL-sensitizing activity of mitoxantrone. 
 
Kinetic Evaluation of Mitoxantrone's TRAIL-Sensitization Activity in Prostate 
Cancer.  Previous studies have almost exclusively examined the TRAIL-sensitization 
activity of drugs after treatment of said drugs for 24 hours (and an additional 24 hours for 
TRAIL combinations).  However it is possible that pre-treating the cells for periods less 
than 24 hours could be sufficient to induce TRAIL sensitization in the malignant cells.  
With this in mind experiments were set up to evaluate the kinetics of TRAIL-
sensitization following treatments of mitoxantrone.  PC3-TR cells were treated with 
single-agent mitoxantrone (0-100 μM) for 30 mins, 2, 6, and 24 hours after which time 
MTT analysis was carried out directly (single-agent treatment) or the mitoxantrone-
containing media was removed and refreshed with media containing 10 ng/mL TRAIL 
for 24 hours (combination treatment).  The results of these experiments are shown in 
Figure 4.1.  These results indicate that there is a significant loss of viable cells when 
comparing single-agent mitoxantrone to combination treatments of mitoxantrone and  
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Figure 4.1  Kinetic dose response for mitoxantrone in PC3-TR human prostate cancer 
cells.  Cells were treated with mitoxantrone for (a) 30 minutes, (b) 2 hours, (c) 6 hours, 
and (d) 24 hours.  For single-agent treatments (dark grey diamonds) the cell viability was 
assessed following the mitoxantrone treatments.  For combination treatments (light grey 
squares), 10 ng/mL of TRAIL was applied for 24 hours following the initial mitoxantrone 
treatments.  Comparisons were made between the single agent and combination 
treatments; asterisks (*) and (**) indicate p-values < 0.05 and <0.01, respectively.  Data 
are presented on a logarithmic scale for x-axes in the plots. 
 
TRAIL for all of the treatment times tested.  In the case of the 30 minute treatment 
(Figure 4.1a), the single agent treatments have little to no effect on cell viability with the  
LC50 value being difficult to determine since the highest concentration treatment (100 
μM) gives no loss of viability.  Following the combination treatments with TRAIL, the 
LC50 value drops to about 0.33 μM as the viability continues to decrease to about 20% 
with the highest concentration treatments.  The 2 hour treatment results (Figure 4.1b) 
97 
exhibit similar trends to the 30 minute treatments with the LC50 value for the single agent 
treatment being difficult to determine while the LC50 for the combination treatment is less 
than 0.33 μM.  After 6 hours (Figure 4.1c), the highest concentrations of mitoxantrone 
begin to start reducing viability with the 100 μM treatment causing a reduction to about 
75% (though it is still not clear what the LC50 value is).  The 6 hour combination 
treatments reduce the viability to 15-25% for all combinations tested.  Combination 
treatment studies at 24 hours had previously been conducted during the initial JHCCL 
screening studies (Figure 2.8a).  The results from this experimental set (Figure 4.1d) 
showed a much larger loss of cell viability for both single agent and combination 
treatments.  However, additional investigations concluded that this difference in 
performance of the drug can be attributed to a difference in the cell stocks used to collect 
the data.  Results from these experiments suggest that the cellular changes that sensitize 
cells to TRAIL occur within 6 hours of the initial treatment with mitoxantrone. 
 
To confirm these results, similar experiments were carried out in an alternate prostate 
cancer cell line, PC3 (Figure 4.2).  Unlike in PC3-TR, the 30 minute and 2 hour, low 
concentration treatments (> 3.3 μM) did not show a significant reduction in viability 
when comparing single agent and combination treatments (Figure 4.2a & b).  However, 
the 30 minute combination treatments showed a significant reduction in cell viability at 
concentrations above 20 μM, while 2 hour combination treatments showed synergy at 
concentrations above 6.6 μM.  Similar to PC3-TR, the single agent treatments of the drug 
at 30 minutes and 2 hours showed little to no effect on cell viability, resulting in LC50  
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Figure 4.2  Kinetic dose response for mitoxantrone in PC3 human prostate cancer cells.  
Malignant cells were treated with mitoxantrone for (a) 30 minutes, (b) 2 hours, and (c) 24 
hours.  For single-agent treatments (dark grey diamonds) the cell viability was assessed 
following the mitoxantrone treatments.  For combination treatments (light grey squares), 
10 ng/mL of TRAIL was applied for 24 hours following the initial mitoxantrone 
treatments.  Comparisons were made between the single agent and combination 
treatments; asterisks (*) and (**) indicate p-values < 0.05 and <0.01, respectively.  Data 
are presented on a logarithmic scale for x-axes in plots. 
 
values greater than 100 μM.  The LC50 value for the 30 minute and 2 hour combination 
treatments were approximately 20 and 9 μM respectively.  Twenty-four hour combination 
experiments with PC3 cells were also conducted during the initial JHCCL screening 
studies (Figure 2.8b) but unlike the PC3-TR cells, there was good agreement between 
those studies and the results shown in Figure 4.2c.  As seen previously, the 24 hour 
combination treatments show a significant reduction in cell viability as compared to the 
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single agent treatments.  The LC50 value for the 24 hour single agent treatments is 5 μM 
while the LC50 for the combination treatments is about 0.1 μM.  The results of these 
studies confirm the observations made in the PC3-TR line and add credence to the notion 
that the cellular event that leads to mitoxantrone sensitizing cells to TRAIL occurs within 
the first few hours of treatment. 
 
An increase in ROS generation is known to occur within the first few hours of treatment 
and because ROS is known to have proapoptotic activities [116, 159] it was hypothesized 
that the generation of ROS by mitoxantrone could explain the drug's TRAIL-sensitizing 
activities.  In both of experimental sets, it is important to note that the 10 ng/mL TRAIL 
alone treatment showed a 0-10% reduction in cell viability and this effect was taken into 
account when determining statistically significance. 
 
In order to verify the importance of kinetics in TRAIL-sensitization activity of 
mitoxantrone, cells were treated with an annexin V and propidium iodide (PI) stain.  In 
these experiments, single-agent treatments were treated with mitoxantrone for 2 hours 
and then incubated with a buffer only control for an additional 24 hours.  Combination 
treatments were treated with mitoxantrone for 2 hours followed by treatment with 10 
ng/mL TRAIL for another 24 hours.  Analysis of these images indicate that treatments of 
single-agent mitoxantrone and single-agent TRAIL have little effect on the cell viability; 
neither treatment produces a large amount of green or red fluorescing cells (Figure 4.3).  
However, it is clear that the combination treatments with mitoxantrone and TRAIL 
produce a large number of cells that are undergoing apoptosis or dying.  These results can  
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Figure 4.3  Microscopy images of single-agent and combination treatments in PC3-TR 
cells; mitoxantrone treatments were for 2 h, while TRAIL treatments were for 24 h.  Left 
column shows phase contrast images and right column shows fluorescence images 
visualized with an annexin V and propidium iodide stain.  Apoptotic cells exhibit green 
fluorescence only.  Dead cells can exhibit either lone red fluorescence or red and green 
fluorescence simultaneously.  Live cells are non-fluorescent. 
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be compared to those shown in Figure 2.18 where the same experiment was carried out 
for 24 hour mitoxantrone treatments.  In both cases the live control, single-agent TRAIL, 
and the combination treatments show similar behavior, but a key difference is seen when 
comparing the single-agent mitoxantrone treatments.  The 24 hour single-agent 
mitoxantrone treatments are shown to cause the cells to die or become apoptotic while the 
2 hour treatments do not have this effect.  This is significant since mitoxantrone is an 
antineoplastic drug and its primary, DNA intercalating, activity is expected to reduce cell 
viability.  However, these results confirm that combination treatments are still effective 
after only a 2 hour treatment with mitoxantrone while the single agent treatment has little 
to no effect.  Because TRAIL is known to be selective toward malignant cells it is 
possible that shorter treatments of mitoxantrone can reduce the primary, non-specific, 
effect of the drug without sacrificing the efficacy of the combination treatment.  
Additionally, this information also indicates that important cellular changes occur during 
the first few hours of treatment which have the effect of sensitizing the cells to TRAIL 
treatments.  This means that by identifying what changes occur during this period, it will 
become easier to narrow down the mechanisms responsible for mitoxantrone's TRAIL-
sensitization activity. 
 
Dose Response Studies with Mitoxantrone in Prostate and Pancreatic Cancer:  
Mitochondrial Membrane Potential.  To begin we looked into mitoxantrone's ability to 
depolarizes the mitochondria of malignant cells.  As described in Chapter 1, mitochondria 
serve as key checkpoints in the induction of apoptosis.  The release of pro-apoptotic 
proteins from the mitochondria is though as the "point of no return" in the apoptotic 
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mechanism [83].  Therefore, it is important to understand if mitoxantrone actively 
damages the mitochondria because this mechanism might be related to the TRAIL-
sensitization activity of the drug.  Prior to testing mitoxantrone, a dose response 
experiment using a known mitochondrial depolarizer, antimycin A [160], was conducted 
to ensure the experimental conditions were optimized and were relevant to the chosen 
system.  PC3-TR cells were cultured and changes in MMP were measured by tracking the 
fluorescent activity of the cationic dye, 5,5’,6,6’-tetrachloro-1,1’,3,3’-
tetraethylbenzimidazolylcarbocyanine iodide (JC-1).  JC-1 in its monomeric form emits 
at approximately 527 nm after a 488 nm excitation while the aggregate form emits at 590 
nm with the same excitation.  The largely negative mitochondrial membrane potential 
causes the dye to form aggregate at the mitochondrial membrane but if the membrane 
potential decreases the dye aggregates revert to their monomeric form in the cytoplasm 
[161].  Therefore, changes in the MMP can be tracked by measuring the fluorescent 
activity of the dye at both emission wavelengths.  The red fluorescence/green 
fluorescence ratio is calculated and normalized as described in the Methods and plotted 
against the time each reading was collected.  For the antimycin experiment, 
measurements of the MMP were taken every 15 minutes during the first hour of treatment 
followed by readings every hour until 5 hours of treatment with a final reading at 24 
hours (data point not shown).  These results, shown in Figure 4.4, indicate that as the 
concentration of antimycin A increased, the R/G fluorescent ratio (representative of 
MMP) showed an equivalent decrease.  These results are consistent with the fact that 
antimycin A is a known mitochondrial depolarizer and serves as validation that the 
experimental conditions are suitable for a screening experiment.  This experiment also  
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Figure 4.4  Response of PC3-TR cells following treatment with Antimycin A.  
Mitochondrial membrane potential (MMP) was measured using the fluorescent dye JC-1 
following treatments with a known mitochondrial depolarizing agent, Antimycin A.  The 
fluorescent emission of JC-1 changes based on the MMP and will emit red at high 
membrane potentials and green at low membrane potentials.  Data is presented as the 
change in the normalized red fluorescent/green fluorescent ratio. 
 
provided some insight into the time scale over which depolarization occurs in which it is 
clear that during the first hour there is a large decrease in the MMP and that, as time 
progresses, this effect begins to stabilize.  Additionally, these results also provide a 
positive control for all future experiments since it is clear that antimycin A at 
concentrations of 50 µM and higher is able to induce depolarization. 
 
Since the method for measuring changes in MMP was found to be effective experiments 
measuring the effect of mitoxantrone on MMP was evaluated.  The depolarizing activity  
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Figure 4.5  Response of prostate cancer following treatment with increasing 
concentrations of mitoxantrone.  The change in membrane potential in the cell lines a) 
PC3-TR and b) PC3 shows dose dependence.  Lines connecting data are for visualization 
only. 
 
of mitoxantrone was determined by testing a concentration range from 0 to 100 µM.  
Figure 4.5 gives a kinetic dose response for (a) PC3-TR and (b) PC3 prostate cancer cell 
lines.  As expected, both cell lines show a dose dependant response to the mitoxantrone 
treatments and the speed and extent of the depolarization increases as concentration 
increases.  Some interesting differences arise when comparing the PC3-TR results and 
the PC3 results.  Most notably is that the PC3 cell line seems to be more resistant to the 
depolarization induced by mitoxantrone at higher concentrations, but more susceptible to 
depolarization induced by the drug at lower concentrations when compared to the PC3-
TR line.  Over 6 hours, PC3-TR shows a very small decrease in the R/G ratio (> 5%) 
using a concentration of 0.33 µM and about a 75% decrease with a 100 µM 
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concentration.  Alternatively, PC3 shows a 30% reduction in the R/G ratio with a 0.33 
µM concentration and a 60% reduction with 100 µM after the same 6 hour period.  
Additionally, there is also a clear different in the efficacy of the antimycin control in 
these two cell lines.  In the PC3-TR line, antimycin causes a 60% decrease in the R/G 
ratio over six hours, but it only causes a 40% decrease in PC3.  PC3-TR cells are derived 
from a PC3 parent line, and resistance to the protein TRAIL has been attributed to the 
over expression of the anti-apototic protein, c-FLIP.  However, it is unclear if the 
different responses these two lines exhibit can be attributed to the effect of c-FLIP, or if 
additional factors play a role.  Regardless, in both lines our studies show a significant loss 
of membrane potential over a period of six hours following treatment with mitoxantrone. 
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 Figure 4.6  Response of pancreatic cancer following treatment with increasing 
concentrations of mitoxantrone.  The change in membrane potential in the cell lines a) 
BXPC-3 and b) MIAPaCa-1 shows dose dependence.  Lines connecting data are for 
visualization only. 
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In addition to the prostate cancer lines tested, dose response studies were also carried out 
in two human pancreatic cancer lines.  Figure 4.6 shows the change in the MMP over a 
six hour period in (a) BXPC-3 and (b) MIAPaCa2, following treatments with 
mitoxantrone.  In these two cell lines there is also a dose dependant response to the 
mitoxantrone treatments.  0.33 µM mitoxantrone causes a 10% decrease in the R/G ratio 
over a six hour period in both cell lines, while a 100 µM treatment causes a 75% decrease 
in BXPC-3 and a 70% decrease in MIAPaCa2.  The antimycin control reduces the R/G 
ratio by approximately 50% in both cell lines.  These results indicate that the two 
pancreatic cancer lines exhibit nearly identical responses to the mitoxantrone treatments.  
These responses are also very similar to what is seen in the PC3-TR prostate cancer line 
(Figure 4.5a).  This suggests that the mechanisms of depolarization are likely similar in 
both pancreatic cancer lines and in the PC3-TR line.  
  
Additionally, the depolarizing effect of mitoxantrone was also tested in the MDA-MB-
231 breast cancer cell line shown in Figure 4.7.  As previously seen with the prostate and 
pancreatic cancer cell lines, the MDA-MB-231 cells also show a does dependant 
response to the mitoxantrone treatments.  One of the key differences between treatments 
in this cell line and the other tested lines is that the kinetics of depolarization seem to take 
place almost exclusively during the first hour of treatment.  At the 100 µM treatment 
concentration, the R/G ratio decrease by almost 60% during the first hour and after six 
hours of treatment there is little additional depolarization caused by the drug.  These 
results are interesting since in the four other lines tested, there was a large initial decrease  
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Figure 4.7  Response of breast cancer following treatment with increasing concentrations 
of mitoxantrone.  Change in membrane potential in the MDA-MB-231 cell line shows 
dose dependence.  Lines connecting data are for visualization only. 
 
in the R/G ratio and the ratio continued to steadily decrease for a few hours after the 
initial hour.  It is only after an approximate 4 hour treatment time that the change in the 
ratio begins to equilibrate.  Furthermore, low concentration treatments of mitoxantrone, 
in the MDA-MB-231 cell line, seem to be ineffective; after a 6 hour treatment with 0.33 
µM mitoxantrone, there is a very slight increase in the R/G ratio of the cells (5%).  
Overall it does appear that the breast cancer line shows a higher resistance to the 
depolarization activity of mitoxantrone than lines like PC3-TR and BXPC-3 although the 
difference is small. 
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All previous results have been obtained by taking measurements of fluorescent intensity 
using a microplate reader.  However, in order to confirm the microplate reader results, 
fluorescent microscopy was employed to visualize the effects of mitoxantrone in JC-1 
stained, PC3-TR cells.  Figure 4.8 shows microscopy images at 0 and 4 hours for cells 
treated with (a) the JC-1 dye alone (live control) and (b) 20 µM mitoxantrone.  Average 
R/G ratios for each treatment condition are also given for each fluorescent image.  In 
Figure 4.8a there is an increase in the amount of green fluorescence when comparing the 
0 h and 4 h live controls, which is attributed to the fact the that JC-1 dye by itself has 
some depolarizing activity.  In order to make meaningful comparisons of other drug 
treatments, this effect is accounted for by normalization the data against the live control 
and standardizing the measurements.  This sets the R/G ratio of the live control to 100% 
for all time points as is demonstrated in the figure.  Figure 4.8b shows the effects of 
mitoxantrone treatments in which there is a clear increase in the intensity of the green 
fluorescence when comparing the 0 h and 4 h treatments.  Importantly these studies show 
that the relative fluorescence for the 0 h live control and the 0 h mitoxantrone treatment 
are nearly equal which is expected since at the initial treatment point the effects of the 
drug are not expected to be acting.  The microscopy results confirm the results obtained 
using the fluorescent plate reader.  The only notable different between the two 
measurements is that, after 4 hours, the plate reader shows a 60% decrease in the R/G 
ratio with a 20 µM mitoxantrone treatment and the microscopy measurements only shows 
a 25% decrease.   However, some variation in the measurements taken is expected since 
different systems are being used to measure and collect the data.  In the plate reader the 
fluorescent signal is measured directly while in the microscopy experiments the  
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Figure 4.8  Microscopy images of PC3-TR cells for depolarization studies.  Images were 
captured for a) live control cells (dye only) and b) mitoxantrone treated cells at 0 and 4 
hours.  Fluorescent images are presented as an overlay of red and green fluorescent 
images in which the JC-1 dye fluoresces red when it aggregates near mitochondria and 
fluoresces green when the dye dissociates into the cytoplasm.  Normalized ratios of the 
fluorescent intensity (R/G) in each image are also presented. 
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fluorescent signal is determined though image analysis.  Another important difference is 
that, in the plate reader, the dye is excited at 485/40 nm and emission measurements are 
taken at 528/20 and 590/35 nm.  However, in the microscopy experiments, the dye is first 
excited at 470/40 nm with emissions taken at 525/50 nm (green fluorescence) and then 
excited at 550/25 nm with emissions taken at 605/70 nm (red fluorescence).  Since the 
red fluorescent measurements are not taken using the same excitation wavelengths, it 
makes sense that there would be difference in the intensity measurements taken and could 
account for the difference in measurements observed.  Regardless, both the microplate 
results and the microscopy results demonstrate the ability of mitoxantrone to depolarize 
mitochondria in prostate and pancreatic cancer cell lines and that the kinetics of this 
activity occur within the first few hours of treatment. 
 
Dose Response Studies with Mitoxantrone in Prostate and Pancreatic Cancer:  
Reactive Oxygen Species.  Loss of MMP and the generation of reactive oxygen species 
(ROS) are closely related processes as described in Chapter 1.  Mitochondria consistently 
generate  ROS, but the organelles are equipped with the mechanisms necessary to control 
the concentrations of these species.  However, damaged mitochondria will not be able to 
effectively control ROS concentrations.  Similarly, high concentrations of ROS can cause 
an otherwise healthy mitochondrion to being to malfunction.  Since the loss of MMP and 
the generation of ROS are coupled it became important to know how treatments of 
mitoxantrone were changing ROS concentrations.  The kinetics of the change in these 
levels will vary from system to system and so an important question that we will be 
trying to answer is if a decrease in MMP leads to an increase in ROS or vice-versa.   
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Figure 4.9  Reactive oxygen species generation in mitoxantrone treated, PC3-TR prostate 
cancer cells.  Time point measurements of ROS generation were made over a 24 hour 
period based on the fluorescent intensity of the DCFH-DA dye.  Comparisons were made 
against the live control; asterisks (*) and (**) indicate p-values < 0.05 and < 0.01, 
respectively.  Data are presented as the normalized fluorescent intensity based on the live 
control measurements.  Data are presented on a logarithmic scale for y-axes in the plots. 
 
DCFH-DA was used to measure ROS levels as described in Methods.  DCFH-DA is a 
non-fluorescent, cell permeable molecule.  When the compound permeates the cell, it is 
deacetylated by cellular esterases to form non-fluorescent DCFH. DCFH is then oxidized 
by ROS to form the fluorescent molecule, 2',7'-Dichlorofluorescin (DCF) (i.e. as ROS 
levels increase, fluorescent intensity increases).  Figure 4.9 shows a dose response 
experiment with mitoxantrone in the PC3-TR cell line.  The hydrogen peroxide control 
rapidly increases the fluorescent signal, as expected, and over time the signal steadily  
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Figure 4.10  Reactive oxygen species generation in mitoxantrone treated, MIAPaCa-2 
pancreatic cancer cells.  Time point measurements of ROS generation were made over a 
24 hour period based on the fluorescent intensity of the DCFH-DA dye.  Comparisons 
were made against the live control; asterisks (*) and (**) indicate p-values < 0.05 and < 
0.01, respectively.  Data are presented as the normalized fluorescent intensity based on 
the live control measurements.  Data are presented on a logarithmic scale for y-axes in 
the plots. 
 
weakens.  This suggests that the positive control is working and that this system is 
sensitive enough to track changes in ROS generation.  The results show that after 3 hours 
of mitoxantrone treatments at concentrations above 20 µM, there is a significant increase 
in the concentration of intracellular ROS.  The ROS levels then continue to increase until 
the 24 hour time point when measurements were ceased.  After 24 hours, the 100 µM 
treatment shows an approximate 300% increase in the fluorescent intensity, while 100% 
and 200% enhancements are seen for 20 and 33.3 µM treatments respectively.  From 
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these results it also appears that low concentrations of mitoxantrone (6.6 µM and below) 
do not results in a significant increase in the ROS concentration even after 24 hours of 
treatment (only a 10% increase in fluorescent intensity).  This is interesting because at a 
concentration of 6.6 µM, the treated cells showed a significant decrease in the R/G ratio 
compared to the untreated controls (Figure 4.5a).   
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Figure 4.11  Reactive oxygen species generation in mitoxantrone treated, BXPC-3 
pancreatic cancer cells.  Time point measurements of ROS generation were made over a 
24 hour period based on the fluorescent intensity of the DCFH-DA dye.  Comparisons 
were made against the live control; asterisks (*) and (**) indicate p-values < 0.05 and < 
0.01, respectively.  Data are presented as the normalized fluorescent intensity based on 
the live control measurements.  Data are presented on a logarithmic scale for y-axes in 
the plots. 
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A dose response study of ROS generation in the pancreatic cancer line MIAPaCa-2 
(Figure 4.10) was also performed.  The trend of these results mimics that of the PC3-TR 
cells except, in this cell line, the effects happen more quickly and with greater intensity.  
MIAPaCa-2 cells show that after 2 hours, ROS levels significantly increase after 
treatment with mitoxantrone at and above 20 µM.  This can be compared to the PC3-TR 
data where only the 100 µM treatment showed a significant increase in ROS levels after 2 
hours.  Additionally, the level of ROS production is much greater than in the prostate 
cancer cell line; after 24 hours the 100 µM mitoxantrone treatment showed an 
approximate 700% increase in the fluorescent intensity, while 200% and 500% 
enhancements were seen for 20 and 33.3 µM treatments respectively.  
 
These experiments were also carried out in the BXPC-3 pancreatic cancer line (Figure 
4.11) where the trend of ROS production shows a significant increase in the 20 and 33.3 
μM concentrations after only 2 hours which is similar to the rate at which MIAPaCa-2 
cells showed significant increases in ROS concentrations.  However, the level of ROS 
production seems to be less than in the PC3-TR and MIAPaCa-2 cell lines.  After 24 
hours the 100 μM treatment shows an approximate 300% increase in the fluorescent 
intensity signal which is comparable to the PC3-TR experiments but the 20 and 33.3 μM 
treatments only show 50% and 100% increases respectively.  In measuring changes in the 
MMP, PC3-TR, MIAPaCa-2, and BXPC-3 all showed similar responses to the 
mitoxantrone treatments (Figures 4.5a and 4.6) yet the three different cell lines showed 
varying levels of ROS production.  It stands to reason that the production of ROS is not 
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solely dependent on the magnitude of the change in MMP since the response can vary 
between cell lines when the change in MMP is mostly constant. 
 
10
1000
0 1 2 3 4 6 24
N
o
rm
al
iz
e
d
 F
lu
o
re
sc
e
n
t 
In
te
n
si
ty
 (
%
)
Time (h)
MDA-MB-231Live (No Treatment)
H2O2 Control
6.6 uM Mitoxantrone
20 uM Mitoxantrone
33.3 uM Mitoxantrone
100 uM Mitoxantrone
**
**
**
** **
**
**
****
**
**
**
* *
*
*
*
*
**
 
Figure 4.12  Reactive oxygen species generation in mitoxantrone treated, MDA-MB-231 
breast cancer cells.  Time point measurements of ROS generation were made over a 24 
hour period based on the fluorescent intensity of the DCFH-DA dye.  Comparisons were 
made against the live control; asterisks (*) and (**) indicate p-values < 0.05 and < 0.01, 
respectively.  Data are presented as the normalized fluorescent intensity based on the live 
control measurements.  Data are presented on a logarithmic scale for y-axes in the plots. 
 
The effect of mitoxantrone on ROS levels in MDA-MB-231 cells was also evaluated as 
shown in Figure 4.12.  In this experiment the treatment concentration of the H2O2 control 
was reduced in order to provide a better an improved scale over which to view the 
treatment data but all other conditions were kept constant.  After 2 hours, mitoxantrone 
116 
treatments greater than 20 µM start to show a significant increase in the ROS 
concentrations.  After 24 hours of treatment, the 100 µM condition shows a 5.5-fold 
increase in the ROS concentration while the 20 µM and 33.3 µM conditions show 1.5 and 
2.5-fold increases respectively.  Compared to the other cell lines tested, the ability and 
extent of mitoxantrone to generate ROS in MDA-MB-231 falls between the highest 
efficacy in the MIAPaCa-2 pancreatic cancer line and the lower efficacy in the PC3-TR 
prostate cancer cell line.  The kinetics of the ROS production also appear to be quite 
rapid since there it only takes 2 hours for the ROS concentration to be significantly 
higher than the no treatment controls. 
 
The manner in which ROS are generated appears to be different from the manner in 
which the MMP decreases.  As the time of treatment increases the ROS levels continue to 
increase, but the loss in MMP occurs within the first few hours of treatment and there is 
no significant change in the potential at later time points.  Figure 4.13 compares the rate 
of mitochondrial depolarization to the rate of ROS generation in the MIAPaCa-2 
pancreatic cancer cell line following treatment with 20 µM of mitoxantrone.  When 
comparing the data sets in this manner, it is easy to visualize the rate at which the two 
phenomena occur.  By comparing the slope of the line connecting data points it is clear 
that in the first hour there is a much greater loss of MMP than an increase in ROS 
production; the MMP decreases by approximately 40% of its initial value while the 
fluorescent signal generated by the ROS has only increased by 10%.  The figure also 
demonstrates that while the initial loss of membrane potential is high, the subsequent 
reading do not show depolarization and the response seems to stabilize over time.   
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Figure 4.13  Kinetic comparison between mitochondrial depolarization and ROS 
generation.  Normalized data are compared over a 6 hour time period in the MIAPaCa-2 
human pancreatic cancer cell line. 
 
However, the rate of ROS generation steadily increases during the initial 6 hours and 
continues to increase up to the the 24 hour time point.  What this seems to indicate is that 
a loss of MMP facilitates the increased production of ROS.  This is an important 
distinction since the two phenomena are part of a feed-forward loop and there is the 
potential that the increase in ROS could cause a change in MMP due to oxidative stress. 
 
Evaluating the Effect of N-acetylcysteine on the TRAIL-Sensitizing Activity of 
Mitoxantrone.  In order to evaluate the effect ROS had on the TRAIL-sensitizing 
activity of mitoxantrone, the ROS scavenger N-acetylcysteine (NAC) was used to reduce 
ROS concentrations.  Dose response studies with mitoxantrone where carried out in PC3- 
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Figure 4.14  The effect of N-acetylcysteine (NAC) on reactive oxygen species generation 
in PC3-TR prostate cancer cells.  Time point measurements of ROS generation were 
made over a 6 hour period based on the fluorescent intensity of the DCFH-DA dye.  
Asterisks (*) and (**) indicate p-values < 0.05 and < 0.01, respectively.  Data are 
presented as the normalized fluorescent intensity based on the live control measurements. 
 
TR cells with and without co-treatments of NAC (Figure 4.14).  In these studies 
hydrogen peroxide was used as a positive control and the effect of the treatments was 
evaluated over a 6 hour period.  The positive controls showed an immediate increase in 
fluorescent intensity for the cells not treated with NAC but the cells treated with NAC 
showed only a slightly elevated fluorescent intensity (compared to the live control).  
Between 1 and 6 hours this difference between the cells with and without NAC and 
treated with hydrogen peroxide showed a 13-fold increase between the two conditions.  
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Mitoxantrone treatments did not generate the same high levels of ROS as the positive 
control but the treatments containing no NAC did increase significantly.  The ROS levels 
of the mitoxantrone and NAC co-treated cells did not exhibit a significant increase over 
the live control cells.  The difference between the mitoxantrone treated cells with and 
without NAC became statistically significant after the 2nd hour of treatment.  These 
results indicate that the ROS-scavenger NAC is able to significantly reduce the 
intracellular concentrations of the ROS generated both by hydrogen peroxide and by 
mitoxantrone. Upon verification that NAC could limit the production of ROS by 
mitoxantrone, it was hypothesized that if ROS were contributing to the TRAIL-
sensitizing activity of mitoxantrone then limiting the ROS concentration should protect 
the mitoxantrone treated cells from TRAIL-mediated apoptosis.  Cell viability was 
measured following single agent and combination treatments with mitoxantrone in cases 
with and without NAC.  2 hour single agent treatments of 0-100 μM mitoxantrone 
showed no statistical difference between the viability of cells with and without NAC 
(Figure 4.15a).  These results are important because they indicate that the NAC 
treatments do not reduce the cell viability and will not contribute to the toxic effects of 
mitoxantrone.  Results from the 2 hour combination mitoxantrone/TRAIL treatments 
show that for all concentrations tested, cell viability was higher for the cells treated with 
the ROS scavenger NAC (Figure 4.15b).  These data also shows that at several 
concentrations (0.33, 3.3, 6.6, 13.3, 33.3, and 100 μM) the difference between the cells 
with and without NAC was statistically significant.  On average cells treated with NAC 
show approximately 12.2% (+/- 5.8%) higher viability than those without NAC. 
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Figure 4.15  Mitoxantrone dose response (2 h; 0-100 μM) with N-acetylcysteine co-
treatments in PC3-TR prostate cancer cells. (a) Single agent and (b) sequential 
combination treatments with 10 ng/mL TRAIL.  Comparisons were made between 
treatments with and without NAC; asterisks (*) and (**) indicate p-values < 0.05 and 
<0.01, respectively.  Data are presented on a logarithmic scale for x-axes in the plots. 
 
This experiment was also performed for 24 hour treatments of mitoxantrone.  For the 24 
hour single agent treatments it is apparent that there is a significant difference between 
the NAC treatments (Figure 4.16a).  For all concentrations tested, cells treated with NAC 
so less loss of viability than those without the treatment, and only in two cases was the 
difference between those treatments not statistically significant (1 and 100 μM).  On 
average cells treated with NAC show an 8.2% (+/- 3.6%) increase in viability as 
compared to cells without NAC.  These results add credence to the assertion that 
mitoxantrone generates ROS and that the effect of ROS contributes to the drug's 
antineoplastic activities.  Examination of the 24 hour mitoxantrone/TRAIL combination  
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Figure 4.16  24 hour mitoxantrone dose response with N-acetylcysteine co-treatments in 
PC3-TR prostate cancer.  0-100 μM (a) single agent and (b) sequential combination 
treatments with 10 ng/mL TRAIL.  Comparisons were made between treatments with and 
without NAC; asterisks (*) and (**) indicate p-values < 0.05 and <0.01, respectively.  
Data are presented on a logarithmic scale for x-axes in the plots. 
 
treatments indicates that NAC treatments reduce the efficacy of the treatments (Figure 
4.16b).  For all concentrations tested, the difference between the treatments with and 
without NAC is statistically significant (p > 0.01) with the exception of the highest 
concentration tested (100 μM).  Cells treated with NAC show an average 14% (+/- 6.5%) 
increase in viability.  These results further confirm that reducing the intracellular ROS 
concentrations, reduces the efficacy of mitoxantrone and TRAIL combination treatments.  
In fact, the results from these combination treatments indicate that the cell viability for 
single-agent mitoxantrone without NAC, and the viability for combination treatments 
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with NAC are not statistically different when taking the effect of TRAIL into 
consideration (8.8% reduction in viability). 
 
The results from the 2 hour mitoxantrone treatments (Figure 4.15) show that treatments 
of NAC do not have an effect on viability when considering the single agent treatments 
but cells treated with NAC are protected from the combination treatment of mitoxantrone 
and TRAIL.  The 24 hour mitoxantrone treatments (Figure 4.16) indicate NAC protects 
cells from mitoxantrone as a single agent treatment and as a combination treatment with 
TRAIL.  The results also show that single-agent mitoxantrone treatments and 
combination treatments with NAC are equivalent.  These results strongly suggest that 
ROS play an integral part in mitoxantrone's TRAIL sensitization activity.  Cells with 
lower concentrations of ROS show significant increases in cell viability when undergoing 
combination treatments.  
 
Comparison of the Efficacy of Mitoxantrone and the Mitoxantrone-Analog, 
Pixantrone.  Pixantrone is an aza-anthracenedione that, similar to mitoxantrone, acts as a 
topoisomerase II inhibitor and DNA intercalating agent [157, 162, 163].  The drug is 
undergoing FDA approval trials for the treatment of lymphoma, leukemia, breast cancer 
and has recently completed Phase III clinical trials for Non-Hodgkins Lymphoma [164, 
165].  The drug has attracted significant attention as a chemotherapeutic agent because 
the drug has been shown to be less cardiotoxic than other antineoplastic drugs like 
mitoxantrone without reducing overall efficacy [156, 166].  Importantly, the drug 
generates fewer reactive oxygen species, which is thought to be the reason for the drug's 
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lower cardiotoxicity [157].  This mitoxantrone analog serves as an important control to 
mitoxantrone since the drug has similar activity to mitoxantrone with a key difference 
being the generation of ROS.  If the TRAIL-sensitizing activity of mitoxantrone is 
dependent on the generation of ROS, then combination treatments with pixantrone should 
show lower efficacies. 
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Figure 4.17  Response of PC3 and PC3-TR prostate cancer cells following treatments 
with increasing concentrations of pixantrone.  The change in mitochondrial membrane 
potential in the cell lines (a) PC3-TR and (b) PC3 shows dose dependence.  Lines 
connecting data are for visualization only. 
 
In order to confirm that pixantrone did result in generation of lower concentrations of 
ROS, experiments were performed using the same probes and experimental conditions as 
previously used for mitoxantrone (Detailed in Chapter 4).  In these experiments, cellular 
changes during the first 6 hours of treatment were tracked in the two prostate cancer cell 
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lines, PC3-TR and PC3.  The JC-1 dye was used to track changes in MMP following the 
treatment of the two cell lines with pixantrone (Figure 4.17).  In these experiments a 
positive control of 20 μM mitoxantrone was used to confirm the assay was working and 
to serve as a basis for comparison between the two drugs.  These studies show a dose 
dependant response to the pixantrone treatments since the calculated R/G ratio decreases 
with increasing pixantrone concentration.  Another interesting trend is that like the same 
experiment run with mitoxantrone (Figure 4.5), PC3 cells appear to be more resistant to 
the depolarization induced by pixantrone than PC3-TR cells.  Over 6 hours, PC3-TR 
shows a very small increase in the R/G ratio (6%) using a concentration of 0.33 μM and a 
50% reduction with a 100 μM concentration.  Most importantly, during this 6 hour period 
the 20 μM mitoxantrone treatment gives a 40% reduction in the normalized R/G ratio.  
This indicates that at one fifth of the concentration, 20 μM of mitoxantrone is nearly as 
effective as 100 μM of pixantrone (Figure 4.17a).  PC3 cells show an approximate 10% 
increase in the R/G ratio following a 0.33 μM treatment of pixantrone over a 6 hour 
period.  During this time, 100 μM of the drug results in a 34% decrease in the R/G ratio.  
Following treatments of 20 μM mitoxantrone the PC3 cells also show a 34% decrease in  
the R/G ratio.  This suggests that in this line, 20 μM of mitoxantrone and 100 μM of 
pixantrone depolarizes the mitochondria to the same extent (Figure 4.17b).  Results from 
both cell lines indicate that pixantrone is less effective at inducing the loss of MMP than 
mitoxantrone.  As discussed previously, the loss of MMP and the generation of ROS are 
closely related and so it is expected that pixantrone would cause less disruption to the 
membrane potential if the drug does generated fewer ROS than its analog, mitoxantrone.  
DCFH-DA was used to measure ROS levels in the same manner as when measurements  
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Figure 4.18  Reactive oxygen species generation in pixantrone treated, PC3-TR prostate 
cancer cells.  ROS concentrations measurements were made over a 6 hour period based 
on the fluorescent intensity of the DCFH-DA dye.  Comparisons were made against the 
live control; asterisks (*) and (**) indicate p-values < 0.05 and < 0.01, respectively.  Data 
are presented as the normalized fluorescent intensity based on the live control 
measurements. 
 
were taken with mitoxantrone.  In these experiments an increase in fluorescent signal 
corresponds to an increase in ROS concentrations.  Figure 4.18 shows a dose response 
experiment with pixantrone in the PC3-TR cell line.  Hydrogen Peroxide is used as a 
positive control and as expected it shows the largest and fastest increase in fluorescent 
intensity as previously shown in the H2O2 treatments without NAC shown in Figure 
4.14.  An important distinction between this experiment and the earlier experiment is that 
the H2O2 concentration was reduced significantly from 3.3 mM to 0.33 mM so that the  
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Figure 4.19  Reactive oxygen species generation in mitoxantrone treated, PC3 human 
prostate cancer cells.  ROS concentrations measurements were carried out over a 6 hour 
period based on the fluorescent intensity of the DCFH-DA dye.  Comparisons were made 
against the live control; asterisks (*) and (**) indicate p-values < 0.05 and < 0.01, 
respectively.  Data are presented as the normalized fluorescent intensity based on the live 
control measurements. 
 
effect of the positive control didn't dwarf the more subtle changes of the drug treatments.  
Figure 4.18 shows a low concentration treatment of pixantrone (1 μM) and the four 
highest treatment concentrations (20, 33.3, 66.6, and 100 μM) of the drug.  Interestingly, 
the high concentration treatments are shown to significantly reduce the fluorescent 
intensity as compared to the live control.  This is very unexpected since although the drug 
is known to generate fewer ROS than mitoxantrone there have been no indications that 
the drug has ROS scavenging activity.  However, there is only a 6.5% difference between 
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the live control and treatment of pixantrone that showed the greatest decrease in 
fluorescence (100 μM, 1 hour) indicating that while the difference is significant, the 
effect is small considering the H2O2 treatments cause show an approximately 60% 
increase in the normalized fluorescent intensity.  Similarly when comparing these values 
to the mitoxantrone treatments in the same cell line (Figure 4.14), there is an 
approximate 160-180% increase in the normalized fluorescence when looking at 6 hour 
treatments of 20-100 μM mitoxantrone (without NAC treatments). 
 
The ROS studies were also performed in PC3 cells (Figure 4.19).  These results contrast 
those seen in the PC3-TR cell line since none of the pixantrone treatments show 
statistically significant reductions in the fluorescence intensity.  Treatments of pixantrone 
start to show significant increases in the fluorescent signal at the initial time point (1 μM) 
but it is only after 2-3 hours that the increased fluorescence remains consistent.  During 
this 2-3 hour time 1, 20, 33.3, and 66.6 μM treatments of pixantrone all show a 
significant increase in the normalized fluorescent signal as compared to the live control. 
 
At 6 hours the 33.3 μM pixantrone treatment gives a 6% increase in the normalized 
fluorescence, the highest increase observed in any of the pixantrone treatments.  
However, this 6% is inconsequential when compared to the 70% increase caused by 
H2O2.  ROS studies for mitoxantrone were not performed in PC3 cells but 20-100 μM 
treatments of mitoxantrone in MIAPaCa-2 pancreatic cancer cells showed a 100-300% 
increase in normalized fluorescent intensity after 6 hours (Figure 4.10) , and MDA-MB-
231 breast cancer cells showed a 50-150% increase after 6 hours (Figure 4.12).  Taken 
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together these results all indicate that pixantrone treatments produce minuscule ROS 
concentrations when compared to the mitoxantrone treatments.  These results support the 
findings found in the literature and provide experimental proof that pixantrone can 
suitably be used to study whether or not the TRAIL-sensitization activity of mitoxantrone 
depends on the generation of ROS. 
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Figure 4.20  Kinetic dose response for pixantrone in PC3 human prostate cancer cells.  
Malignant cells were treated with mitoxantrone for (a)  2 hours, and (b) 24 hours.  For 
single-agent treatments (dark grey diamonds) the cell viability was assessed following the 
mitoxantrone treatments.  For combination treatments (light grey squares), 10 ng/mL of 
TRAIL was applied for 24 hours following the initial mitoxantrone treatments.  
Comparisons were made between the single agent and combination treatments; asterisks 
(*) and (**) indicate p-values < 0.05 and <0.01, respectively.  Data are presented on a 
logarithmic scale for x-axes in plots.  (c) Chemical structures for mitoxantrone (left) and 
pixantrone (right). 
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Single agent and combination treatment studies were conducted in the PC3 prostate 
cancer cell line with treatments of pixantrone and 10 ng/mL of TRAIL (Figure 4.20).  In 
these studies, single-agent TRAIL treatments induced an approximate 10% loss in cell 
viability.  The expanded dose range of pixantrone showed a dose dependant response 
after both 2 and 24 hours of treatment.  While the pixantrone/TRAIL combination 
treatments consistently showed higher efficacies than the single agent treatments, 
statistically significant sensitization only occurred for the high concentration drug 
treatments.  The 2 hour pixantrone treatment (Figure 4.20a) showed significant 
differences in cell viability after 13.3, 33.3, 66.6, and 100 μM treatments of TRAIL; the 
greatest difference in cell viability between the single agent and combination treatments 
was 27% (66.6 μM) which is then adjusted to 17% to account for the effect of single 
agent TRAIL.  This is in contrast to the 2 hour combinatorial studies performed in the 
same cell line with mitoxantrone (Figure 4.2b) where 6.6-100 μM treatments all showed 
a highly significant difference in the cell viability when comparing single agent and 
combination treatments.  These studies indicated that the largest difference in cell 
viability between the treatments to be 83% (66.6 μM) after taking the effect of TRAIL 
into consideration.  The LC50 analysis between the pixantrone and mitoxantrone 
treatments indicate that it is not possible to compare the value for the single agent drug 
treatments, but when looking at the combination treatments the LC50 value for pixantrone 
is greater than 100 μM while the value for mitoxantrone is approximately 9 μM.  These 
results indicate that pixantrone is a poor TRAIL sensitizer when compared to its analog 
mitoxantrone.  Although statistically pixantrone seems to have some synergy with 
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TRAIL, the overall effectiveness of the treatments is less than that of mitoxantrone, and 
requires significantly larger concentrations to achieve those effects. 
 
The 24 hour pixantrone treatments (Figure 4.20b) showed a significant difference in 
viability at 33.3 and 66.6 μM concentrations; the greatest difference in cell viability 
between the single agent and combination treatments was 22% (66.6 μM) after the 
adjustment made for the effect of single-agent TRAIL.  These results can be compared to 
the 24 hour combinatorial studies performed with mitoxantrone in PC3 cells (Figure 
4.2c).  These studies showed all treatments (0.33-100 μM) gave highly significant 
differences in the cell viability when comparing single agent and combination treatments.  
In the mitoxantrone studies, the greatest enhancement in drug activity occurred at the 
0.33 μM concentration where there was a 40% difference (the effect of TRAIL accounted 
for) in the cell viability between single agent and combination treatments.  By comparing 
the single agent LC50 values we see that pixantrone gives an LC50 value of approximately 
45 μM while mitoxantrone gives a value of 5 μM.  The LC50 values for the combination 
treatments are 20 μM and 0.1 μM for pixantrone and mitoxantrone respectively.  This 
suggest that a pixantrone dose is 200 time higher than an equivalent mitoxantrone dose 
when considering combination treatments.  These results confirm that, while it does 
appear to have some TRAIL-sensitization activity, the overall effect of pixantrone is 
significantly less than that of mitoxantrone.  The TRAIL-sensitization activity of 
mitoxantrone occurs following lower concentrations of treatment and is also more highly 
effective.  Additionally, these results indicate that single agent pixantrone is also less 
effective than single agent mitoxantrone.  The LC50 value for pixantrone is 9 times higher 
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than mitoxantrone.  This is not fully unexpected since the 24 hour, single agent, NAC 
viability experiments (Figure 4.16a) showed the ROS scavenging activity of NAC was 
able to reduce the effectiveness of single agent mitoxantrone which indicates that some of 
the toxicity of the drug is related to the generation of ROS; in the case of pixantrone this 
ROS generation is significantly reduced. 
 
Analysis of the pixantrone, a mitoxantrone analog, have shown that the drug is less 
effective at inducing mitochondrial depolarization, and generates lower concentrations of 
ROS.  It was hypothesized that the ROS mitoxantrone generates were primarily 
responsible for the TRAIL-sensitization activity of the drug and that since pixantrone 
generates fewer ROS, it should be less effective at sensitizing the cells to TRAIL.  These 
results confirm this hypothesis and provide additional evidence that ROS are key in the 
mitoxantrone sensitization mechanism. 
 
 
Western Blot Analysis of Pro-Apoptotic Mechanisms Influenced by Reactive 
Oxygen Species.  As mentioned previously, ROS are known to have a wide range of pro-
apoptotic activities.  As discussed in the previous chapter, excessive production of ROS 
can disrupt the electron transport chain and as a result the mitochondria can become 
damaged.  The resulting loss of mitochondrial membrane integrity can then facilitate the 
release of pro-apoptotic proteins like cytochrome C and SMAC/DIABLO [153].  
Additionally, ROS can also induce pro-apoptotic changes earlier in the apoptotic 
mechanism.  Elongation factors are a family of enzymatic proteins responsible for 
facilitating the movement of mRNA through the ribosome during protein synthesis [167].  
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One of these proteins called elongation factor 2 (EF-2) is known to be susceptible to 
oxidative phosphorylation caused by ROS; the phosphorylation of EF-2 deactivates the 
enzyme thereby decreasing overall protein synthesis [168].  As a result, the concentration 
of proteins with short half-lives begins to decrease and the effect of such proteins is 
attenuated [116].  Several anti-apoptotic proteins like cFLIP [169], XIAP [170], and 
survivin [171] are known to have short half-lives and as a result ROS are able to decrease 
resistance to apoptosis through this mechanism.  Additionally, ROS can also induce 
stresses in the endoplasmic reticulum leading to the activation of the CCAAT/ehnancer 
binding protein homologous protein (CHOP) [172].  Transcriptional DR5 expression can 
be regulated by CHOP as the protein binds to promoter regions of the DR5 gene [172, 
173].  As a result, expression of the death receptors increase, thereby making the cells 
more susceptible to extrinsically activated apoptosis. 
  
Our previous results indicated that ROS play a role in the TRAIL-sensitization activity of 
mitoxantrone and based on the known effects ROS can have on apoptotic functions, we 
targeted three specific proteins (DR5, CHOP, and c-FLIP) to understand what effects 
mitoxantrone-generated ROS were having.  Combination treatment experiments were 
carried out and analyzed using Western blot techniques (Figure 4.21).  The results of this 
analysis indicated that mitoxantrone had apparent effects on each of the proteins 
screened.  Using the live control (no treatment) as a basis for comparison, DR5 
concentrations all seemed to increase with the exception of the 6 hour single agent 
treatment.  The combination treatments at 6 and 24 hours showed 70% to 90% increases 
in DR5 concentration as summarized in Table 4.1.    The analysis suggests that CHOP  
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Figure 4.21  Western blot analysis following combination experiments with 
mitoxantrone.  PC3-TR prostate cancer cells were treated with 1 μM mitoxantrone for 2, 
6, and 24 hours.  For single agent treatments cell lysates were immediately collected (cell 
death was equal to 0%, 0%, and 70% for 2, 6, and 24 hours respectively); for 
combination treatments mitoxantrone was removed and treatments continued with 10 
ng/mL TRAIL for an additional 24 hours (cell death was equal to 75%, 85%, and 98% for 
2, 6, and 24 hours respectively.  Quantification of these results is provided in Table 4.1 
below. 
 
concentrations are highest for the single agent treatments with 70%, 210%, and 60% 
increases at 2, 6, and 24 hours respectively.  The combination treatment tend to slightly 
decrease CHOP concentrations.  The c-FLIP concentrations all appear to decrease for all 
treatment conditions tested with the combination treatments all producing 50% decreases 
in the concentration as compared to the live control.   
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Table 4.1  Summary of Western blot densitometry analysis.  Values are first normalized 
against the house-keeper protein (beta-actin) and then against the live control.  SA: Single 
Agent, CT: Combination Treatment. 
 
   
2 Hours 6 Hours 24 Hours 
 
Live 
Control 
TRAIL 
Alone SA CT SA CT SA CT 
DR5 1.0 1.3 ±0.3 1.2 ±0.1 1.2 ±0.0 1.0 ±0.0 1.7 ±0.3 1.3 ±0.2 1.9 ±0.2 
CHOP 1.0 0.9 ±0.1 1.7 ±0.1 0.8 ±0.0 3.1 ±0.8 0.8 ±0.0 1.6 ±0.2 1.0 ±0.0 
c-FLIP 1.0 0.8 0.7 0.5 0.9 0.5 0.8 0.5 
 
Taken together, the results from the Western blot protein analysis seem to follow the 
expected trends and provide confirmation that the generation of ROS is responsible for 
the TRAIL-sensitization activity of mitoxantrone.  The concentrations of DR5 and CHOP 
are related since excessive ROS leads to endoplasmic reticulum stress which cause an up-
regulation of CHOP followed by DR5.  The analysis shows that DR5 concentrations 
increase with the most significant of these increases occurring following the combination 
treatments at 6 and 24 hours.  The CHOP concentrations appear to greatly increase 
following the single agent treatments but then decrease during the combination 
treatments.  These results are somewhat surprising because the effect of the ROS should 
drive the concentrations of CHOP up much in the same manner DR5 concentrations 
increase.  To understand why this may be occurring it is important to identify how the 
timing of the experiment is set up.  For single agent treatments, protein lysates are 
collected after 2, 6, and 24 hours.  For combination treatments, the lysates are collected 
after 26, 30 and 48 hours due to the additional 24 hours added to each treatment (due to 
TRAIL).  Previous studies have shown CHOP mRNA to have a half-life of less than 4 
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hours [174].  The Western blot analysis seems to suggest that there is an initial increase 
in the CHOP expression between 2 and 6 hours but as the treatment time progresses to 
24, 26, 30, and 48 hours, CHOP expressions decrease significantly.  Because ROS also 
influence translational activity, the half-life of CHOP may be low enough that less of the 
protein is synthesized at the longer treatment times.  Analysis of the c-FLIP results 
indicate that concentrations of the protein decrease for each of the conditions tested.  This 
is in agreement with the expected trends since the ROS should reduce translational 
activity, leading to a decrease in the levels of c-FLIP (40 minute half-life [169]).  Since 
the combination treatments have the highest total treatment times, they show the greatest 
reduction in c-FLIP concentrations. 
 
The results of this analysis indicate that the TRAIL-sensitization activity of mitoxantrone 
is related to the generation of ROS.  The Western blot analysis has shown that 
mitoxantrone facilitates the CHOP-mediated, up-regulation of DR5 while simultaneously 
limiting translational activity resulting in the down-regulation of c-FLIP.  Both of these 
activities have pro-apoptotic effects and make the induction of apoptosis by TRAIL less 
difficult. 
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CONCLUSIONS 
Kinetic and mechanistic studies were used to identify the mechanisms responsible for 
mitoxantrone's TRAIL-sensitization activity.  These studies identified mitoxantrone as a 
mitochondrial depolarizing agent and confirmation studies showed that the drug 
consistently decreased the mitochondrial membrane potential over a wide variety of 
concentrations in different prostate, pancreatic, and breast cancer cell lines.  The 
concentrations of reactive oxygen species were also measured and shown to increase 
following treatments of mitoxantrone.  Results indicated that these cellular changes 
occurred during the first 6 hours of treatment with mitoxantrone and further kinetic 
studies indicated that the changes occurring during this time are sufficient to sensitize 
treated cells to TRAIL-mediated apoptosis.  Since ROS have been shown to have pro-
apoptotic activities, the ROS-scavenger NAC was characterized and shown to limit the 
TRAIL-sensitization activity of mitoxantrone.  The mitoxantrone analog, pixantrone was 
shown to produce few ROS than mitoxantrone and was also shown to be a comparatively 
poor TRAIL-sensitizer.  These results further implicated ROS as a major factor in 
TRAIL-sensitization.  Finally, Western blot analyses were conducted to determine what 
effects mitoxantrone treatments were having on apoptosis-related proteins.  Knowing that 
ROS appeared to play a role in the sensitization activity, a small screen of these proteins 
showed that mitoxantrone treatments limit the generation of the anti-apoptotic protein c-
FLIP, and increase the expression of the pro-apoptotic proteins CHOP and DR5. 
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CHAPTER 5 
FUTURE DIRECTIONS 
 
INTRODUCTION 
The primary objective of the research presented to this point has revolved around the 
identification of FDA-approved drugs that can be used in novel chemotherapeutic 
treatment methodologies and how these methodologies can be improved and enhanced.  
To this end we have:  1) described the screening and identification of drugs that act 
synergistically with the pro-apoptotic protein TRAIL, 2) worked to design, build, and test 
a microfluidic device that can be used to optimize the experimental conditions to make 
the combination treatments more effective, 3) and identified the mechanism responsible 
for the TRAIL sensitization activity of the antineoplastic drug, mitoxantrone.  In this 
outline the work that I believe to be the next steps in the evolution of this work.  
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FUTURE DIRECTION 1:  Screen the remaining drugs in the John Hopkins 
Clinical Compound Library for TRAIL-sensitization activity and identify the 
mechanism of action of identified leads. 
Introduction 
Chapter 2 describes how we screened a small set of FDA-approved antineoplastic drugs 
for their ability to work synergistically with TRAIL to induce cell death in various cancer 
cell lines.  This selective screen was done with antineoplastic agents since some of the 
antineoplastic drugs from the library had previously been shown to work in combination 
with TRAIL and we could verify the results of our screen by comparing the drugs we 
identified with those in the literature.  It was also beneficial to study antineoplastic drugs 
since the majority of these drugs are nucleosides and their activities are closely coupled 
with the apoptotic machinery used by TRAIL.  During this screen we identified several 
drug candidates which showed an enhanced effect when used in combination with 
TRAIL and we further characterized the activity in additional cell lines while confirming 
our results.  Additionally, we also looked at how the combination treatment 
methodologies could be changed and what effect that would have on cell viability.  In 
order to expand these studies it will be necessary to perform a rigorous mechanistic 
evaluation of the identified leads in order to understand why TRAIL-sensitization is 
occurring like the one completed for mitoxantrone.  It is also desirable to complete the 
screening studies with the remaining compounds in the drug library to see if there are 
drugs that fall outside of the antineoplastic class that also show synergy with TRAIL. 
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Hypothesis 
Our previous research has already identified several chemotherapeutic drugs that 
sensitize various types of cancer cells to TRAIL-mediated apoptosis.  Future research 
should expand the screen outside of the antineoplastic drug class in an attempt to 
indentify addition FDA and foreign approved drugs that exhibit TRAIL-sensitization 
activity.  By developing a detailed understanding of how the sensitization activity occurs 
it will be possible to develop treatment strategies with these drugs that can be rapidly 
translated from benchtop to patient bedsides.  Additionally, an understanding of these 
mechanisms can lead to the identification/development of other drugs useful for 
combination treatments with TRAIL.   
 
Experimental Design 
The previous screening of the antineoplastic agents was manually done in 96-well plates 
with an initial screen conducted at 20 µM followed by a screening at 10 µM for drugs 
that showed a decrease in cell viability greater than 30%.  Drug concentrations were kept 
low in these experiments in order to limit the toxicity of the drugs since their primary 
activity was specific to the treatment of cancer.  The activities of the single-agent drug 
treatments were then compared to the activity of the drugs used in combination with 
TRAIL (sequential treatment).  Leads were identified as drugs that showed a decrease in 
cell viability that was significantly greater than the loss of viability induced by the sum of 
the single-agent drug and single-agent TRAIL treatments.  Screening of the remaining 
compounds should be carried out using the same process but in the case of the treatment 
concentrations, it may be necessary to screen at concentrations above 20 µM since it may 
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be difficult to determine what concentrations of these drugs will be effective for treating 
cancer when the majority of the remaining drugs are not used for this purpose.  In order 
to rapidly screen the remaining compounds in the drug library it would be advantageous 
to use a high-throughput liquid handling system (LHS).  In order to a LHS it will be 
necessary to generate a working protocol that mimics the studies performed in the well 
plate but that is amenable to use by the screening robot.  Drugs from the compound 
library are provided as 10 µM aliquots and distributed among several 96-well plates.  The 
first step in preparing the drugs for treatment would be making 2000 µM drug dilutions 
for the initial 20 µM treatment.  2000 µM stock concentrations are necessary so the total 
treatment volume is not below the working range of the machine (< 1 µL) and that the 
total solvent concentration is less than 1% (v/v) when the drug is applied to the cells.  By 
providing a 96 well plate prefilled with the solvents for each drug, it will be possible to 
use a LHS to mix the drug dilutions thereby creating a 96 well plate of 2000 µM drug 
dilutions.  These 2000 µM drug plates can then be used to treat plates of adherent cells 
directly.  For single agent treatments, following the incubation of drug treated cells for 24 
hours, the LHS will remove and refresh the culture media and then the LHS will be used 
to treat cells using the MTT assay.  The conversion of the MTT reagent to MTT can be 
measured using the microplate reader as previously described.  For combination 
treatments, the cells should be incubated with 10 ng/mL of TRAIL following the initial 
drug treatment.  In this case, the TRAIL can be premixed with the cell culture media and 
applied when the LHS refreshes the media after the first 24 hour treatment.  An MTT 
analysis should then be carried out after an additional 24 hour TRAIL treatments.  In all 
experimental cases, replicate experiments should be set up across different 96 well plates 
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since the LHS is not able to apply the same drug treatment to adjacent wells.  For 
example, the screening of one 2000 µM drug plate will require three separate 96 well 
plates with adherent cells for triplicate data. 
 
When running the experiments using the liquid handling system the rate determining step 
will be how fast cells can be grown to confluence and the number of 96 well plates the 
cells will be able to fill; making drug dilutions and doing drug treatments should only 
take a few minutes to run using the LHS.  There are a total of 24 drug plates in the 
JHCCL and assuming that all results will only need to be run at a single concentration in 
triplicate, the single agent treatments will require 72 plates with adherent cells and the 
combination treatments will require an additional 72 plates.  The rate of cell growth is 
dependent on the line, but a conservative estimate would be that 18 plates can be made in 
a week which means that the total screening project could be finished in as little as 2 
months but it would likely take closer to 3 months since it is unlikely that 20 µM will be 
the optimum concentration for all 24 drug plates. 
 
Along with screening the remaining compounds in the JHCCL, the second part of this 
study should be the rigorous mechanistic evaluation of the lead compounds that showed 
TRAIL sensitizing activity.  Such an analysis would be similar to that described in 
Chapter 4 of this document although since different drugs will have different activities, 
the exact progression of the evaluations will vary, but a general outline will be described.  
The ability of TRAIL to induce cell death in malignant cells is a result of the drug 
activating the extrinsic apoptotic mechanism.  As previously described, TRAIL binds to 
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death receptors on the outer membrane of the cell which leads to the eventual formation 
of the death-inducing signaling complex (DISC) which can either induce apoptosis 
directly or can use the intrinsic pathway as an amplification loop and induce apoptosis in 
that manner.  In order to evaluate the mechanism of action of the TRAIL sensitizing 
drugs it will be necessary to monitor the levels of proteins that are involved in TRAIL-
induced apoptosis.  Specifically we will monitor the levels of pro-apoptotic proteins (e.g. 
DR 4 and 5, caspase 3, cytochorme c) and anti-apoptotic proteins (Decoy Receptors 1 and 
2, c-FLIP, Bcl-2) to determine if combination treatments show any changes in the protein 
expression levels and if so which ones.  These studies will be carried out using Western 
blots.  Since the activity of TRAIL is rooted in apoptosis, monitoring the levels of 
apoptotic proteins provides an excellent starting point for the mechanistic evaluation.  It 
is expected that in most cases there will be some change in the apoptotic machinery that 
makes TRAIL-induced apoptosis more effective.  The TRAIL sensitizing activity of 
doxorubicin is well characterized and is partially attributed to the down-regulation of c-
FLIP [108, 113] and the up-regulation of pro-apoptotic caspases [114, 115].  Using 
information such as this, we can form hypotheses based on the results we see and the 
treatments we are using as to why a particular drug treatment works synergistically with 
TRAIL.   
 
The results from the antineoplastic drug screen identified several drugs that showed the 
ability to sensitize cells to TRAIL.  This is expected since the activity of these drugs is 
related to their ability to cause DNA damage and is therefore closely related to the 
induction of apoptosis.  The mechanisms of action of many of these drugs have been 
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described while the mechanisms for many others have not.  By monitoring changes in the 
protein levels and comparing our results to the activity of other drugs described in the 
literature it should be possible to evaluate why the lead candidates in this screen (e.g. 
mitoxantrone and mithramycin) are effective with TRAIL.  Following the complete 
screening of the JHCCL it is possible that additional TRAIL sensitizers that fall outside 
of the antineoplastic drug class will be identified.  Describing the mechanism of 
sensitization of such drugs will be potentially more difficult since the activity may fall 
outside of the apoptotic pathway.  However, by using the known activity of TRAIL as a 
starting point and monitoring cellular changes the drugs induce, it should be possible to 
elucidate these types of mechanism as well. 
 
Evaluating a large library of FDA-approved drugs has both short-term and long-term 
advantages.  On the short-term side, identifying alternative uses for FDA-approved drugs 
provides a means of reducing the costs associated with the research and development of 
drugs as well as the costs associated with the FDA testing and approval of the drugs; the 
drugs are already made and a portion of the FDA testing is already completed so time and 
money are saved.  This means that the transition between the lab findings and patient 
treatments could be significantly reduced.  The future trajectory of these short-term 
studies should be centered around the testing of these different combination treatments 
in-vivo.  Before any type of transition to patients occurs it is necessary to confirm that the 
combination treatments are effective outside of plate based experiments and that such 
treatments are not overly harmful to healthy tissue. 
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In addition to in-vivo experiments, future work with these drugs/TRAIL should include a 
strategy for the delivery.  Although the effect of TRAIL is cancer cell specific, the effect 
of many other drugs is not.  It may be possible to mitigate this effect by using relatively 
low concentrations of the sensitizer drugs but non-specific effects are always a concern.  
Developing a cancer-targeting delivery system should not only reduce damage to non-
malignant cells but can also enhance the efficacy of the treatment.  In addition to 
targeting functionality, the delivery systems could potentially incorporate both the drug 
and TRAIL on a single carrier making it possible to apply a single treatment instead of 
multiple ones.  One limitation of any delivery system is that the system itself has to be 
approved for use by the FDA and while the focus of our work is to limit the cost 
associated with the FDA approval, delivery systems may be necessary to limit the non-
specific effects of a given treatment.      
 
The long-term advantages of screening the library and identifying the mechanism of 
action of the drugs is that it may be possible to determine what functionality the drugs 
have and how it relates to their TRAIL sensitizing activity.  From this information it may 
be possible to model the effect of specific TRAIL sensitizing activities and using this 
information to identify compounds outside of the JHCCL that may also have this activity.  
Although our research is mainly concerned with identifying leads that have already been 
approved by the FDA, this strategy could also be applied to designing new drugs with a 
specific TRAIL sensitization functionality.  Essentially, the complete screening and 
understanding of this library will provide specific information about the chemical 
characteristics that help these drugs work synergistically with TRAIL and so the directed 
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synthesis of compounds that take advantage of these characteristics could should 
enhanced efficacy and specificity. 
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FUTURE DIRECTION 2:  Design and testing of in-vitro systems that emulate the 
tumor microenvironment of pancreatic cancer. 
Introduction 
The objective of this proposed research is to develop an in-vitro model of the 
desmoplastic reaction associated with pancreatic cancer in order to maximize the 
treatment efficacy of chemotherapeutic treatments.  The study described in Chapter 2 
identified several FDA-approved chemotherapeutic drugs that sensitize pancreatic cancer 
cells to TRAIL-mediated apoptosis in-vitro.  The proposed research will test the efficacy 
of these drugs in an environment in which pancreatic cancer are co-cultured with 
pancreatic stellate cells and fibroblasts in order to rapidly identify drugs that retain their 
TRAIL sensitizing effect in the pro-survival microenvironment while simultaneously 
developing a platform that can be used for the testing of other treatment methodologies. 
 
Pancreatic cancer is the fourth most lethal cancer in the United States.  Every year, 
approximately 44,000 individuals are diagnosed with pancreatic cancer and over 37,000 
people die from the disease [175].  The most common type of pancreatic cancer is 
pancreatic ductal adenocarcinoma (PDAC), accounting for more than 85% of occurrences 
[176].  PDAC has a 5-year survival rate between 3-5% and a median survival of less than 
6 months [177].  The extreme lethality of pancreatic cancer demands new and effective 
ways to combat the disease and to improve the quality of life of patients.  The poor 
efficacy of chemotherapeutic drugs can be partially attributed to the fibrotic 
(desmoplastic) response in PDAC [178-180].  Specifically, pancreatic cancer cells can 
recruit other cell types, like fibroblasts and stellate cells, to create an environment that 
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promotes proliferation of the cancer cells [181].  Components of the extracellular matrix 
form and help protect malignant cells by limiting the access of chemotherapeutic drugs, 
thereby decreasing the overall effect [180].  The fibrotic response and its associated 
microenvironment present a key challenge in the effective treatment of pancreatic cancer. 
 
The median survival of patients with PDAC is six months with a 5-year survival rate of 
3-5% [177]. Surgical options are available if the disease is diagnosed early, increasing the 
median survival to 18 months and the 5-year survival to approximately 25 percent [182, 
183].  However, only 10-15% of PDAC cases are eligible for surgery upon diagnosis 
[184].  The fibrotic (desmoplastic) response [178-180] in PDAC is largely responsible for 
the low efficacy of chemotherapeutic drugs. Pancreatic cancer cells will recruit other 
types of cells, including stellate cells and fibroblasts, to promote cell survival. Formation 
of an extracellular matrix (collagen) promotes pancreatic cancer survival through the 
expression of genes that promote proliferation, while simultaneously limiting drug 
penetration [185, 186].  Effective PDAC treatment methods need to be developed in 
order to improve the prognosis of the individuals afflicted with this disease. 
 
The expression levels of Death Receptors 4 and 5 (DR4 and DR5) are significantly 
elevated in PDAC compared to non-malignant pancreatic cells [187, 188].  Although 
PDAC cells express death receptors, they are resistant to low concentration treatments of 
TRAIL (1-100 ng/mL) as shown in our initial finding.  At higher concentrations (> 200 
ng/mL) investors report increased cell death with TRAIL treatment [189]. In-vitro studies 
have also shown the sensitivity of PDAC cells to TRAIL treatments correlate with their 
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levels of DR4 and DR5 expression [190]
 
and K-Ras status [191].  In-vivo studies have 
shown that patient primary tumor xenografts included a mix of TRAIL-sensitive and 
TRAIL-resistant pancreatic tumors [192]. Furthermore, death receptors antagonist 
antibodies have demonstrated antitumor activities in PDAC cell lines and animal models 
[61, 193]. These results all indicate that TRAIL-based therapies are a viable treatment 
option for PDAC. 
 
Hypothesis 
By co-culturing pancreatic cancer with pancreatic stellate cells and fibroblasts in collagen 
and Matrigel, it should be possible to create an in-vitro screening model that better 
emulates the tumor microenvironment associated with PDAC.  It will also be interesting 
to examine how the co-cultures will react when grown on top of amikacin hydrogels 
developed in our lab; these hydrogels shown that a large number of cell lines cultured on 
these hydrogels have the propensity to aggregate and for spheroids.  These platforms will 
be useful for the design and testing of chemotherapeutic options, potentially leading to 
lowered failure rates and higher probability of translation.  In addition, the in-vitro 
systems developed in this research can be used to develop targeted treatments and 
delivery vehicles that exploit the characteristic properties of the microenvironment aiding 
in the treatment and prevention of the disease. 
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Experimental Design 
Previous investigations (described in Chapter 2) identified several chemotherapeutic 
drugs that exhibited the ability to sensitize pancreatic cancer to TRAIL-mediated cell 
death.  The immediate studies can be used to determine if these chemotherapeutic 
treatments are effective in systems that are more representative of the pancreatic tumor 
microenvironment.  To replicate these environments we it will be interesting to study 
both well-plate based, and microfluidic based experiments (as described in Chapter 4).  
Research should focus on looking at co-cultures of pancreatic cancer cells and pancreatic 
stellate cells/fibroblasts and how collagen, Matrigel, and the amikacin hydrogels can be 
used to make more representative, in-vitro models. 
 
Well plate based experiments should primarily focus on growing co-cultures in 
collagen/Matrigel [185, 194, 195] and using amikacin hydrogels to form spheroids.  
Cultures of cells can be plated in a variety of different manners in order to test as many 
different geometries as possible in order to determine the limitations associated with 
different geometries.  Some geometries that can be considered are: cultured cells grown 
on a plate bottom with collagen/Matrigel on top of the cells; cells grown on top of 
collagen/Matrigel; cells cultured between a sandwich of collagen/Matrigel; and three-
dimensional geometries in which cells are cultured within a collagen/Matrigel support 
structure; importantly, the amikacin hydrogels are shown to be able to form three-
dimensional spheroids without the need for collagen/Matrigel support structures.  These 
systems are of particular interest because they create a physical barrier that will need to 
be overcome in order to effectively treat the pancreatic cancer.  Cells will be treated with 
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the sensitizing drug/TRAIL treatment as previously described but in addition to analyzing 
cell-viability, it will be important to identify how the treatments diffuse into the different 
geometries. 
 
 
Figure 5.1  Microfluidic based, co-culture experiments.  The experimental set-up for 
these experiments is divided into 3 stages.  The first stage is the seeding of the PDAC and 
stellate/fibroblasts.  The second stage is treatment with the TRAIL-sensitizing drug and 
the final stage is treatment with TRAIL. 
 
Microfluidic based experiments will focus on identifying how the efficacy of 
chemotherapeutic drugs change when malignant cell lines are co-cultured with cells that 
promote a pro-survival environment.  It will be important to also investigate how the 
composition of these co-cultures will effect chemotherapeutic options.  To do this we will 
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use the microfluidic device described in Chapter 2.  The methodology of how we will set 
up and test the experiments is shown in Figure 5.1.  In the first stage of the experiment a 
cell solution of PDAC cells will be injected into one of the inlets of the microfluidic 
device while a cell solution of pancreatic stellate/fibroblasts will be injected into the 
other.  This will create a gradient of different cell mixtures in the microfluidic device.  
For example 100% PDAC/0% Stellate cells to 0% PDAC/100% Stellate cells.  The 
second stage of the experiment will be the treatment of the co-cultures with a TRAIL-
sensitizing drug for 24 hours (although it is possible to apply the drug for any period of 
time).  In this case the drug gradient will be produced via LabView and manipulation of 
the pneumatic valves.  For single agent analysis the experiment should conclude after the 
second stage at which point the cells are stained for fluorescent image analysis.  In the 
case of combination treatments, the third stage is the treatment of the co-cultures with 
TRAIL for an additional 24 hours.  In this stage a single concentration of TRAIL is 
injected into both microfluidic inlets.  This is the limiting step in our experiment since we 
can only test one concentration of TRAIL at a time but the speed with which experiments 
can be run on the microfluidic platform should prevent this from being a problem. 
 
In order to better understand the interactions between the pancreatic cancer and the 
stellate cells it will be important to monitor molecular mechanisms.  By monitoring the 
levels of proteins that have been implicated in the recruitment of stellate cells by 
malignant pancreatic cancer cells (e.g. interleukin (IL)-1, (IL)-6, transforming growth 
factor (TGF)-β1) [181, 196, 197] and the levels of proteins expressed in an environment 
that is favorable to cancer cell growth (e.g. α-SMA, collagen) [181] it will be possible to 
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determine if the co-culture systems we are developing are better models for the tumor 
microenvironment than systems where only pancreatic cancer cells are present.  In 
addition, it is also important to understand the behavior of cells after drug treatments 
since we are interested in measuring the efficacy of our sensitizer drug/TRAIL 
treatments.  This information can then be used to understand why a particular treatment is 
effective and potentially suggest/develop better treatment methodologies. 
 
The first set of mechanistic evaluations will compare protein levels of the pancreatic 
cancer cells grown alone, pancreatic stellate/fibroblasts grown alone, and the cells grown 
in co-culture.  The levels of proteins that relate to the tumor microenvironment and of 
apoptotic related proteins, specifically those involved in the execution/inhibition of 
TRAIL-mediated apoptosis (e.g. DR 4 and 5, XIAP, c-FLIP, Bcl-2) should all be 
monitored.  This can be done with a variety of different co-culture ratios in order to 
determine how protein levels in these systems change based on the concentration of 
different cells in co-culture.  Protein levels can be evaluated using Western Blots in plate-
based experiments.  In addition to the mechanistic studies, it will be necessary to 
understand if/how the cell viability will change in these experiments.  It should be noted 
that although the primary studies on viability changes in cells grown as co-culture will be 
explored using the microfluidic system, it will be important to document these changes in 
the well plate experiments as well.  This will also allow for a comparison between the 
two experimental set ups.  
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The second set of mechanistic evaluations should examine how cancer cells react when 
grown in the presence of collagen/Matrigel or when grown on amikacin hydrogels.  
Using these results we will be able to compare the protein levels in co-culture with and 
without collegen/Matrigel and protein levels of spheroids formed on amikacin gels.  
Additionally, the cell viability in these systems should also be evaluated. 
 
Additional mechanistic evaluations will focus on the health of cells following treatments 
with TRAIL-sensitizing drugs and TRAIL.  These results can be compared to cell 
treatments carried out in non-co-culture experiments.  This can help identify the reason 
for any discrepancies in efficacy between the single cell type and co-culture systems.  
These evaluations are important in developing treatment methodologies that are more 
effective in a pro-survival type of microenvironment. 
 
Successful completion of this aim will result in the development of an in-vitro system 
that better emulates the tumor microenvironment associated with pancreatic cancer.  Such 
a platform would be of extreme value for the design and testing of chemotherapeutic 
treatment options.  While our studies are mainly focused on combinatorial treatments 
with TRAIL, this is only a single treatment methodology and the system could potentially 
be used for any pancreatic cancer therapies.  Being able to mimic the physiological 
conditions associated with pancreatic cancer would certainly be of high value and it could 
lead to improved treatment methodologies.  Such a system would also provide the 
opportunity to exploit the characteristic properties of the microenvironment for targeting 
and delivery purposes. 
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APPENDIX A 
IDENTIFICATION OF MITOCHONDRIA DAMAGING AGENTS USING A 
PARALLEL SCREEN OF ANTINEOPLASTIC DRUGS 
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INTRODUCTION 
Mitochondria represent key components in the intrinsic apoptotic pathway. An important 
step in this process involves the mitochondrial permeability transition which represents a 
"point of no return" in the execution of cellular apoptosis [198].  This loss of 
mitochondrial integrity results in the release of pro-apoptotic proteins (e.g. cytochrome-c, 
SMAC/DIABLO, and apoptosis inducing factor) from the mitochondria into the 
cytoplasm, leading to the activation of execution caspases and ultimately apoptosis [198].  
Traditional chemotherapeutics typically induce genomic DNA damage in order to trigger 
apoptosis signaling in cancer cells; while DNA-damaging chemotherapeutics have been 
relatively successful either by themselves or in combination therapies [41, 76], many 
studies indicate that the over expression of anti-apoptotic proteins is responsible for 
overcoming the pro-apoptotic signal triggered by these chemotherapeutics and is partly 
responsible for less effective treatments and increased cellular resistances [44, 77, 199].  
For instance, the anti-apoptotic protein, Bcl-2 prevents the mitochondrial pore opening 
resulting in the resistance of cancer cells to chemo/radiation therapy [78, 200].  
Consequently,  therapeutic strategies that directly damage the mitochondrial and induce 
cellular apoptosis are attractive since they can bypass resistance mechanisms that act 
upstream of the mitochondria to prevent mitochondrial pore opening and apoptosis (e.g. 
p53 mutation / knockdown, over-expression of bcl-2, etc.) [75, 83, 201, 202]. 
 
The large negative potential gradient (approximately -160 mV) across the mitochondrial 
membrane [82]
 
drives the mitochondrial accumulation of positively charged amphipathic 
molecules. Additionally, cancer cells possess a higher potential difference (-200 to 220 
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mV) across mitochondrial membranes compared to non-malignant cells, which accounts 
for some inherent selectivity of this therapeutic approach.  In time, the localization of 
these molecules results depolarization of the mitochondrial membrane.  This in turn leads 
to the membrane permeability transition and ultimately the release of pro-apoptotic 
proteins from the mitochondria resulting in apoptosis [83].  By monitoring changes in the 
mitochondrial membrane potential (MMP), we can assess the effect of different treatment 
options at depolarizing the mitochondrial membrane.  In addition to changes in the 
membrane potential and the related increase in pro-apoptotic proteins, mitochondrial 
health can also be evaluated by monitoring several other factors including reactive 
oxygen species (ROS), pH, and concentrations of ATP, calcium, and potassium [203, 
204]. 
 
This appendix describes the parallel screening of fifty-five FDA-approved 
chemotherapeutic drugs used to identify agents that demonstrate the ability to cause 
direct damage to the mitochondria of prostate, pancreatic, and breast cancer cells.  
Mitochondrial health was assessed my monitoring changes in the mitochondrial 
membrane potential using the fluorescent dye, JC-1.  Drugs were first screened at a 
concentration of 20 M using PC3-TR prostate cancer cells.  Drug candidates that 
demonstrated mitochondrial depolarizing activity were rescreened at a concentration of 
50 µM.  A total of five potential mitochondria depolarization agents were identified from 
the screen.  Of these leads, only mitoxantrone showed consistent depolarization activity.  
To maximize the therapeutic potential of mitoxantrone to depolarize/damage 
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mitochondria, we have incorporated the drug into micellular-based, drug delivery 
systems. 
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METHODS 
Cell Culture Techniques 
Two human prostate cancer cell lines (PC3, and PC3-TR), two human pancreatic cancer 
lines (MIAPaCa2, and BXPC-3), and one human breast cancer line (MDA-MB-231) 
were used in the current study.  PC3-TR (TR: TRAIL resistant) [101] cells were a 
generous gift from Dr. Aria Olumi at the Massachusetts General Hospital in Boston, MA. 
Cells were grown in 75 cm
2
 Corning cell culture flasks with RPMI 1640 tissue culture 
media supplemented with 10% Fetal Bovine Serum and 1% penicillin / streptomycin 
(10000 units/mL penicillin G and 10000 μg/mL streptomycin) at 37°C with 5% CO2.  
 
Reagent/Drug Preparation 
The Johns Hopkins Chemical Compound Library (JHCCL) [102] was purchased from 
The Johns Hopkins University School of Medicine. The library contains a total of 1514 
FDA- and foreign-approved drugs.  The anti-neoplastic plate (plate #1) consists of 55 
FDA-approved approved anti-cancer drugs and was employed in the screen for 
identifying mitochondria depolarizing agents.  Stock solutions of the drugs included in 
the library were supplied as 10 mM aliquots solubilized in either DMSO or water. For 
expanded dose-response experiments, additional mitoxantrone were purchased from 
Sigma. All solutions were prepared to ensure that the final solvent (DMSO or water) 
concentration in cell treatments would be less than 1% (v/v) to limit non-specific activity.   
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Mitochondrial Depolarization Experiments 
Cells were plated in black, clear-bottom 96 well plates at a density of 8,400 cells/well and 
incubated at 37°C with 5% CO2 for approximately 24 hours. Cells were then incubated 
with 6.39 µM of JC-1 dye (Sigma) for 1-1.5 hours after which the cell culture media was 
removed and refreshed.  Drug solutions were then added to the dye-treated cells; a set of 
control wells were treated with 1% (v/v) of the solvent alone to serve as a live control 
although, there was no difference between the cells treated with 1% solvent (water and 
DMSO) and cells with no treatment.  After the final treatment, fluorescent measurements 
were immediately taken using the Biotech Synergy 2 Multi-Detection Microplate Reader 
for green fluorescence (Ex. 485/40, Em. 528/20) and red fluorescence (Ex. 485/40, Em. 
590/35).  Following the fluorescence measurement, cells were incubated at 37°C with 5% 
CO2 and were periodically removed to take readings at various time points. 
 
Analysis of the JC-1 fluorescent data was carried out in order to determine changes in the 
MMP of the treated cells compared to the live control cells.  First the ratio of red 
fluorescent intensity/green fluorescent intensity was calculated for each well.  The 
average R/G ratio for the live control cells was calculated and the remaining R/G ratios 
were normalized against this value.  This is done in order to account for the decrease in 
the R/G ratio caused by the dye.  A second normalization was then performed for each 
treatment against itself at the 0 hour reading (i.e. all R/G ratios measured in a given well 
were divided by the R/G ratio in that well at the 0 hour time point).  This normalization is 
done so comparisons between data can be easily made since at the 0 hour time point, all 
wells will give a normalized value of 100%. 
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Statistical Analyses 
All experiments were performed in at least triplicate. Data are presented as the mean  
one standard deviation.  Standard deviation of a data set was calculated based on 
experimental variation.  ANOVA was performed using the t-test function in Microsoft 
Excel. 
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RESULTS AND DISCUSSION 
In this study, a library fifty-five FDA- and foreign-approved antineoplastic drugs from 
the Johns Hopkins Clinical Compound Library (JHCCL) was screened in order to 
identify drugs that caused direct mitochondrial damage to prostate and pancreatic cancer 
cell lines.  PC3-TR (TR: TRAIL resistant) human prostate cancer cells were used in the 
primary screening, since little work studying mitochondrial depolarization had been done 
in the cell line and because the cells are representative of cancer that posses inherent 
resistance to apoptosis. 
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Figure A.1  50 µM screening of the John Hopkins Clinical Compound Library for 
mitochondrial depolarization activity.  53 antineoplastic drugs were screened at a 20 µM 
concentration and those that showed a depolarizing effect were retested at 50 µM.   
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Screening and Identification of Mitochondria Depolarization Agents from a Library 
of FDA-Approved, Antineoplastic Drugs.  The library of fifty-five, FDA-approved, 
antineoplastic drugs was initially screened using a drug concentration of 20 µM (data not 
shown).  The drug concentration was kept low in order to limit the cytotoxicity of the 
drugs since the goal of the screen is to identify drugs that induce mitochondrial damage 
and that do not outright kill the cells due to their primary effects (e.g. nucleoside).  This 
initial 20 µM screen identified five drugs that appeared to induce mitochondrial 
depolarization:  Anthracene, arsenic trioxide, gold sodium thiosulfate, mitoxantrone, and 
quinaldine blue.  In general, the loss of MMP caused by these drugs was low to moderate 
so, in order to confirm their depolarizing activities, the drugs were tested at a 
concentration of 50 µM as shown in Figure A.1.  These data shows that arsenic, gold, 
mitoxantrone, and quinaldine blue all cause a reduction in the R/G ratio and that 
anthracene initially shows a small increase in the R/G ratio but at later time points 
showed a very small loss of membrane potential. 
 
Of these drug candidates, mitoxantrone was of particular interest due to the fact that our 
previous studies had identified the drug as a potent TRAIL sensitizer and we had also 
elucidated the mechanisms by which TRAIL-sensitization occurred.  Of the other drugs 
identified, both arsenic and gold have been shown to have a depolarization effect [205, 
206].  Anthracene has not been previously shown to have depolarizing activity, but its 
limited efficacy at both 20 µM and 50 µM restrict its use in additional experiments.  To 
the best of our knowledge, quinaldine blue has not been previously identified as a 
mitochondria depolarizing agent and so it and mitoxantrone were selected for additional 
182 
characterization via expanded dose range experiments.  However, it was during these 
additional experiments that the behavior of quinaldine blue was found to be quite erratic; 
in some experiments the drug had a depolarizing effect while in others treatments caused 
an increase in membrane potential.  It is for this reason that work with quinaldine blue 
was suspended and our focus on became identifying methodologies that could be used to 
selectively deliver mitoxantrone to malignant cells and provide an opportunity for the 
drug to induce mitochondrial depolarization. 
 
Depolarization Study of Mitoxantrone-Loaded Micelles.  Due to the elevated, negative 
membrane potential of cancer cells, it is expected that cationic mitochondria damaging 
agents should have some selectivity toward malignant cells.  However, since 
mitoxantrone is a genotoxic compound, it is important to protect healthy cells from non-
specific activity.  To this end our studies shifted from drug discovery to drug delivery and 
identifying a suitable delivery system for mitoxantrone.  Such a system should be able to 
maintain the efficacy of the mitoxantrone treatment while providing a backbone from 
which targeting bodies can be attached for the treatment of malignant cells. 
 
Polyethylene glycol- phosphoethanolamine (PEG-PE) based micelles have previously 
been used to encapsulate a wide variety of drugs including antineoplastic compounds like 
paclitaxel [207] and docetaxel [208].  In general, PEG-PE micelles are used for 
encapsulating drugs with low solubility in water [209] but what is more relevant to the 
current study is that the micelles have been shown to increase the efficacy of 
encapsulated drugs when conjugated with targeting molecules that help to selectively 
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delivery the drugs to the area of affliction [210, 211].  These previous results suggested 
that PEG-PE micelles could be used to encapsulate mitoxantrone and that these 
mitoxantrone-loaded micelles could then be delivered to cancer cells.  The studies 
detailing these studies are the subject of an article titled "Sensitizing cancer cells to 
TRAIL-induced death by micellar delivery of mitoxantrone."  The article is currently 
undergoing revisions for submission into Nanomedicine-UK.  These studies have shown 
that PEG-PE micelles with different end functionalities, can be loaded with mitoxantrone 
and separated from empty micelles using size exclusion chromatography.  
Characterization of these mitoxantrone-loaded micelles includes size and zeta potential 
measurements using dynamic light scattering, confirmation of mitoxantrone 
encapsulation using NMR and confocal microscopy, and loading and stability 
measurements calculated using the standard adsorption curve generated for known 
concentrations of the drug.  These studies represent a significant amount of effort but 
most of this work was done by my colleague and will be detailed in the published 
document.  However, the focus of that article is on the mitoxantrone-encapsulated 
micelle's ability to retain their TRAIL-sensitizing activity.  These studies focus on the 
study of the mitochondrial depolarizing activity of the drug-loaded micelles. 
 
The depolarization efficacy of mitoxantrone-loaded micelles was evaluated and 
compared to the performance of mitoxantrone alone, of empty micelles, and of a free 
mixture of the drug and empty micelles in PC3-TR cells (Figure A.2).  In these 
experiments measurements were only taken at the initial 0 hour time point and after 6 
hours since our kinetic studies suggested that the depolarization effects of mitoxantrone  
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Figure A.2  Mitochondrial depolarization studies of mitoxantrone-loaded PEG-PE 
micelles in PC3-TR prostate cancer.  Cells were treated with 20 µM of free mitoxantrone, 
20 µM of mitoxantrone encapsulated in micelles, and an equivalent volume of the empty 
micelles both as a single agent and in a mixture with 20 µM of the drug.  Asterisks (**) 
indicate p-values of < 0.01 when comparing the 0 hour and 6 hour data. 
 
equilibrated after 6 hours and there is only a small reduction in the cell viability.  These 
results showed that mitoxantrone, mitoxantrone-loaded micelles, and the free 
mitoxantrone/empty micelle mixture all caused a significant decrease in the normalized 
R/G fluorescent ratio when compared to the 0 hour reading.  Additionally, all three 
treatments appear to have the same effect and after 6 hours the treatments show an 
approximate 60-70% decrease in the R/G ratio suggesting an overall loss of MMP.  The 
empty micelle control showed an approximate 8% decrease in the R/G ratio.  Although 
the 8% difference is not statistically significant here, it is likely that the empty micelles 
are having a depolarizing effect on the cells since at higher concentrations, the empty 
micelles do cause a significant reduction in the R/G ratio (not shown).  Additionally, this 
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depolarizing effect of empty micelles explains why the free mitoxantrone/empty micelle 
mixture and the mitoxantrone loaded micelles show a slightly higher loss in the R/G ratio 
as compared to the mitoxantrone alone treatments.  Taken together, these results suggest 
that the mitochondrial depolarizing activity of mitoxantrone is maintained after it is 
encapsulated into PEG-PE micelles and that there is application of the micelles as a 
delivery vehicle for the drug.  Our lab has been able to form carboxy, amine, and 
methoxy-terminated, mitoxantrone-loaded micelles all of which provide their own 
advantages for the linking of various targeting, imaging, or sensitization agents.  The 
micelles provide the backbone for a drug delivery system that can carry mitoxantrone and 
potentially transport the drug to an afflicted area while limiting the drug's exposure to 
healthy tissue.  
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CONCLUSIONS 
In the current study, fifty-five FDA-approved antineoplastic drugs were screened in order 
to identify chemotherapeutic compounds that initiated loss of mitochondrial membrane 
potential.  At the concentrations tested, the screen identified mitoxantrone as a 
depolarization agent and confirmation studies showed that the drug consistently 
decreased the membrane potential over a wide variety of concentrations and in different 
prostate, pancreatic, and breast cancer cell lines.  The concentrations of reactive oxygen 
species were also measured in order to verify the mitochondria damaging activity of the 
drug and to better understand the kinetics of the drug's reaction upon treatment.  Finally, 
our studies have shown that mitoxantrone can be encapsulated in PEG-PE micelles 
without loss of activity and that these micelles provide  potential vehicle for targeted drug 
delivery.  
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APPENDIX B 
ADDITIONAL COMBINATION TREATMENT EXPERIMENTS IN ALTERNATE 
CELL LINES AND USING ALTERNATE DRUGS 
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INTRODUCTION 
In addition to the combination screening experiments conducted using the John's Hopkins 
Clinical Compound Library (JHCCL), additional combination treatment experiments were 
conducted using drugs that were approved by the FDA after the JHCCL had already been 
assembled and other drugs that show promise as chemotherapeutic agents but that have not been 
approved for use by the FDA.  In addition combination treatments were also carried out in a 
murine bladder cancer cell line.  The results of these different combinatorial studies are complied 
and discussed in this appendix. 
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Cell Culture Techniques 
Three human prostate cancer cell lines (PC3, PC3-TR, and 22Rv1) and one murine bladder 
cancer line (MB49) were used in this study. PC3-TR (TR: TRAIL resistant) [101] cells were a 
generous gift from Dr. Aria Olumi at the Massachusetts General Hospital in Boston, MA. Cells 
were grown in 75 cm
2
 Corning cell culture flasks with RPMI 1640 tissue culture media 
supplemented with 10% Fetal Bovine Serum and 1% penicillin / streptomycin (10000 units/mL 
penicillin G and 10000 μg/mL streptomycin) at 37°C with 5% CO2.  
 
Reagent/Drug Preparation 
All reagents and drugs used in this study were reconstituted in either deionized water, ethanol, or 
DMSO depending on solubility.  TRAIL was purchased from R&D Systems and reconstituted in 
PBS at a 10 µg/mL stock concentration in 50 µL aliquots to prevent multiple freeze/thaw cycles.  
Solutions were prepared to ensure that the final solvent concentration in cell treatments would be 
less than 1% (v/v) to limit non-specific activity.   
 
Single Agent and Combination Treatments 
Cells were plated in 96 well plates at a density of 10,000 cells/well and incubated at 37°C and 
5% CO2 for approximately 24 hours. For single-agent treatments, cells were exposed to 0-100 
μM (mitoxantrone, mithramycin, cabazitaxel, and abiraterone) or 0-10 mM (dichloroacetic acid) 
treatments for 2 and/or 24 hours at which point the media was refreshed, and cell viability was 
determined using the MTT (3-(4,5-dimethylthiazolyl-2) -2,5-diphenyltetrazolium bromide) 
assay. For sequential combination treatments, cells were first treated with a sensitizer drug 
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candidate for 2 and/or 24 hours. The media was then removed, replaced with fresh serum-
containing media, and the cells were treated with 10 ng/mL TRAIL. Cells were incubated for an 
additional 24 h after which, viability measurements were carried out using the MTT assay. 
 
Determination of Cell Viability 
Cell viability was assessed using the MTT cell proliferation assay (ATCC CA#30-1010k). 
Following addition of the MTT reagent (3 h at 37
o
C), cells were treated with a lysis buffer from 
the kit and kept at room temperature in the dark for at least two hours in order to carry out 
complete lysis and to solubilize the MTT product. The absorbance of each well was measured 
using a Biotech Synergy 2 Multi-Detection Microplate Reader at 570 nm. Each experiment 
included a set of blank wells (media only), a live control (no treatment) and a dead control (0.5 
μL of MTT lysis buffer). Fractional cell viability was calculated as:  (OD of sample – OD of 
dead control)/(OD of live control – OD of dead control) where OD is the optical density. 
Percentage cell viability was calculated by multiplying the fractional viability by 100. Data are 
plotted as percentage reduction in cell viability compared to control (untreated cells) in which, a 
0% value on the graph means 100% viability and 100% value on the graph means 0% viability. 
 
Statistical Analyses 
Screening experiments were carried out in duplicate and expanded dose responses with identified 
leads were performed at least in triplicate. Data are presented as the mean  one standard 
deviation. The standard deviation of each set was calculated based on the variation between 
experiments. ANOVA was performed using the t-test function in Microsoft Excel.  Analysis of 
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the single-agent treatment was performed in order to determine whether or not a drug had a 
significant effect when compared to the live (untreated) control. Efficacies of sensitization were 
determined by comparing the decrease in cell viability following combination treatments (i.e. 
drug in combination with TRAIL) to the reduction in cell viability as a consequence of the 
additive effect of single-agent treatments (drug alone + 10 ng/mL TRAIL alone). 
  
192 
RESULTS AND DISCUSSION 
Combination Treatment Studies in MB49 Bladder Cancer Cells.  The research described up 
to this point, has focused on using combination therapy techniques on treating prostate, breast, 
and pancreatic cancer cells.  However, bladder cancer represents the fourth most common cancer 
in men and it is estimated that over 55,000 new cases were diagnosed in 2012 [1].  Fortunately, 
in many instances of bladder cancer, tumors are superficial and non-invasive.  Typically these 
tumors are removed via transurethral resection and the afflicted is area is treated using 
intravesical therapy [212].  Such treatments are enticing for our purposes because it allows for 
the direct delivery of the drug to the afflicted area without needing to develop systems for 
targeted delivery.  Based on our successful studies with sensitizer drug/TRAIL combination 
treatments in other malignant lines, we became interested in determining if these combination 
therapies would also be effective in bladder cancer cells. 
 
Does response studies for TRAIL-combination therapies were evaluated in MB-49 murine 
bladder cancer cells using mitoxantrone and mithramycin.  Both of these drugs were found to be 
effective in sensitizing several malignant cell lines to TRAIL-mediated apoptosis (Figures 2.7, 
2.8, 2.12, 2.13).  Mitoxantrone/TRAIL combination studies at 2 and 24 hours are shown in 
Figure B1.  These results indicate that there is a significant loss of viable cells when comparing 
single-agent mitoxantrone to combination treatments of mitoxantrone and TRAIL for both 
treatment times tested, although there are treatment concentrations for both conditions that do not 
exhibit a statistically significant difference (primarily due to large variation between replicates).  
In the case of the 2 hour treatments  
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Figure B.1  Kinetic dose response for mitoxantrone in MB49 murine bladder cancer cells.  Cells 
were treated with mitoxantrone for (a) 2 hours, and (b) 24 hours.  For single-agent treatments 
(dark grey diamonds) the cell viability was assessed following the mitoxantrone treatments.  For 
combination treatments (light grey squares), 10 ng/mL of TRAIL was applied for 24 hours 
following the initial mitoxantrone treatments.  Comparisons were made between the single agent 
and combination treatments; asterisks (*) and (**) indicate p-values < 0.05 and <0.01, 
respectively.  Data are presented on a logarithmic scale for x-axes in the plots. 
 
(Figure B1a), single agent mitoxantrone has little to no effect on cell viability with the  LC50 
value being difficult to determine since the highest concentration treatment (100 μM) only shows 
a 12% reduction in viability.  However, mitoxantrone/TRAIL combination treatments all show 
large increases in cell death as compared to the single agent treatments (with the exception of the 
0.66 μM treatment); single agent TRAIL only produced a 2.6% loss in cell viability so it appears 
that the mitoxantrone/TRAIL treatments act synergistically.  The LC50 value for the combination 
treatments drops to about 3.3 μM and the viability linearly to about 4% following the 100 μM 
treatments.  The greatest difference in cell viability between the single agent and combination 
treatments is 84% at the 100 μM treatment condition.  The 24 hour treatment results (Figure 
B.1b) indicate that the single agent mitoxantrone treatments is effective at reducing cell viability 
over this time period with the LC50 value found to be between 0.66 and 1 μM for these 
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treatments.  For the 24 hour combination treatments the LC50 value was found to be 
approximately 0.2 μM.  While the 24 hour treatments do indicate that there is synergy between 
the mitoxantrone and TRAIL treatments, the overall effect is much less than the activity seen in 
the 2 hour treatments as is evident by the relatively small change in the LC50 value.  This is also 
confirmed by the fact that the largest significant decrease in cell viability between the single 
agent and combination treatments is 22% (6.6 μM) as compared to the 88% decrease seen after 
the 2 hour treatments.  These results are important because they further demonstrate the 
importance of the kinetic response of mitoxantrone/TRAIL combination treatments.  The results 
also indicate that mitoxantrone and TRAIL is effective at reducing the viability of bladder cancer 
in-vitro. 
 
Mithramycin/TRAIL combination studies at 24 hours are shown in Figure B2.  These results 
indicate that there is no significant loss of viable cells when comparing single-agent mithramycin 
treatments to combination treatments with 10 ng/mL TRAIL.  These results are somewhat 
surprising considering that mithramycin showed synergy in all the cell lines tested previously 
and exhibited some of the highest synergistic activity in those experiments.  However, 
additionally experiments need to be conducted to understand if the kinetics of treatment can 
improve the activity of the drugs; the combination treatments with mitoxantrone in this line 
showed higher efficacy when the sensitizing drug was applied for less time.  It is possible that 
similar circumstances may exist for mithramycin.  The fact that the combination treatments 
seems to be ineffective also provides an interesting opportunity to better understand the 
mechanism behind mithramycin's TRAIL sensitization activity.  By identifying characteristics 
that differ between the MB49 cells and the other cells tested it may be possible to determine 
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what effect mithramycin has in other cells that it does not have in MB49 cells.  It should be noted 
that although recombinant human TRAIL is used in all the combination studies, the drug has 
been previously shown to be effective in murine cell lines [213, 214] although the effect of the 
drug is not well characterized in the MB49 line specifically. 
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Figure B.2  Kinetic dose response for mithramycin in MB49 murine bladder cancer cells.  Cells 
were treated with mithramycin for 24 hours.  For single-agent treatments (dark grey diamonds) 
the cell viability was assessed following the mithramycin treatments.  For combination 
treatments (light grey squares), 10 ng/mL of TRAIL was applied for 24 hours following the 
initial mithramycin treatments.  Comparisons were made between the single agent and 
combination treatments; asterisks (*) and (**) indicate p-values < 0.05 and <0.01, respectively.  
Data are presented on a logarithmic scale for x-axes in the plots. 
 
Evaluation of the TRAIL-Sensitization Activity of Additional Therapeutic Compounds.  In 
addition to the drugs screened in the JHCCL, results were collected for compounds that were not 
included in the library.  Two of these drugs were only recently approved by the FDA as cancer 
therapeutics.  The other compound is not approved by the FDA, but it has been shown to be a 
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promising chemotherapeutic agent in laboratory experiments and has also attracted significant 
media attention as a "cheap" and "safe" chemotheraputic option [215].  This compound, called 
dichloroacetic acid (DCA) was initially found to be effective at selectively killing cancer cells 
and was shown to reduce tumor growth in animal models [216].  It has been shown to inhibit 
pyruvate dehydrogenase kinase (PDK) which in turn disrupts glycolysis.  Since cancer cells 
express increased glycolysis, the loss of PDK forces the cells to shift to energy production using 
oxidative phosphorylation.  Since the mitochondria is the "point of no return" for apoptosis, 
restoring function to the organelle allows it to identify the cells as damaged, and induce 
apoptosis.  Since healthy cells would not be identified as dangerous or damaged the treatments 
would be cancer cell selective [216].  Since the compound was found to selectively target 
malignant cells and because its mechanism of action involves the induction of apoptosis we were 
interested in testing the drug in combination with TRAIL to see if DCA had any sensitization 
properties (Figure B.3).  Treatments were carried out in PC3-TR prostate cancer cells using 0 to 
10 mM DCA concentrations (24 hour treatments).  The results indicated that the single-agent 
DCA and combination treatments with 10 ng/mL TRAIL did not show any significant difference 
in their activities.  Overall the effect of the treatments seemed somewhat limited with most 
treatments falling around a 20-30% reduction in cell viability.  This suggests that higher  
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Figure B.3  (a) Dose response for dichloroacetic acid (DCA) in PC3-TR human prostate cancer 
cells.  Malignant cells were treated with DCA for 24 hours.  For single-agent treatments (dark 
grey diamonds) the cell viability was assessed following the initial treatments.  For combination 
treatments (light grey squares), 10 ng/mL of TRAIL was applied for 24 hours following the 
initial DCA treatments.  Comparisons were made between the single agent and combination 
treatments; asterisks (*) and (**) indicate p-values < 0.05 and <0.01, respectively.  Data are 
presented on a logarithmic scale for x-axes in plots.  (b) Chemical structures of DCA. 
 
concentrations of the drug need to be tested to determine which concentrations of the drug can 
cause higher reductions in cell viability.  However, at the concentrations tested there are no 
indications that DCA is sensitizing the PC3-TR cells to TRAIL-mediated apoptosis. 
 
Additionally, two drugs recently approved by the FDA as chemotherapeutics were also tested for 
their TRAIL-sensitization activity.  Abiraterone was approved for use by the FDA in April 2011 
for the treatment of last stage prostate cancer [217].  The drug works by suppressing the 
production of testosterone through the inhibition of 17 α-hydroxylase/C17,20 lyase (CYP17A1).  
The second drug, Cabazitaxel, was approved for use by the FDA in June 2010 for the treatment 
of metastatic hormone-refractory prostate  
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Figure B.4  (a) Dose response for abiraterone in PC3 human prostate cancer cells.  Malignant 
cells were treated with abiraterone for 24 hours.  For single-agent treatments (dark grey 
diamonds) the cell viability was assessed following the initial treatment.  For combination 
treatments (light grey squares), 10 ng/mL of TRAIL was applied for 24 hours following the 
initial treatments.  Comparisons were made between the single agent and combination 
treatments; asterisks (*) and (**) indicate p-values < 0.05 and <0.01, respectively.  Data are 
presented on a logarithmic scale for x-axes in plots.  (b) Chemical structures of abiraterone. 
 
cancer in combination with prednisone [218].  The drug binds to tubulin and prevents the 
formation of microtubules which in turn limits cell mitosis [219].  Dose response studies for 
abiraterone/TRAIL combination studies in PC3 prostate cancer cells are shown in Figure B.4.  
The results of these studies show that the combination treatments reduce cell viability slightly 
more than the single agent abiraterone, but when taking the effect of single agent TRAIL 
(approximately 12%) this difference is not significant.  These results suggest that abiraterone is 
not effective as a TRAIL-sensitizing agent.  Additional experiments evaluating the effects of 
changing the treatment times or concentrations of abiraterone can be studied, but at this time 
there is little indication that would suggest these experiments would show TRAIL-sensitization 
activity either. 
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Figure B.5  Dose response for cabazitaxel in (a) PC3 and (b) 22Rv1 human prostate cancer cells.  
Malignant cells were treated with cabazitaxel for 24 hours.  For single-agent treatments (dark 
grey diamonds) the cell viability was assessed following the initial treatments.  For combination 
treatments (light grey squares), 10 ng/mL of TRAIL was applied for 24 hours following the 
initial cabazitaxel treatments.  Comparisons were made between the single agent and 
combination treatments; asterisks (*) and (**) indicate p-values < 0.05 and <0.01, respectively.  
Data are presented on a logarithmic scale for x-axes in plots.  (c) Chemical structures of 
cabazitaxel. 
 
Dose response studies for cabazitaxel/TRAIL combination studies in PC3 and 22Rv1 prostate 
cancer cells are shown in Figure B.5.  These results indicate that there is a significant loss of 
viable cells when comparing single-agent cabazitaxel to combination treatments of cabazitaxel 
and TRAIL for in both PC3 (Figure B.5a) and 22Rv1 cells(Figure B.5b).  For PC3 cells, the 
cell viability of single agent cabazitaxel treatments actually appears to increase with increasing 
cabazitaxel concentration in a trend that holds over 2 independent experiments.  Cell viability 
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then begins to decrease at concentrations above 20μM.  While these results have been shown to 
be reproducible, the actual viabilities measured between these readings mainly stay between 60-
70% (i.e. the amount the cell viability increases is relatively small) and it would be necessary to 
test lower and higher concentrations of the drug to determine if the trends seen in these initial 
experiments hold true.  More importantly, the experiments show that the cell viability of 
combination treatments are significantly reduced, compared to the single agent treatments; this 
suggests cabazitaxel has some TRAIL-sensitization activity.  The largest difference between the 
cell viabilities of the single agent and combination treatments is 35% (0.33 μM).  However, it is 
difficult to do a LC50 analysis for these studies because the combination treatment experiments 
also indicate that viability increases with increasing cabazitaxel concentrations.  In fact there is a 
25% increase in cell viability between the 0.33 μM and the 100 μM treatments.  These results, 
while unexpected, still indicate that there is synergy between the cabazitaxel and TRAIL for 
0.33-33.3 μM treatments.  Treatments in the 22Rv1 cells (Figure B.5b) showed similar behavior 
to the results seen in the PC3 line.  In this cell line, both the single agent and combination 
treatments showed increases in cell viability with increasing concentrations up to about 33.3 μM.  
However, this cell line also showed a significant difference in cell viability when comparing 
single agent and combination treatments for all concentrations tested with the exception of 100 
μM.  The largest difference between these treatment methods was 18% which is significant 
considering the single agent TRAIL treatments showed almost no loss of viability.  Taken 
together, these results suggest that cabazitaxel is able to moderately sensitize prostate cancer 
cells to TRAIL.  To our knowledge these are the first studies done to show this and while there 
are aspects of these treatments that need to be evaluated more fully (e.g. the increase in cell 
viability with increasing concentration), these initial results are promising.   
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CONCLUSIONS 
In the current study mitoxantrone and mithramycin combination treatment experiments were 
carried out in the MB49 murine bladder cancer cell and the effect of an additional three 
compounds were evaluated in various prostate cancer cell lines.  These studies indicated that 
mitoxantrone/TRAIL combination treatments did synergistically enhance cell death in MB49 
cells, but that the effect appears to be heavily influenced by the treatment kinetics.  These studies 
also indicated that mithramycin/TRAIL combination treatments were not effect in MB49 cells.  
Dichloroacetic acid, abiraterone, and cabazitaxel were tested in combination with TRAIL to 
determine if any of these compounds could sensitize prostate cancer cells to TRAIL.  The results 
of these studies indicated that both dichloroacetic acid and abiraterone were ineffectual as 
TRAIL-sensitizing agents.  However, cabazitaxel/TRAIL combination treatments were shown 
have synergy in both PC3 and 22Rv1 prostate cancer cells.  Overall these studies have 
demonstrated the therapeutic potential of mitoxantrone and TRAIL in bladder cancer, and have 
also identified cabazitaxel as a new candidate for additional optimization/mechanistic studies. 
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